



European
Crohn's and Colitis
Organisation

Inflammatory Bowel Diseases

Scientific Programme



Programme 2008-2022

www.ecco-ibd.eu

"Navigating the Oceans of IBD"

Thursday, February 17, 2022

Scientific programme day by day (as per February 9, 2022)

11:00 - 12:00	Industry Sponsored Satellite Symposia 1a, 1b, 1c, 1d
12:15 - 12:30	1: Opening L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
12:30 - 14:00	Scientific Session 1: Developing environmental recipes for IBD J. Colombel, New York, United States W. Reinisch, Vienna, Austria
12:30 - 12:50	2: What is the role of the environment in IBD? J. Lindsay, London, United Kingdom
12:50 - 13:00	3: OP01: Withdrawal of infliximab or anti-metabolite therapy in Crohn's Disease patients in sustained remission on combination therapy: A randomized unblinded controlled trial (SPARE) E. Louis, Liège, Belgium
13:00 - 13:20	4: What environmental factors are modifiable? Lessons from non-IBD conditions B. Nemery de Belleaux, Leuven, Belgium
13:20 - 13:30	5: OP02: The breastmilk proteomics of women with Inflammatory Bowel Disease (IBD) and its impact on fecal calprotectin and microbiota composition in their babies J. Guedelha Sabino, Leuven, Belgium
13:30 - 13:40	6: OP03: Standardized faecal microbiota transplantation with microbiome-guided donor selection in active UC patients: A randomized, placebo-controlled intervention study C. Caenepeel, Leuven, Belgium
13:40 - 14:00	7: Interventional trials addressing environmental factors in IBD J. Guedelha Sabino, Leuven, Belgium
14:00 - 14:30	Break

14:30 - 16:00	<i>Scientific Session 2: Keeping the patient at home: Is telemedicine the future?</i> H. Gordon, London, United Kingdom M. Pierik, Maastricht, The Netherlands
14:30 - 14:50	<i>8: I want to see my patient in person vs. I can manage my patient remotely</i> G. Doherty, Dublin, Ireland R. Panaccione, Calgary, Canada
14:50 - 15:00	<i>9: OP04: Vedolizumab intravenous is effective across multiple treatment targets in chronic pouchitis: Results of the randomised, double-blind, placebo-controlled EARNEST trial</i> S. Travis, Oxford, United Kingdom
15:00 - 15:20	<i>10: Point of care testing</i> N. Teix, Innsbruck, Austria H. Tilg, Innsbruck, Austria
15:20 - 15:30	<i>11: OP05: Outcome of induction therapy with vedolizumab in children: Results from the prospective, multi-centre VEDOKIDS study</i> D. Turner, Jerusalem, Israel
15:30 - 15:40	<i>12: OP06: The influence of different prednisolone tapering algorithms on the effectiveness of infliximab in patients with Ulcerative Colitis – A real-world cohort study</i> P. Ovesen, Herlev, Denmark
15:40 - 16:00	<i>13: Can IBD Nurses replace IBD physicians?</i> S. Ben-Horin, Ramat Gan, Israel K. Greveson, London, United Kingdom
16:00 - 17:20	<i>Scientific Session 3: Aiming high with treatment goals in IBD: The modern Icarus</i> A. Dignass, Frankfurt, Germany S. Restellini, Geneva, Switzerland
16:00 - 16:20	<i>14: Disease clearance in UC: Is it possible and how do we achieve it?</i> S. Danese, Milan, Italy
16:20 - 16:40	<i>15: Transmural vs. endoscopic healing in CD: What is the ultimate goal?</i> T. Kucharzik, Lüneburg, Germany C. Maaser, Lüneburg, Germany
16:40 - 16:50	<i>16: OP07: Exploring disease control by combining clinical, biological, and health-related quality of life remission with endoscopic improvements among Ulcerative Colitis patients treated with filgotinib: A post-hoc analysis from the SELECTION trial</i> S. Schreiber, Kiel, Germany

16:50 - 17:00	17: OP08: The effects of maintenance therapy with upadacitinib on abdominal pain, bowel urgency, and fatigue in patients with moderately to severely active Ulcerative Colitis: Phase 3 U-ACHIEVE maintenance results S. Danese, Milan, Italy
17:00 - 17:20	18: Molecular healing: Looking into the future R. Atreya, Erlangen, Germany
17:30 - 18:30	Digital Oral Presentations (Sessions 1-5) see page 13
18:45 - 19:45	Industry Sponsored Satellite Symposia 2a, 2b, 2c, 2d, 2e

Friday, February 18, 2022

Scientific programme day by day (as per February 9, 2022)

07:15 - 08:15	<i>Industry Sponsored Morning Satellite Symposia 3b, 3d</i>
08:30 - 10:30	<i>Scientific Session 4: Modern monitoring of IBD</i> K. Karmiris, Heraklion, Greece H. Yanai, Tel Aviv, Israel
08:30 - 08:50	<i>19: What is the optimal timing and method for monitoring?</i> E. Louis, Liège, Belgium
08:50 - 09:00	<i>20: OP09: Proactive therapeutic drug monitoring is superior to standard treatment during maintenance therapy with infliximab; results from a 52-week multicentre randomised trial of 450 patients; the NOR-DRUM B study</i> K. Jørgensen, Oslo, Norway
09:00 - 09:10	<i>21: OP10: Comparative efficacy of biologics for endoscopic healing of the ileum and colon in Crohn's Disease</i> N. Narula, Hamilton, Canada
09:10 - 09:20	<i>22: OP11: Expanded genome-wide association study of Inflammatory Bowel Disease identifies 174 novel loci and directly implicates new genes in disease susceptibility</i> L. Fachal, Hinxton, United Kingdom
09:20 - 09:40	<i>23: ECCO Guidelines on Ulcerative Colitis – Medical and Surgical Treatment</i> Y. Panis, Clichy, France T. Raine, Cambridge, United Kingdom
09:40 - 09:50	<i>24: OP12: Segmental vs Total Colectomy for Crohn's Disease of the colon in the biologic era. Results from the SCOTCH international, multicentric study</i> G. Pellino, Naples, Italy
09:50 - 10:00	<i>25: OP13: Modified 2-stage vs. 3-stage ileal pouch-anal anastomosis result in equivalent long-term functional outcomes and pouch survival: A matched-pair analysis</i> S. Holubar, Cleveland, United States
10:00 - 10:10	<i>26: OP14: Interpreting genome-wide association studies of Inflammatory Bowel Disease through the lens of single-cell sequencing</i> M. Krzak, Hinxton, United Kingdom
10:10 - 10:30	<i>27: What is the optimal way of diagnosing and monitoring fibrosis?</i> K. Gecse, Amsterdam, The Netherlands P. Paolantonio, Rome, Italy
10:30 - 11:00	<i>Break</i>

11:00 - 12:30	<i>Scientific Session 5: Histology in IBD: What the gastroenterologist should know</i> D. Duricova, Prague, Czech Republic M. Svrcek, Paris, France
11:00 - 11:20	<i>28: AI and histology</i> A. Pollett, Toronto, Canada
11:20 - 11:30	<i>29: OP15: A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis</i> T. Parigi, Birmingham, United Kingdom
11:30 - 11:50	<i>30: Fibrosis in CD vs. UC</i> F. Ungaro, Milan, Italy
11:50 - 12:00	<i>31: OP16: The first Virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis</i> M. Iacucci, Birmingham, United Kingdom
12:00 - 12:10	<i>32: OP17: Maintenance phase propensity score adjusted effectiveness and persistence at week-52 in biologic-naïve Ulcerative Colitis patients treated with vedolizumab or anti-TNF (VEDO IBD-study)</i> B. Bokemeyer, Minden, Germany
12:10 - 12:30	<i>33: What is the best histologic index?</i> L. Biedermann, Zurich, Switzerland A. Walsh, Oxford, United Kingdom
12:30 - 13:30	<i>Break</i>
12:40 - 13:20	<i>Industry Sponsored Lunch Satellite Symposia LS1, LS2, LS3, LS4, LS5</i>
13:30 - 15:00	<i>Scientific Session 6: Do we see light at the end of the fistula track?</i> G. Pellino, Aversa, Italy G. Rogler, Zurich, Switzerland
13:30 - 13:50	<i>34: Limitations of medical approaches</i> W. Bemelman, Amsterdam, The Netherlands
13:50 - 14:00	<i>35: OP18: Efficacy and safety of filgotinib for the treatment of perianal fistulizing Crohn's Disease: Results from the phase 2 DIVERGENCE 2 study</i> W. Reinisch, Vienna, Austria
14:00 - 14:20	<i>36: Positioning medical options</i> A. Armuzzi, Milan, Italy
14:20 - 14:30	<i>37: OP19: Classifying perianal fistulising Crohn's Disease: An expert-consensus to guide decision-making in daily practice and clinical trials</i> J. Geldof, Ghent, Belgium
14:30 - 14:40	<i>38: OP20: Perianal fistulas are characterised by expansion of interleukin-22 producing invariant natural killer T-cells and CD4+ T-cells which drive dysregulation of the extracellular matrix</i> L. Constable, London, United Kingdom

14:40 - 15:00	39: Is endoscopic treatment really an option? P. Kotze, Curitiba, Brazil
15:00 - 15:30	Break
EITHER:	
15:30 - 16:14	Scientific Session 7: COVID and non-COVID infections T. Kucharzik, Lüneburg, Germany V. Pittet, Lausanne, Switzerland
15:30 - 15:44	40: Lessons from the COVID pandemic for IBD management S. Ng, Hong Kong, China
15:44 - 15:54	41: OP21: COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab J. Alexander, London, United Kingdom
15:54 - 16:04	42: OP22: Antibody decay, T cell immunity and breakthrough infections following SARS-CoV-2 vaccination in infliximab- and vedolizumab-treated patients S. Lin, Exeter, United Kingdom
16:04 - 16:14	43: Infections with biologics and small molecules: Impact on drug positioning P. Ellul, Sliema, Malta
16:14 - 17:14	Scientific Session 8: IBD Horizons M. Samaan, London, United Kingdom S. Schreiber, Kiel, Germany
16:14 - 16:24	44: OP23: The efficacy and safety of guselkumab induction therapy in patients with moderately to severely active Ulcerative Colitis: Phase 2b QUASAR Study results through week 12 A. Dignass, Frankfurt, Germany
16:24 - 16:34	45: OP24: Clinical efficacy and safety of guselkumab maintenance therapy in patients with moderately to severely active Crohn's Disease: Week 48 analyses from the phase 2 GALAXI 1 study S. Danese, Milan, Italy
16:34 - 16:44	46: OP25: Patients with moderate to severe Crohn's Disease with and without prior biologic failure demonstrate improved endoscopic outcomes with risankizumab: Results from phase 3 induction and maintenance trials M. Ferrante, Leuven, Belgium
16:44 - 16:54	47: OP26: Efficacy and safety of mirikizumab as induction therapy in patients with moderately to severely active Ulcerative Colitis: Results from the Phase 3 LUCENT-1 study G. D'Haens, Amsterdam, The Netherlands

16:54 - 17:04	48: OP27: A Phase 1 Study evaluating the bioequivalence of the proposed commercial and clinical formulations of Etrasimod 2mg, and the effect of food on the pharmacokinetics of the proposed commercial formulation in healthy volunteers C. Lee, San Diego, United States
17:04 - 17:14	49: OP28: A randomized placebo controlled clinical trial with 5-hydroxytryptophan in patients with quiescent Inflammatory Bowel Disease and fatigue (Trp-IBD) M. Truyens, Ghent, Belgium
OR:	
15:30 - 17:10	Scientific Session 9: Basic Science: From basic science to practical approach I. Dotan, Petah Tikva, Israel M. Scharl, Zurich, Switzerland
15:30 - 15:50	50: Predicting response to medications in IBD – from basic science to practical approach Y. Chowers, Haifa, Israel
15:50 - 16:00	51: OP29: Peripheral blood DNA methylation biomarkers accurately predict clinical- and endoscopic response to vedolizumab in a real-life cohort of Crohn's Disease patients V. Joustra, Amsterdam, The Netherlands
16:00 - 16:10	52: OP30: Upadacitinib modulates inflammatory pathways in gut tissue in patients with Ulcerative Colitis: Transcriptomic profiling from the Phase 2b study, U-ACHIEVE B. Verstockt, Leuven, Belgium
16:10 - 16:30	53: What is the real impact of diet on organ biology outside microbiome? T. Adolph, Innsbruck, Austria
16:30 - 16:40	54: OP31: Dietary and Multi-Omic characterization of new onset treatment naive Crohn Disease identifies factors that may contribute to disease pathogenesis Y. Haberman Ziv, Ramat Gan, Israel
16:40 - 16:50	55: OP32: Pyroptosis inhibition prevents the cytotoxicity induced by IL-17 without impairing its beneficial effects S. Hong, Seoul, South Korea
16:50 - 17:10	56: Will the revolution of OMICs translate into a better care? K. Aden, Kiel, Germany
17:25 - 18:25	Digital Oral Presentations (Sessions 6-10) see page 13
18:40 - 19:40	Industry Sponsored Satellite Symposia 4a, 4b, 4c, 4d, 4e

Saturday, February 19, 2022

Scientific programme day by day (as per February 9, 2022)

08:30 - 10:20	Scientific Session 10: Beyond the gut A. De Vries, Rotterdam, The Netherlands Z. Zelinkova, Bratislava, Slovakia
08:30 - 08:50	57: What can we learn from rheumatology in terms of sequencing therapies M. D'Agostino, Rome, Italy D. Aletaha, Vienna, Austria
08:50 - 09:00	58: OP33: Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results from the UPA Phase 3 programme J. Colombel, New York, United States
09:00 - 09:20	59: Impact of EIMs on drug choice P. Lakatos, Budapest, Hungary; Montreal, Canada
09:20 - 09:30	60: OP34: Efficacy and safety of advanced induction and maintenance therapies in patients with moderately to severely active Ulcerative Colitis: An indirect treatment comparison using Bayesian network meta-analysis R. Panaccione, Calgary, Canada
09:30 - 09:50	61: ECCO Guidelines on Sexuality, Fertility, Pregnancy and Lactation J. Torres, Lisbon, Portugal J. van der Woude, Rotterdam, The Netherlands
09:50 - 10:00	62: OP35: Natural history of anal ulcerations in pediatric-onset Crohn's Disease: A population-based study M. Fumery, Amiens, France
10:00 - 10:10	63: OP36: Efficacy and safety of combination induction therapy with guselkumab and golimumab in participants with moderately-to-severely active Ulcerative Colitis: Results through week 12 of a phase 2a randomized, double-blind, active-controlled, parallel-group, multicenter, proof-of-concept study B. Sands, New York, United States
10:10 - 10:20	64: OP37: Bacterial suppression of intestinal fungi via activation of human gut Vδ2+ T-cells L. Mathew, London, United Kingdom
10:20 - 10:50	Break

10:50 - 12:20	Scientific Session 11: Minimising malignancy risks: Clinical cases C. Af Björkesten, Helsinki, Finland P. Irving, London, United Kingdom
10:50 - 11:10	65: Small bowel dysplasia/malignancy: Proactive or reactive? P. Juillerat, Bern, Switzerland
11:10 - 11:20	66: OP38: Tofacitinib for the treatment of Ulcerative Colitis: An integrated summary of safety data from the global OCTAVE and RIVETING clinical trials R. Panaccione, Calgary, Canada
11:20 - 11:40	67: Skin cancer in IBD: Practical advice from a dermatologist A. Van Laethem, Leuven, Belgium
11:40 - 11:50	68: OP39: Shorter disease duration is associated with better outcomes in patients with moderately to severely active Crohn's Disease treated with risankizumab: Results from the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
11:50 - 12:00	69: OP40: Efficacy of risankizumab induction and maintenance therapy by baseline Crohn's Disease location: Post hoc analysis of the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies P. Bossuyt, Bonheiden, Belgium
12:00 - 12:20	70: ECCO Guidelines on IBD and Malignancies H. Gordon, London, United Kingdom T. Raine, Cambridge, United Kingdom
12:20 - 13:15	Scientific Session 12: ECCO Lecture L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France B. Siegmund, Berlin, Germany
12:20 - 12:50	71: A European IBD voyage S. Vermeire, Leuven, Belgium
12:50 - 13:05	72: Awards and Closing remarks
13:05 - 13:15	The ECCO Film

"IBD precise"

Thursday, July 8, 2021

Scientific programme day by day

11:00 - 12:00	Industry Sponsored Satellite Symposia 1a, 1b & 1c
12:15 - 12:30	1: Opening L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France
12:30 - 13:45	Scientific Session 1: Sophisticated strategies within reach P. Irving, London, United Kingdom S. Vermeire, Leuven, Belgium
12:30 - 12:45	2: Head to head trials S. Ghosh, Cork, Ireland
12:45 - 12:55	3: OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial A. Levine, Holon, Israel
12:55 - 13:10	4: Switching from IV to SC: Benefits beyond merely convenience? S. Schreiber, Kiel, Germany
13:10 - 13:20	5: OP02: Ustekinumab versus adalimumab for induction and maintenance therapy in Moderate-to-Severe Crohn's Disease: The SEAVUE study P. Irving, London, United Kingdom
13:20 - 13:30	6: OP03: Anti-SARS-CoV2 antibody responses are attenuated in patients with Inflammatory Bowel Disease treated with infliximab N. Kennedy, Exeter, United Kingdom
13:30 - 13:45	7: Combining biologics: Pros and cons D. Rubin, Chicago, United States
13:45 - 14:00	Break
14:00 - 15:15	Scientific Session 2: Safety first? M. Adamina, Winterthur, Switzerland L. Lopetuso, Rome, Italy
14:00 - 14:15	8: When do we really know the safety profile of a drug? J. Rahier, Yvoir, Belgium
14:15 - 14:25	9: OP04: Safety analysis of filgotinib for Ulcerative Colitis: Results from the phase 2b/3 SELECTION study and phase 3 SELECTIONLTE long-term extension study S. Schreiber, Kiel, Germany

14:25 - 14:40	10: Are we safer with biologics or small-molecules? E. Louis, Liège, Belgium
14:40 - 14:50	11: OP05: Association of ultra-processed food intake with risk of Inflammatory Bowel Disease from the prospective urban rural epidemiology (PURE) study: A prospective cohort study N. Narula, Hamilton, Canada
14:50 - 15:00	12: OP06: 5-aminosalicylates are not associated with adverse outcomes in Inflammatory Bowel Disease patients with COVID-19: Analysis from an international registry R. Ungaro, New York, United States
15:00 - 15:15	13: Are surgical interventions really more harmful than medical treatment? O. Faiz, Harrow, United Kingdom
15:15- 15:30	Break
15:30 - 16:35	Scientific Session 3: Hot and (almost) happening J. Burisch, Hvidovre, Denmark C. Maaser, Lüneburg, Germany
15:30 - 15:45	14: How machine learning will affect IBD treatment S. Ennis, Southampton, United Kingdom
15:45 - 16:00	15: Artificial intelligence: A strategic alliance between the machine and the endoscopist P. Bossuyt, Bonheiden, Belgium
16:00 - 16:10	16: OP07: Artificial intelligence surpasses gastrointestinal experts in the classification of endoscopic severity among Ulcerative Colitis B. Lo, Hvidovre, Denmark
16:10 - 16:20	17: OP08: Automatic detection of enteric ulcers and erosions in capsule endoscopy using a convolutional neural network M. Saraiva, Porto, Portugal
16:20 - 16:35	18: How to set-up a virtual clinic? M. Pierik, Maastricht, The Netherlands
16:35- 16:45	Break
16:45 - 17:45	Digital Oral Presentations (Sessions 1-5)
17:45- 17:55	Break
17:55 - 18:55	Industry Sponsored Satellite Symposia 2a, 2b & 2c

Friday, July 9, 2021

Scientific programme day by day

07:15 - 08:15	Industry Sponsored Morning Satellite Symposia 3a, 3b & 3c
08:30 - 09:20	Scientific Session 4.1.: Next generation diagnostics T. Kucharzik, Lüneburg, Germany N. Yassin, Birmingham, United Kingdom
08:30 - 08:50	19: What histology can tell us: Are we speaking the same language? R. Feakins, London, United Kingdom F. Magro Dias, Porto, Portugal
08:50 - 09:00	20: OP09: Patient reported outcomes reflect histologic disease activity in patients with Ulcerative Colitis: Interim analysis of the APOLLO study B. Verstockt, Leuven, Belgium
09:00 - 09:10	21: OP10: Response to biologics in IBD patients assessed by Computerized image analysis of Probe Based Confocal Laser Endomicroscopy with molecular labeling and gene expression profiling M. Iacucci, Birmingham, United Kingdom
09:10 - 09:20	22: OP11: Longitudinal profiling of mucosal immune cell composition using multiplex immunohistochemistry identifies drug-and response-specific patterns in Ulcerative Colitis V. Volk, Hannover, Germany
09:20 - 09:30	Break
09:30 - 10:30	Scientific Session 4.2.: Next generation diagnostics T. Kucharzik, Lüneburg, Germany N. Yassin, Birmingham, United Kingdom
09:30 - 09:45	23: Fluorescence in IBD surgery M. Slooter, Amsterdam, The Netherlands
09:45 - 09:55	24: OP12: Blood proteins related to immunoregulation or cellular junctions reveal distinct biological profiles associated with the risk of short-term versus mid/long-term relapse in Crohn's Disease patients stopping infliximab N. Pierre, Liège, Belgium
09:55 - 10:05	25: OP13: Mucosal organoids capture Innate Lymphoid Cells (ILC) tissue-specific development and reveal that Inflammatory Bowel Disease-associated ILC modulate intestinal remodelling J. Neves, London, United Kingdom
10:05 - 10:15	26: OP14: Extracellular RNAs as liquid biopsy non-invasive biomarker in IBD B. Verstockt, Leuven, Belgium

10:15 - 10:30	27: The future of radiology for IBD A. Laghi, Rome, Italy
10:30 - 10:45	Break
10:45 - 12:00	Scientific Session 5: The young and the old T. Raine, Cambridge, United Kingdom P. Van Rheenen, Groningen, The Netherlands
10:45 - 11:00	28: Lessons from paediatric IBD – early disease intervention, nutrition, genetic testing J. Van Limbergen, Amsterdam, The Netherlands
11:00 - 11:10	29: OP15: Cyclic exclusive enteral nutrition to maintain longterm drug-free remission in Paediatric Crohn's Disease: the CD HOPE study of the GETAID pédiatrique B. Pigneur Arnaud, Paris, France
11:10 - 11:25	30: Drug safety in the elderly patients with IBD T. Lobatón Ortega, Ghent, Belgium
11:25 - 11:35	31: OP16: Characterization of the Clinical Features and Outcomes of Paediatric Patients with Isolated Colonic Crohn's Disease: A Multi-center Study from the Porto Group of ESPGHAN D. Shouval, Petah Tiqwa, Israel
11:35 - 11:45	32: OP17: Impact of phenotypic and genetic factors on Crohn's Disease evolution in a cohort of 13,926 patients Q. Zhang, Cambridge, United Kingdom
11:45 - 12:00	33: Body image and sexuality P. Tozer, London, United Kingdom
12:00 - 12:10	Break
12:10 - 12:50	Industry Sponsored Lunch Satellite Symposia LS1, LS2, LS3 & LS4
12:50 - 13:00	Break
13:00 - 14:15	Scientific Session 6: Bottoms behaving badly A. Armuzzi, Rome, Italy Z. Zelinkova, Bratislava, Slovakia
13:00 - 13:15	34: New surgical approaches for perianal disease P. Kotze, Curitiba, Brazil
13:15 - 13:25	35: OP18: Treatment of perianal fistulas in Crohn's Disease: Surgical closure after anti-TNF induction treatment versus anti-TNF without surgery (PISA II) - A patient preference RCT E. Meima-van Praag, Amsterdam, The Netherlands
13:25 - 13:40	36: Looking beyond anti-TNF S. Vavricka, Zurich, Switzerland
13:40 - 13:50	37: OP19: Disease course and treatment outcomes of early resected Crohn's Disease patients: A Danish nationwide cohort study from 1997 to 2015 M. Zhao, Hvidovre, Denmark

Friday, July 9, 2021, cont.

Scientific programme day by day

13:50 - 14:00	38: OP20: Risk and predictors of surgery in a newly diagnosed cohort of IBD patients in the biologic era: Results from the EpidemiIBD study M. Chaparro, Madrid, Spain
14:00 - 14:15	39: When it is not IBD G. Bouguen, Rennes, France
14:15 - 14:30	Break
14:30 - 15:20	Scientific Session 7: Milestones in clinical care R. Atreya, Erlangen, Germany P. Gionchetti, Bologna, Italy
14:30 - 14:45	40: Endoscopy or ultrasound for disease activity assessment? M. Iacucci, Birmingham, United Kingdom M. Allocca, Rozzano, Italy
14:45 - 14:55	41: OP21: Predictive value of Milan Ultrasound Criteria in Ulcerative Colitis: A prospective observational cohort study M. Allocca, Rozzano, Italy
14:55 - 15:05	42: OP22: Factors independently associated with fatigue in IBD: Results from the baseline dataset of the PREdiCCt study L. Derikx, Edinburgh, United Kingdom
15:05 - 15:20	43: ECCO Guidelines: Prevention and management of Opportunistic Infections T. Kucharzik, Lüneburg, Germany S. Vavricka, Zurich, Switzerland
15:20 - 15:35	Break
15:35 - 16:25	Scientific Session 8: IBD Horizons B. Verstockt, Leuven, Belgium J. Torres, Loures, Portugal
15:35 - 15:45	44: OP23: Efficacy and safety of upadacitinib as induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from phase 3 U-ACCOMPLISH study S. Vermeire, Leuven, Belgium
15:45 - 15:55	45: OP24: Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study S. Danese, Rozzano, Italy
15:55 - 16:05	46: OP25: Efficacy of filgotinib in patients with Ulcerative Colitis by line of therapy in the phase 2b/3 SELECTION trial I. Dotan, Petah Tikva, Israel

16:05 - 16:15	47: OP26: Risankizumab induces early clinical remission and response in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies S. Schreiber, Kiel, Germany
	48: OP27- WITHDRAWN
16:15 - 16:25	49: OP28: The effect of guselkumab induction therapy on early clinical outcome measures in patients with Moderately to Severely Active Crohn's Disease: Results from the phase 2 GALAXI 1 study S. Danese, Rozzano, Italy
16:25- 16:45	Break
16:45 - 17:45	Digital Oral Presentations (Sessions 6-10)
17:45- 17:55	Break
17:55 - 18:55	Industry Sponsored Satellite Symposia 4a, 4b & 4c

Saturday, July 10, 2021

Scientific programme day by day

07:15 - 08:15	Industry Sponsored Satellite Symposia 5a & 5b
08:30 - 09:55	Scientific Session 9: Basic Science: The microbiome as game changer in IBD? A. Kaser, Cambridge, United Kingdom P. Rosenstiel, Kiel, Germany
08:30 - 08:45	50: Current knowledge: What is the problem with FMT therapy? M. Joossens, Ghent, Belgium
08:45 - 08:55	51: OP29: Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome L. Bolte, Groningen, The Netherlands
08:55 - 09:05	52: OP30: Lyophilised orally administered faecal microbiota transplantation for Active Ulcerative Colitis (LOTUS study) C. Haifer, Sydney, Australia
09:05 - 09:20	53: Precision editing of the gut microbiota S. Zeissig, Dresden, Germany
09:20 - 09:30	54: OP31: RESTORE: Interim analysis of a Phase 2 study of QBECO SSI for the induction and maintenance of clinical and endoscopic remission in subjects with Moderate to Severe Crohn's Disease B. Bressler, Vancouver, Canada
09:30 - 09:40	55: OP32: Stool microbiome communities predict remission in treatment-naïve Pediatric Crohn's Disease patients C. Verburgt, Amsterdam, The Netherlands
09:40 - 09:55	56: Remote control of immune and metabolic homeostasis by the gut microbiome and its potential impact on health M. Chamailard, Lille, France
09:55 - 10:10	Break
10:10 - 11:00	Scientific Session 10.1.: CD and UC: Similar disease burden and treatment goals? Is it the organ or the disease process? I. Dotan, Petah Tikva, Israel A. Spinelli, Rozzano, Italy
10:10 - 10:25	57: Disease burden C. Le Berre, Nantes, France
10:25 - 10:35	58: OP33: Oral ritlecitinib and brepocitinib in patients with Moderate to Severe Active Ulcerative Colitis: Data from the VIBRATO umbrella study W. Sandborn, La Jolla, United States

10:35 - 10:50	59: Deep healing M. Ferrante, Leuven, Belgium
10:50 - 11:00	60: OP34: AJM300, an Oral Antagonist of $\alpha 4$-Integrin, as induction therapy for patients with moderately active Ulcerative Colitis: A Phase 3, randomized, double-blind, placebo-controlled induction study M. Watanabe, Tokyo, Japan
11:00 - 11:10	Break
11:10 - 12:00	Scientific Session 10.2.: CD and UC: Similar disease burden and treatment goals? Is it the organ or the disease process? I. Dotan, Petah Tikva, Israel A. Spinelli, Rozzano, Italy
11:10 - 11:30	61: Can we cure IBD with surgery? J. Colombel, New York, United States T. Pinkney, Birmingham, United Kingdom
11:30 - 11:40	62: OP35: Effect of maintenance ustekinumab on corticosteroid-free endoscopic and clinical outcomes in patients with Crohn's Disease - Week 48 analysis of the STARDUST trial S. Danese, Rozzano, Italy
11:40 - 11:50	63: OP36: Risankizumab therapy induces improvements in endoscopic endpoints in patients with Moderate-to-Severe Crohn's Disease: Results from the phase 3 ADVANCE and MOTIVATE studies P. Bossuyt, Bonheiden, Belgium
11:50 - 12:00	64: OP37: Rapidity of symptom improvements during filgotinib induction therapy in patients with Ulcerative Colitis: Post hoc analysis of the phase 2b/3 SELECTION study S. Danese, Rozzano, Italy
12:00 - 13:00	Break
12:10 - 12:50	Industry Sponsored Satellite Symposia LS5 & LS6
13:00 - 14:15	Scientific Session 11: Personalised medicine U. Kopylov, Tel Aviv, Israel J. Gisbert, Madrid, Spain
13:00 - 13:15	65: Stratified management for mild and severe IBD? J. Halfvarson, Örebro, Sweden
13:15 - 13:25	66: OP38: Developing a Cost-Effective Genomic Biomarker of Cancer Risk in Patients with Ulcerative Colitis using Low-Pass Whole Genome Sequencing of Unselected Endoscopic Biopsies: A Case-Control Study I. Al Bakir, London, United Kingdom
13:25 - 13:40	67: Precision medicine to prevent disease complications M. Scharl, Zurich, Switzerland

Saturday, July 10, 2021, cont.

Scientific programme day by day

13:40 - 13:50	68: OP39: The effect of phenotype and genotype on the plasma proteome in patients with Inflammatory Bowel Disease A. Bourgonje, Groningen, The Netherlands
13:50 - 14:00	69: OP40: Analysis of clinical features associated with favourable outcomes from ustekinumab treat-to-target strategy in Crohn's Disease patients in the STARDUST trial S. Danese, Rozzano, Italy
14:00 - 14:15	70: Personalised surgery in IBD C. Buskens, Amsterdam, The Netherlands
14:15 - 14:25	Break
14:25 - 15:15	Scientific Session 12: ECCO Lecture L. Peyrin-Biroulet, Vandœuvre-Lès-Nancy, France B. Siegmund, Berlin, Germany
14:25 - 14:40	71: SARS-CoV-2 vaccination completed – end of pandemic? T. Ahmad, Exeter, United Kingdom
14:40 - 15:00	72: ECCO Lecture: IBD clinical trials: Where do we go from here? W. Sandborn, La Jolla, United States
15:00 - 15:15	The ECCO Film

"IBD beyond 2020"

Thursday, February 13, 2020

Scientific programme day by day (as of January 15, 2020)
Plenary Hall, Hall D, Reed Messe Wien

11:00 - 12:00	Industry Sponsored Satellite Symposia 1a (Plenary Hall), 1b (Parallel Hall) & 1c (Lehar 1-3)
12:15 - 12:20	1: Welcome H. Tilg, Innsbruck, Austria
12:20 - 12:30	2: Opening S. Danese, Milan, Italy
12:30 - 14:00	Scientific Session 1: Hot debates in IBD W. Reinisch, Vienna, Austria N. Yassin, Birmingham, United Kingdom
12:30 - 12:50	3: Is there still a place for anti-TNF in 2020? T. Ahmad, Exeter, United Kingdom J. Lindsay, London, United Kingdom
12:50 - 13:00	4: OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study J. Colombel, New York, United States
13:00 - 13:20	5: Early Crohn's: Surgery first and early medicine later? A. Armuzzi, Rome, Italy A. D'Hooore, Leuven, Belgium
13:20 - 13:30	6: OP02: Impact of therapeutic strategies on intestinal resection rate in paediatric Inflammatory Bowel Diseases: A population-based cohort study over a 24-year period (1988-2011) D. Ley, Lille, France
13:30 - 13:40	7: OP03: Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn's Disease: Long-term follow up of the LIRIC trial T. Stevens, Amsterdam, The Netherlands
13:40 - 14:00	8: Monitoring IBD: Can we abandon endoscopy? C. Hedin, Stockholm, Sweden E. Louis, Liège, Belgium
14:00 - 14:30	Coffee break

14:30 - 16:00	<i>Scientific Session 2: When location makes the difference</i> J. Burisch, Hvidovre, Denmark F. Magro Dias, Porto, Portugal
14:30 - 14:50	<i>9: Colonic versus small bowel CD: Same mechanism – same treatment?</i> B. Siegmund, Berlin, Germany
14:50 - 15:00	<i>10: OP04: Long-term outcomes after ileocolonic resection in Crohn's Disease according to severity of early endoscopic recurrence</i> N. Hammoudi, Paris, France
15:00 - 15:20	<i>11: Proctitis – a lonely disease?</i> T. Raine, Cambridge, United Kingdom
15:20 - 15:30	<i>12: OP05: Validation of the Lémann Index in Crohn's Disease</i> B. Pariente, Lille, France
15:30 - 15:40	<i>13: OP06: Comparison between Crohn and celiac diseases small intestine transcriptomics and microbial data define similarities and divergent pathways linked to pathogenesis</i> Y. Haberman Ziv, Tel Aviv, Israel
15:40 - 16:00	<i>14: Surgery for enteric IBD – does location matter?</i> C. Buskens, Amsterdam, The Netherlands
16:00 - 17:20	<i>Scientific Session 3: Reducing the burden of IBD</i> N. Ding, Fitzroy, Australia J. Gisbert, Madrid, Spain
16:00 - 16:20	<i>15: Reducing infections with biologics and immune-modulators</i> S. Ben-Horin, Ramat Gan, Israel
16:20 - 16:40	<i>16: Reducing neoplastic complications of therapy</i> L. Beaugerie, Paris, France
16:40 - 16:50	<i>17: OP07: The epidemiology of Inflammatory Bowel Diseases among immigrants to Denmark: A population-based cohort study</i> M. Agrawal, New York, United States
16:50 - 17:00	<i>18: OP08: Inflammatory Bowel Disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden</i> J. Axelrad, New York, United States
17:00 - 17:20	<i>19: Reducing postoperative complications</i> K. Gecse, Amsterdam, The Netherlands
17:30 - 18:30	<i>Digital Oral Presentations (Sessions 1-5)</i> See pg. 14
18:45 - 19:45	<i>Industry Sponsored Satellite Symposia 2a (Plenary Hall), 2b (Parallel Hall) & 2c (Lehar 1-3)</i>

Friday, February 14, 2020

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

07:15 - 08:15	<i>Industry Sponsored Morning Satellite Symposia 3b (Parallel Hall) & 3c (Lehar 1-3)</i>
08:30 - 10:30	<i>Scientific Session 4: IBD out of the gut</i> L. de Ridder, Rotterdam, The Netherlands G. Mantzaris, Athens, Greece
08:30 - 08:50	20: Orofacial Crohn's S. Sebastian, Hull, United Kingdom
08:50 - 09:00	21: OP09: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis M. Quraishi, Birmingham, United Kingdom
09:00 - 09:10	22: OP10: IgA coating of intestinal microbiota is associated with Inflammatory Bowel Disease in twin pairs discordant for Inflammatory Bowel Disease E. Brand, Utrecht, The Netherlands
09:10 - 09:20	23: OP11: Exposure to an inflammatory mix re-induces inflammation in organoids of Ulcerative Colitis patients, independent of the inflammatory state of the tissue of origin K. Arnauts, Leuven, Belgium
09:20 - 09:40	24: Perianal disease or hidradenitis suppurativa – does it matter? W. Reinisch, Vienna, Austria H. Maier, Vienna, Austria
09:40 - 09:50	25: OP12: The incidence and disease course of Perianal Crohn's Disease – A Danish nationwide cohort study M. Wewer, Copenhagen, Denmark
09:50 - 10:00	26: OP13: Glyco-fingerprint as a relevant risk factor on colitis-associated cancer A. Dias, Porto, Portugal
10:00 - 10:10	27: OP14: Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn's Disease: A Scandinavian population-based cohort study O. Olen, Stockholm, Sweden
10:10 - 10:30	28: Managing fatigue in IBD A. Dignass, Frankfurt, Germany
10:30 - 11:00	<i>Coffee break</i>

11:00 - 12:30	<i>Scientific Session 5: Cartels in IBD – Part 1</i> I. Dotan, Petah Tikva, Israel P. Irving, London, United Kingdom
11:00 - 11:20	<i>29: IBD genetics consortium</i> S. Vermeire, Leuven, Belgium
11:20 - 11:30	<i>30: OP15: Multi-omic data integration with network analysis reveal underlying molecular mechanisms driving Crohn's Disease heterogeneity</i> B. Verstockt, Leuven, Belgium
11:30 - 11:50	<i>31: Prevention initiatives</i> J. Colombel, New York, United States
11:50 - 12:00	<i>32: OP16: Influence of early life factors on the development of intestinal microbiota of infants born to mothers with and without IBD</i> J. Guedelha Sabino, Leuven, Belgium
12:00 - 12:10	<i>33: OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD)</i> C. Dong, Saint-Mand�, France
12:10 - 12:20	<i>34: OP18: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's Disease: The SuPREMe-CD Study</i> G. Luglio, San Prisco, Italy
12:20 - 12:30	<i>35: OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017</i> C. Burgess, Edinburgh, United Kingdom
12:30 - 13:30	<i>Break / Guided Poster Session (Hall C)</i> See pg. 16
12:40 - 13:20	<i>Industry Sponsored Lunch Satellite Symposia LS1 (Plenary Hall), LS2 (Parallel Hall), LS3 (Lehar 1-3) & LS4 (Strauss 1-2)</i>

Friday, February 14, 2020, cont.

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

13:30 - 15:00	Scientific Session 6: Cartels in IBD – Part 2 F. Baert, Roeselare, Belgium U. Kopylov, Tel Aviv, Israel
13:30 - 13:50	36: Microbiome consortium J. Raes, Leuven, Belgium
13:50 - 14:00	37: OP20: The gut microbiota during biological therapy for Inflammatory Bowel Disease C. Caenepeel, Kessel, Belgium
14:00 - 14:20	38: TDM consortium K. Papamichail, Bosten, United States
14:20 - 14:30	39: OP21: Positivity thresholds of a total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service N. Kennedy, Exeter, United Kingdom
14:30 - 14:40	40: OP22: Crohn's Disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn's Disease J. Van Limbergen, Amsterdam, The Netherlands
14:40 - 15:00	41: ECCO Quality Standards of Care G. Fiorino, Rozzano, Italy
15:00 - 15:30	Coffee break
EITHER:	
15:30 - 16:10	Scientific Session 7: Milestones in clinical care (Plenary Hall, Hall D, Reed Messe Wien) J. Halfvarson, Örebro, Sweden S. Jäghult, Stockholm, Sweden
15:30 - 15:37	42: I-CARE L. Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France
15:37 - 15:47	43: OP23: Efficacy and safety of vedolizumab SC in patients with Moderately to Severely active Crohn's Disease: Results of the VISIBLE 2 study S. Vermeire, Leuven, Belgium
15:47 - 15:54	44: UR-CARE F. Baert, Roeselare, Belgium
15:54 - 16:04	45: OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's Disease and Ulcerative Colitis S. Ben-Horin, Ramat Gan, Israel
16:04 - 16:10	46: IBD Nurse Education Programme K. Kemp, Manchester, United Kingdom

16:10 - 17:10	Scientific Session 8: IBD Horizons (Penary Hall, Hall D, Reed Messe Wien) G. D'Haens, Amsterdam, The Netherlands S. Schreiber, Kiel, Germany
16:10 - 16:20	47: OP25: Biologics before surgery for IBD – Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative S. Holubar, Cleveland, United States
16:20 - 16:30	48: OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis M. Iacucci, Birmingham, United Kingdom
16:30 - 16:40	49: OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn's Disease: Final results from the Phase 2 open-label extension study M. Ferrante, Leuven, Belgium
16:40 - 16:50	50: OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores K. Gottlieb, Indianapolis, United States
16:50 - 17:00	51: OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry M. Chaparro, Madrid, Spain
17:00 - 17:10	52: OP30: The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn's Disease N. Seyed Tabib, Leuven, Belgium

Friday, February 14, 2020, cont.

Scientific programme day by day (as of January 15, 2020)

Parallel Hall, Hall C, Reed Messe Wien

OR:

15:30 - 17:10	Scientific Session 9: Basic Science: Big Data research (Parallel Hall, Hall C, Reed Messe Wien) S. Zeissig, Dresden, Germany L. Egan, Galway, Ireland
15:30 - 15:50	53: Pits and pearls of Big Data in scientific research: Computational analysis, deconvolution, machine learning and more A. Franke, Kiel, Germany
15:50 - 16:00	54: OP31: Meta-omics reveals microbiome driven proteolysis as a contributing factor to severity of Ulcerative Colitis disease activity P. Dulai, San Diego, United States
16:00 - 16:10	55: OP32: Mincle signaling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn's Disease W. Gong, Nanjing, China
16:10 - 16:30	56: Integrating multi-omics in IBD A. Kaser, Cambridge, United Kingdom
16:30 - 16:40	57: OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosa N. Maimon, Haifa, Israel
16:40 - 16:50	58: OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease R. Kalla, Edinburgh, United Kingdom
16:50 - 17:10	59: How Big Data changes medicine: Concrete examples for translating Big Data into daily clinical practice Y. Chowers, Haifa, Israel
17:25 - 18:25	Digital Oral Presentations (Sessions 6-10) See pg. 15
18:40 - 19:40	Industry Sponsored Satellite Symposia 4b (Parallel Hall), 4c (Lehar 1-3) & 4d (Strauss 1-2)

Saturday, February 15, 2020

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

08:30 - 10:20	Scientific Session 10: Multidisciplinary cases D. Turner, Jerusalem, Israel M. Ferrante, Leuven, Belgium P. Michetti, Lausanne, Switzerland Y. Panis, Clichy, France
08:30 - 08:40	60: GRADE-ing Guidelines: ECCO CD Treatment J. Torres, Loures, Portugal M. Adamina, Winterthur, Switzerland
08:40 - 08:50	61: ECCO ESPGHAN Guideline Pitch on Paediatric CD (update) F. Ruemmele, Paris, France P. Van Rheen, Groningen, The Netherlands
08:50 - 09:00	62: OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study M. Zhao, Hvidovre, Denmark
09:00 - 09:20	63: Clinical Case: Medical CD R. Panaccione, Calgary, Canada
09:20 - 09:30	64: OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease R. Giri, Brisbane, Australia
09:30 - 09:50	65: Clinical Case: Surgical CD P. Kotze, Curitiba, Brazil
09:50 - 10:00	66: OP37: Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response B. Creyns, Leuven, Belgium
10:00 - 10:20	67: Clinical Case: Paediatric CD D. Turner, Jerusalem, Israel
10:20 - 10:50	Coffee break

10:50 - 12:20	<i>Scientific Session 11: What have we got outside our box of drugs?</i> G. Doherty, Dublin, Ireland J. Panes, Barcelona, Spain
10:50 - 11:10	<i>68: The multi-refractory paediatric patients: Out of the box therapeutic treatments</i> D. Wilson, Edinburgh, United Kingdom
11:10 - 11:20	<i>69: OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn's Disease – A multicenter randomized controlled trial</i> M. Jongsma, Rotterdam, The Netherlands
11:20 - 11:40	<i>70: Drugs of the future: Update on developmental agents</i> W. Sandborn, La Jolla, United States
11:40 - 11:50	<i>71: OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epithelium</i> R. Mrsny, San Francisco, United States
11:50 - 12:00	<i>72: OP40: A core transferable microbiota in responders to faecal microbiota transplant for Ulcerative Colitis shape mucosal T-Cell immunity</i> R. Longman, New York, United States
12:00 - 12:20	<i>73: Pathology guided surgery</i> P. Borralho Nunes, Lisbon, Portugal A. Spinelli, Rozzano, Italy
12:20 - 12:50	<i>Scientific Session 12: ECCO Lecture</i> S. Danese, Milan, Italy L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France J. van der Woude, Rotterdam, The Netherlands
12:20 - 12:50	<i>74: ECCO Lecture: How organoids model human disease</i> H. Clevers, Utrecht, The Netherlands
12:50 - 13:05	<i>75: Awards and Closing remarks</i> S. Danese, Milan, Italy J. van der Woude, Rotterdam, The Netherlands
13:05 - 13:15	<i>ECCO Film</i>

"Research drives clinical care"

Thursday, March 7, 2019

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

11:00 - 12:00	Industry sponsored satellite symposia 1a & 1b & 1c See pg. 106
12:15 - 12:20	1: Welcome President of Dansk Selskab for Gastroenterologi og Hepatologi Henning Glerup, Silkeborg, Denmark
12:20 - 12:30	2: Opening Silvio Danese, Milan, Italy
12:30 - 14:00	Scientific Session 1: Silencing IBD Peter Irving, London, United Kingdom Britta Siegmund, Berlin, Germany
12:30 - 12:50	3: Can we prevent IBD? Jean-Frédéric Colombel, New York, United States
12:50 - 13:00	4: OP01: In-depth characterisation of host-genetics and gut microbiome unravels novel host-microbiome interactions in Inflammatory Bowel Disease S. Hu¹ , A. Vich Vila ¹ , R. Gacesa ¹ , V. Collij ¹ , R. Xavier ² , C. Stevens ³ , M. Daly ³ , C. Wijmenga ⁴ , H. van Dullemen ¹ , G. Dijkstra ¹ , M. Visschedijk ¹ , E. Festen ¹ , J. Fu ² , A. Kurilshikov ⁴ , A. Zhernakova ⁴ , R. Weersma ¹ ¹ Universitair Medisch Centrum Groningen, Gastroenterology & Hepatology, Groningen, Netherlands, ² Massachusetts General Hospital, Molecular Biology, Boston, United States, ³ Broad Institute, Boston, United States, ⁴ Universitair Medisch Centrum Groningen, Genetics, Groningen, Netherlands, ⁵ Universitair Medisch Centrum Groningen, Pediatrics, Groningen, Netherlands
13:00 - 13:20	5: Can we cure IBD? Arthur Kaser, Cambridge, United Kingdom
13:20 - 13:30	6: OP02: The role of PTPN2 SNP in the pathogenesis of fibrosis in Crohn's Disease C. Li , J. Kuemmerle Virginia Commonwealth University, Internal Medicine, Richmond, United States
13:30 - 13:40	7: OP03: Inhibition of autophagy exacerbates intestinal fibrosis and EMT J. Cosin-Roger^{1,2} , D. Ortiz-Masia ³ , F. Canet ¹ , A. Trescoli-Garcia ¹ , S. Calatayud ¹ , M. D. Barrachina ¹ ¹ University of Valencia, Pharmacology, Valencia, Spain, ² Hospital Dr Peset, Valencia, Spain, ³ University of Valencia, Medicine, Valencia, Spain
13:40 - 14:00	8: Are fibrotic complications reversible? Geert D'Haens, Amsterdam, The Netherlands Massimo Pinzani, London, United Kingdom
14:00 - 14:30	Coffee break

Thursday, March 7, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

14:30 - 16:00		Scientific Session 2: Complementary treatments: The good and the bad Shomron Ben-Horin, Tel Aviv, Israel Pascal Juillerat, Bern, Switzerland
14:30 - 14:50		9: The crazy stuff – what your patients are taking and why? Fernando Gomollón García, Zaragoza, Spain
14:50 - 15:00		10: OP04: Turning sweet in Inflammatory Bowel Disease: Glycans as novel immunomodulators of T cell-mediated immune response A. Dias ¹ , M. Pereira ¹ , A. Correia ¹ , I. Alves ¹ , V. Pinto ¹ , L. Azevedo ² , L. Maia ³ , R. Marcos-Pinto ³ , M. Vilanova ¹ , P. Lago ³ , S. Pinho¹ ¹ Institute for Research and Innovation in Health (i3S), Immunology, Cancer & GlycoMedicine, Porto, Portugal, ² Medical Faculty, Department of Community Medicine, Information and Health Decision Sciences, Porto, Portugal, ³ Porto Centre Hospital, Gastroenterology, Porto, Portugal
15:00 - 15:20		11: ECCO Topical Review on complementary medicine Joana Torres, Lisbon, Portugal Stephan Vavricka, Zurich, Switzerland
15:20 - 15:30		12: OP05: Crohn's Disease exclusion diet is equally effective but better tolerated than exclusive enteral nutrition for induction of remission in Mild to Moderate Active Paediatric Crohn's Disease: A prospective randomised controlled trial J. Van Limbergen ^{1,2} , E. Wine ³ , A. Assa ⁴ , R. Sigall Boneh ⁵ , R. Shaoul ⁶ , M. Kori ⁷ , S. Cohen ⁸ , S. Peleg ⁹ , H. Shamaly ¹⁰ , A. On ¹¹ , P. Milman ¹² , L. Abramás ⁵ , T. Ziv Baran ¹³ , S. Grant ¹⁴ , A. Levine^{5,13} ¹ Dalhousie University, Halifax, Canada, ² IWK Center, Halifax, Canada, ³ University Alberta, Edmonton, Canada, ⁴ Schneider Medical Center, Petach Tikva, Israel, ⁵ Wolfson Medical Center, Holon, Israel, ⁶ Meyer Hospital, Haifa, Israel, ⁷ Kaplan Hospital, Rehovot, Israel, ⁸ Dana childrens Hospital, Tel Aviv, Israel, ⁹ HaEmek Hospital, Afula, Israel, ¹⁰ French Hospital, Nazareth, Israel, ¹¹ Poriah Hospital, Tiberias, Israel, ¹² Hadassah Hospital, Jerusalem, Israel, ¹³ Tel Aviv University, Tel Aviv, Israel, ¹⁴ Mount Saint Vincent University, Halifax, Canada
15:30 - 15:40		13: OP06: Gut-brain-axis revisited: Shedding light on the mucosa associated microbial composition in IBD patients with psychological distress, anxiety and depression F. Humbel ¹ , P. Juillerat ² , M. Scharl ¹ , B. Misselwitz ² , P. Schreiner ¹ , A. Macpherson ² , G. Rogler ¹ , R. von Känel ³ , B. Yilmaz ^{4,5} , L. Biedermann^{1,5} ¹ University Hospital Zurich, Department of Gastroenterology & Hepatology, Zurich, Switzerland, ² Bern University Hospital, Department of Visceral Surgery and Medicine, Bern, Switzerland, ³ University Hospital Zurich, Consultation-Liaison Psychiatry and Psychosomatic Medicine, Zurich, Switzerland, ⁴ University of Bern, Maurice Müller Laboratories, Bern, Switzerland, ⁵ *Equal, Contribution, Switzerland
15:40 - 16:00		14: Psychological support in IBD Yoram Inspector, London, United Kingdom

Thursday, March 7, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

16:00 - 17:20		Scientific Session 3: Precision medicine: Lessons to learn and paths to the future Axel Dignass, Frankfurt am Main, Germany Jesús Rivera-Nieves, San Diego, United States
	16:00 - 16:20	15: What is system biology? Dermot McGovern, Los Angeles, United States
	16:20 - 16:40	16: Multi-omics profiling of IBD Jonas Halfvarson, Örebro, Sweden
	16:40 - 16:50	17: OP07: Analysing intestinal organoids in a multi-omics, systems biology framework to investigate functional processes affected in Crohn's Disease due to autophagy impairment L. Gul ¹ , E. Jones ^{1,2} , Z. Matthews ³ , P. Sudhakar ^{1,2,4} , A. Treveijl ^{1,2} , D. Divekar ^{2,3} , J. Buck ³ , M. Jefferson ³ , S. Armstrong ⁵ , A. Watson ^{2,3} , S. Carding ^{2,3} , U. Mayer ⁶ , P. Powell ³ , I. Hautefort ¹ , T. Wileman ^{2,3} , T. Korcsmaros^{1,2} ¹ Earlham Institute, Norwich, United Kingdom, ² Quadram Institute, Norwich, United Kingdom, ³ Norwich Medical School, University of East Anglia, Norwich, United Kingdom, ⁴ KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ⁵ University of Liverpool, National Institute of Health Research, Liverpool, United Kingdom, ⁶ School of Biological Sciences, University of East Anglia, Norwich, United Kingdom
	16:50 - 17:00	18: OP08: Long-term efficacy and pharmacodynamics of the anti-Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM-1) monoclonal antibody SHP647 in Crohn's Disease: The OPERA II study G. D'Haens¹ , W. Reinisch ² , S. D. Lee ³ , D. Tarabar ⁴ , E. Louis ⁵ , M. Klopocka ⁶ , J. Klaus ⁷ , S. Schreiber ⁸ , D. I. Park ⁹ , X. Hébuterne ¹⁰ , K. J. Gorelick ¹¹ , S. W. Martin ¹² , A. Banerjee ¹³ , P. Nagy ¹³ , Y. Wang ¹⁴ , F. Cataldi ¹⁴ , W. J. Sandborn ¹⁵ ¹ Academic Medical Centre, Amsterdam, Netherlands, ² Medical University of Vienna, Vienna, Austria, ³ University of Washington, Seattle, WA, United States, ⁴ Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, ⁵ University Hospital of Liège, Liège, Belgium, ⁶ Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, ⁷ University Hospital Ulm, Ulm, Germany, ⁸ University Hospital Schleswig-Holstein, Christian-Albrechts-University of Kiel, Kiel, Germany, ⁹ Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, ¹⁰ University of Nice Sophia Antipolis, Hospital l'Archet, Nice, France, ¹¹ Zymo Consulting Group, Newtown Square, PA, United States, ¹² Pfizer, Cambridge, MA, United States, ¹³ Shire, Zug, Switzerland, ¹⁴ Shire, Lexington, MA, United States, ¹⁵ University of California San Diego, La Jolla, CA, United States
	17:00 - 17:20	19: Stratifying by disease biology to choose the right drug for the right patient Charlie Lees, Edinburgh, United Kingdom
17:30 - 18:30		Digital Oral Presentations (Sessions 1-5) See pg. 41
18:45 - 19:45		Industry sponsored satellite symposia 2a & 2b & 2c See pg. 108

Friday, March 8, 2019

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

07:15 - 08:15	Industry sponsored satellite symposia 3b & 3c See pg. 109
08:30 - 10:30	Scientific Session 4: Best practice in UC Andre D'Hoore, Leuven, Belgium Henit Yanai, Petah Tikva, Israel
08:30 - 08:50	20: When do you start a biologic? Simon Travis, Oxford, United Kingdom
08:50 - 09:00	21: OP09: Histological remission and mucosal healing in a randomised, placebo-controlled, phase 2 study of etrasimod in patients with Moderately to Severely Active Ulcerative Colitis L. Peyrin-Biroulet¹, J. Panés², M. Chiorean³, J. Zhang⁴, S. Vermeire⁵, V. Jairath⁶, A. Yarur⁷, C. Cabell⁴, S. Naik⁴, W. J. Sandborn⁸ ¹ University Hospital of Nancy, Vandœuvre-lès-Nancy, France, ² Hospital Clinic of Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ³ Virginia Mason Medical Center, Seattle, United States, ⁴ Arena Pharmaceuticals, Inc., San Diego, United States, ⁵ University Hospitals Leuven, Leuven, Flanders, Belgium, ⁶ Western University, London, Ontario, Canada, ⁷ Medical College of Wisconsin, Milwaukee, United States, ⁸ University of California San Diego, La Jolla, United States
09:00 - 09:10	22: OP10: Systems genomics of Ulcerative Colitis: Combining GWAS and signalling networks for patient stratification and individualised drug targeting in Ulcerative Colitis J. Brooks^{1,2}, D. Modos³, P. Sudhakar^{4,5}, D. Fazekas^{4,6}, A. Zoufir³, A. Watson^{1,7}, M. Tremelling¹, B. Verstockt⁸, S. Vermeire⁸, A. Bender³, S. Carding^{2,7}, T. Korcsmaros^{2,4} ¹ Norfolk and Norwich University Hospital, Gastroenterology, Norwich, United Kingdom, ² The Quadram Institute Bioscience, Gut Microbes and Health Programs, Norwich, United Kingdom, ³ Centre for Molecular Science Informatics, Department of Chemistry University of Cambridge, Cambridge, United Kingdom, ⁴ Earlham Institute, Norwich Research Park, Norwich, United Kingdom, ⁵ KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ⁶ Eötvös Loránd, Department of Genetics, Budapest, Hungary, ⁷ University of East Anglia, Norwich Medical School, Norwich, United Kingdom, ⁸ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
09:10 - 09:20	23: OP11: Organoids derived from inflamed intestinal biopsies of patients with Ulcerative Colitis lose their inflammatory phenotype during ex vivo culture K. Arnauts^{1,2}, B. Verstockt^{1,3}, M. Vancamelbeke¹, S. Vermeire^{1,3}, C. Verfaillie², M. Ferrante^{1,3} ¹ KU Leuven, Department of Chronic Diseases, Metabolism & Ageing (CHROMETA), Leuven, Belgium, ² KU Leuven, Department of Development and Regeneration, Leuven, Belgium, ³ KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium
09:20 - 09:40	24: Where is the exit? Marc Ferrante, Leuven, Belgium

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

09:40 - 09:50	25: OP12: Targeting inflammation in Ulcerative Colitis by inhibiting glucose uptake R. Gropp¹, H. Jodeleit¹, J. Caesar¹, C. Villarroel Aguilera¹, F. Beigel^{2,3}, S. Breitenreicher³, J. Stallhofer³, M. Siebeck¹ ¹Hospital of the Ludwig Maximilian University, General-, Visceral-, Vascular- and Transplantation Surgery, Munich, Germany, ²Hospital of the Ludwig Maximilian University, Laboratory Medicine, Munich, Germany, ³Hospital of the Ludwig Maximilian University, Medicine II, Munich, Germany
09:50 - 10:00	26: OP13: Molecular response to ustekinumab in Moderate to Severe Ulcerative Colitis by serum protein and biopsy gene expression analysis: Results from the UNIFI phase 3 induction study K. Li¹, F. Yang, K. Hayden, D. Strawn, E. Wadman, S. Bhagat, C. Marano, J. R. Friedman Janssen Research & Development, LLC, Spring House, United States
10:00 - 10:10	27: OP14: Improved endoscopic outcomes and mucosal healing of upadacitinib as an induction therapy in adults with Moderately to Severely Active Ulcerative Colitis: Data from the U-ACHIEVE study W. J. Sandborn¹, S. Schreiber², S. D. Lee³, J. O. Lindsay⁴, X. Hebuterne⁵, W. Zhou⁶, F. Cataldi⁶, A. P. Lacerda⁶, B. Huang⁶, W. Xie⁶, E. V. Loftus Jr⁷ ¹University of California San Diego, La Jolla, United States, ²University Hospital Schleswig-Holstein, Kiel, Germany, ³University of Washington, Seattle, United States, ⁴Centre for Immunobiology, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom, ⁵Service de Gastroentérologie et Nutrition Clinique, Nice, France; Université de Nice-Sophia-Antipolis, Nice, France, ⁶AbbVie Inc., North Chicago, United States, ⁷Mayo Clinic, Rochester, United States
10:10 - 10:30	28: Precision surgery in UC Yves Panis, Clichy, France
10:30 - 11:00 Coffee break	

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

Scientific Session 5: IBD around the world	
11:00 - 12:30	Toshifumi Hibi, Tokyo, Japan Giovanni Maconi, Milan, Italy
11:00 - 11:20	29: Vaccination and travelling with IBD: An update Jean-François Rahier, Yvoir, Belgium
11:20 - 11:30	30: OP15: Cost-analysis in a prospective European population-based inception cohort. Is there a cost-saving effect of biological therapy? J. Burisch¹ , H. Vardi ² , D. Schwartz ³ , Z. Krznaric ⁴ , P. L. Lakatos ⁵ , M. Fumery ⁶ , L. Kupcinskas ⁷ , F. Magro ⁸ , E. Belousova ⁹ , P. Oksanen ¹⁰ , N. Arebi ¹¹ , E. Langholz ¹² , S. Turcan ¹³ , R. D'Inca ¹⁴ , V. Hernandez ¹⁵ , D. Valpiani ¹⁶ , Z. Vegh ⁵ , M. Giannotta ¹⁷ , K. H. Katsanos ¹⁸ , D. Duricova ¹⁹ , K. R. Nielsen ²⁰ , H. A. L. Kievit ²¹ , P. Ellul ²² , R. Salupere ²³ , A. Goldis ²⁴ , I. Kaimakliotis ²⁵ , N. Pedersen ²⁶ , V. Andersen ²⁷ , J. Halfvarson ²⁸ , S. Sebastian ²⁹ , J. F. Dahlerup ³⁰ , P. Munkholm ¹ , S. Odes ³ , Epi-IBD ¹ North Zealand University Hospital, Frederikssund, Denmark, ² Ben Gurion University of the Negev, Beer Sheva, Israel, ³ Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel, ⁴ University Hospital Center Zagreb, Zagreb, Croatia, ⁵ Semmelweis University, Budapest, Hungary, ⁶ Amiens University and Hospital, Amiens, France, ⁷ Lithuanian University of Health Sciences, Kaunas, Lithuania, ⁸ Hospital de São João, Porto, Portugal, ⁹ Moscow Regional Research Clinical Institute, Moscow, Russian Federation, ¹⁰ Tampere University Hospital, Tampere, Finland, ¹¹ Imperial College London, London, United Kingdom, ¹² Herlev University Hospital, Herlev, Denmark, ¹³ State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Moldova, Republic of, ¹⁴ Azienda Ospedaliera di Padova, Padova, Italy, ¹⁵ Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ¹⁶ Morgagni Hospital, Forlì, Italy, ¹⁷ Careggi Regional Referral Center for Inflammatory Bowel Disease, Florence, Italy, ¹⁸ University Hospital, Ioannina, Greece, ¹⁹ Charles University, Prague, Czech Republic, ²⁰ National Hospital of the Faroe Islands, Torshavn, Faroe Islands, ²¹ Herning Hospital, Herning, Denmark, ²² Mater Dei Hospital, Msida, Malta, ²³ Tartu University Hospital, Tartu, Estonia, ²⁴ University of Medicine 'Victor Babes', Timisoara, Romania, ²⁵ American Gastroenterology Center, Nicosia, Cyprus, ²⁶ Slagelse Hospital, Department of medicine, Denmark, ²⁷ Regional Hospital of Viborg, Viborg, Denmark, ²⁸ Örebro University, Örebro, Sweden, ²⁹ Hull and East Yorkshire NHS Trust, Hull, United Kingdom, ³⁰ Aarhus University Hospital, Aarhus, Denmark
11:30 - 11:50	31: Management of IBD outside of Europe: The example of India Rupa Banerjee, Hyderabad, India
11:50 - 12:00	32: OP16: A randomised, multicentre, double-blind, placebo-controlled study of a targeted release oral cyclosporine formulation in the treatment of Mild to Moderate Ulcerative Colitis: Efficacy results S. Bloom¹ , T. Iqbal ² , C. Nwokolo ³ , M. Smith ⁴ , D. O'Donoghue ⁵ , J. Hall ⁶ , B. Dzyngel ⁶ ¹ University College London Hospitals, London, United Kingdom, ² Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom, ³ University Hospital Coventry & Warwickshire, Coventry, United Kingdom, ⁴ Shrewsbury and Telford Hospital, Shrewsbury, United Kingdom, ⁵ St Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, ⁶ Sublimity Therapeutics, Solana Beach, United States



Y-ECCO
Abstract Award

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

12:00 - 12:10	33: OP17: A molecular measure of inflammation in IBD patients based on transcriptional profiles from 2495 intestinal biopsies R. Huang ¹ , H. Irizar ² , R. Kosoy ³ , W.-M. Song ³ , A. Dinarzo ³ , K. Hao ³ , J. Rogers ⁴ , A. Atreja ⁵ , M. Mahajan ³ , A. Stojmirovic ⁵ , J. Perrigoue ⁵ , C. Brodmerkel ⁵ , S. Plevy ⁵ , J. Friedman ⁵ , J.-F. Colombel ⁴ , M. Dubinsky ⁴ , B. Sands ⁴ , E. Schadt ³ , A. Kasarskis ⁵ , B. Losic ³ , C. Argmann ³ , M. Suarez-Farinas^{1,3} ¹ Icahn School at Mount Sinai, Department of Population, Health Science and Policy, New York, United States, ² University College of London, London, United Kingdom, ³ Icahn School at Mount Sinai, Department of Genetics and Genomic Science, New York, United States, ⁴ Icahn School at Mount Sinai, Department of Medicine, Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York City, United States, ⁵ Janssen Research & Development, Janssen Biotech, Johnson & Johnson, Spring House, United States
12:10 - 12:30	34: East meets West: Epidemiology of IBD Johan Burisch, Copenhagen, Denmark Siew Ng, Hong Kong, China
12:30 - 13:30	Break / Guided Poster Session (Hall B) See pg. 65
12:40 - 13:20	Educational Lunchtime Satellite Symposia LS1 & LS2 & LS3 & LS4 See pg. 110
13:30 - 14:40	Scientific Session 6: New ways of doing endoscopy and imaging in IBD Hankje Escher, Rotterdam, The Netherlands Christian Maaser, Lüneburg, Germany
13:30 - 13:50	35: Assessing bowel damage in CD from adult to childhood Anne Griffiths, Toronto, Canada
13:50 - 14:00	36: OP18: Proactive adalimumab trough measurements increase corticosteroid-free clinical remission in paediatric patients with Crohn's Disease: The paediatric Crohn's Disease adalimumab level-based optimisation treatment (PAILOT) trial A. Assa¹ , M. Matar ² , D. Turner ³ , E. Broide ⁴ , B. Weiss ⁵ , O. Ledder ⁶ , A. Guz Mark ⁷ , F. Rinawi ² , S. Cohen ⁷ , C. Topf Olivestone ⁸ , R. Shaoul ⁹ , B. Yerushalmi ¹⁰ , R. Shamir ² ¹ Schneider Children's Hospital, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, ² Schneider Children's medical Center, Gastroenterology, Nutrition and Liver Diseases, Petach Tikva, Israel, ³ Shaare Zedek Medical Center, Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, ⁴ Assaf Harofeh, Pediatric Gastroenterology, Zerifin, Israel, ⁵ Sheba Medical Center, Pediatric Gastroenterology, Ramat Gan, Israel, ⁶ Shaare Zedek Medical Center, Pediatric Gastroenterology, Nutrition and Liver Diseases, Jerusalem, Israel, ⁷ Tel Aviv Medical Center, Pediatric Gastroenterology, Tel-Aviv, Israel, ⁸ Kaplan Medical Center, Pediatric Gastroenterology, Rehovot, Israel, ⁹ Rambam Medical Center, Pediatric Gastroenterology, Haifa, Israel, ¹⁰ Soroka Medical Center, Pediatric Gastroenterology, Beer Sheva, Israel
14:00 - 14:20	37: Best practice in screening for dysplasia Marietta Iacucci, Birmingham, United Kingdom



IIS
Abstract Award

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center (Session 7 & 8)

14:20 - 14:30	38: OP19: Corticosteroid response rectal gene signature and associated microbial variation in treatment naïve Ulcerative Colitis Y. Haberman^{1,2} , R. Karns ² , P. Dexheimer ² , M. Schirmer ³ , T. Braun ¹ , M. Collins ² , A. Mo ⁴ , M. Rosen ² , N. Gotman ⁵ , PROTECT Study group, S. Kugathasan ⁶ , T. D. Walters ⁷ , G. Gibson ⁴ , S. Davis Thomas ⁵ , C. Huttenhower ⁸ , R. J. Xavier ⁹ , J. S. Hyams ¹⁰ , L. A. Denson ² ¹ Sheba Medical Center, Tel Hashomer, Israel, ² Cincinnati Children Hospital Medical Center, Cincinnati, United States, ³ Broad Institute of MIT and Harvard University, Cambridge, United States, ⁴ Georgia Institute of Technology, Atlanta, United States, ⁵ University of North Carolina, Chapel Hill, United States, ⁶ Emory University, Atlanta, United States, ⁷ Hospital For Sick Children, Toronto, Canada, ⁸ Harvard School of Public Health, Boston, United States, ⁹ Broad Institute of MIT and Harvard University, Boston, United States, ¹⁰ Connecticut Children's Medical Center, Hartford, United States
14:30 - 14:40	39: OP20: Mucosal microRNA profiles predict response to autologous stem-cell transplantation in Crohn's Disease A. Lewis¹ , R. Jeffrey ¹ , T. Kumagai ¹ , C. J. Hawkey ² , M. M. Clark ² , M. Allez ³ , J. Satsangi ⁴ , G. Rogler ⁵ , A. Silver ¹ , J. O. Lindsay ⁶ ¹ Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Genomics and Child Health, London, United Kingdom, ² Centre for Digestive Diseases, Queens Medical Centre, Nottingham, United Kingdom, ³ Department of Gastroenterology, Hôpital Saint Louis, APHP, INSERM UMRS 1160, Paris Diderot, Sorbonne Paris-Cité University, Paris, France, ⁴ Translational Gastroenterology Unit, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom, ⁵ Department of Gastroenterology and Hepatology, University Hospital, Zurich, Switzerland, ⁶ Blizard Institute, Barts and The London School of Medicine & Dentistry, Centre for Immunobiology, London, United Kingdom
14:40 - 15:10 Coffee break	
EITHER:	
Scientific Session 7: ECCO Fellowships and Grants (Plenary Hall, Hall A, Bella Center) Edouard Louis, Liège, Belgium Janneke van der Woude, Rotterdam, The Netherlands	
15:10 - 15:55	
15:10 - 15:17	40: Outcomes from the ECCO Pioneer Award 2017: Faecal transplantation using a novel conditioning method for donor and recipient in mild to moderate treatment refractory colitis in Inflammatory Bowel Disease Arie Levine, Tel Aviv, Israel
15:17 - 15:24	41: Outcomes from the ECCO Fellowship 2018: Role of TNF-inducible gene-6 (TSG-6) in fistulising Crohn's Disease Sudharshan Elangovan, Thuwal, Saudi Arabia
15:24 - 15:31	42: Outcomes from the ECCO Fellowship 2018: Monocyte-derived macrophages as crucial players in the resolution of inflammation and tissue repair in Inflammatory Bowel Disease Sales Ibiza, Lisbon, Portugal
15:31 - 15:38	43: Outcomes from the ECCO-IOIBD Fellowship 2017: Precision medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States
15:38 - 15:45	44: Outcomes from the ECCO-IOIBD Fellowship 2018: Deciphering the gut-specific B cell response in Inflammatory Bowel Disease Mathieu Uzzan, Clichy, France
15:45 - 15:55	45: Announcement of ECCO Fellowships & Grants 2019

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center (Session 7 & 8)

Scientific Session 8: IBD Horizons (Plenary Hall, Hall A, Bella Center) Dominik Bettenworth, Münster, Germany Janneke N. Samsom, Rotterdam, The Netherlands	
15:55 - 16:55	
15:55 - 16:05	46: OP21: ABX464 is safe and efficacious in a proof of concept study in Ulcerative Colitis patients S. Vermeire ¹ , X. Hébuterne ² , P. Napora ³ , M. Wisniewska-Jarosinska ⁴ , G. Kiss ⁵ , A. Bourreille ⁶ , Z. Przemyslaw ⁷ , J. Nitcheu ⁸ , P. Gineste ⁸ , J.-M. Steens⁸ , H. Ehrlich ⁸ ¹ University Hospitals Leuven, Leuven, Belgium, ² CHU Nice Hopital Archet ² , Nice, France, ³ Piotr Napora Centrum Badań Klinicznych Lekarze Sp.p., Wrocław, Poland, ⁴ SANTA FAMILIA, Centrum Badań, Profilaktyki i Leczenia, Łódź, Poland, ⁵ Vasútégyszegügyi Nonprofit Közhazsnú Kft, Debrecen, Hungary, ⁶ CHU Nantes Hotel Dieu, Nantes, France, ⁷ KO-Med, Lublin, Poland, ⁸ Abivax, Paris, France
16:05 - 16:15	47: OP22: Mesenchymal stromal cell-derived exosomes stimulate epithelial regeneration in vitro and reduce experimental Colitis M. Barnhoorn¹ , L. Plug ¹ , E. Muller - de Jonge ¹ , E. Bos ² , A. van der Meulen-de Jong ¹ , H. Verspaget ¹ , L. Hawinkels ¹ ¹ Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands, ² Leiden University Medical Center, Cell and Chemical Biology, Leiden, Netherlands
16:15 - 16:25	48: OP23: CKD-506, a novel histone deacetylase (HDAC) 6 inhibitor, ameliorates Colitis in various animal models J. Shin¹ , N. Ha ¹ , D. Bae ¹ , D.-h. Suh ¹ , J.-Y. Baek ¹ , J. H. Jun ¹ , Y. J. Lee ¹ , Y. I. Choi ¹ , K. H. Ryu ¹ , G. S. Youn ² , J. Park ² , S.-M. Lee ³ , S.-K. Seo ³ , J. W. Lee ⁴ , J. S. Kim ^{4,5} ¹ Research Institute, Chong Kun Dang Pharmaceutical Corporation, Yongin, South Korea, ² Hallym University, Department of Biomedical Science, Chuncheon, South Korea, ³ Inje University College of Medicine, Department of Microbiology and Immunology, Gimhae, South Korea, ⁴ Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea, ⁵ Seoul National University Hospital Healthcare System Gangnam Center, Department of Internal Medicine and Healthcare Research Institute, Seoul, South Korea
16:25 - 16:35	49: OP24: Effectiveness and safety of ustekinumab 90 mg every four weeks in Crohn's Disease M. Fumery¹ , L. Peyrin-Biroulet ² , S. Nancey ³ , R. Altwegg ⁴ , P. Veyrard ⁵ , G. Bouguen ⁶ , S. Vienneot ⁷ , F. Poullenot ⁸ , J. Filippi ⁹ , A. Buisson ¹⁰ , A. Bozon ¹¹ , C. Gilletta ¹² , F. Brazier ¹³ , L. Pouillon ² , B. Flourie ¹⁴ , L. Boivineau ⁴ , L. Siproudhis ⁶ , D. Laharie ⁸ , X. Roblin ¹⁵ , X. Treton ¹¹ ¹ Amiens University Hospital, Gastroenterology, Amiens, France, ² Nancy University Hospital, Gastroenterology, Nancy, France, ³ Lyon University Hospital, Lyon, France, ⁴ Montpellier University Hospital, Gastroenterology, Montpellier, France, ⁵ Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France, ⁶ Rennes University Hospital, Gastroenterology, Rennes, France, ⁷ Caen University Hospital, Gastroenterology, Caen, France, ⁸ Bordeaux University Hospital, Gastroenterology, Bordeaux, France, ⁹ Nice University Hospital, Gastroenterology, Nice, France, ¹⁰ Clermont-Ferrand, Gastroenterology, Clermont Ferrand, France, ¹¹ Hopital Beaujon, Gastroenterology, Clichy, France, ¹² Toulouse University Hospital, Gastroenterology, Toulouse, France, ¹³ Amiens University Hospital, Gastroenterology, Amiens, France, ¹⁴ Lyon University Hospital, Gastroenterology, Lyon, France, ¹⁵ Saint Etienne University Hospital, Gastroenterology, Saint-Etienne, France

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center (Session 7 & 8)



IIS
Abstract Award

16:35 - 16:45	50: OP25: Targeting endoscopic outcomes through combined pharmacokinetic and pharmacodynamic monitoring of infliximab therapy in patients with Crohn's Disease E. Dreesen¹, F. Baert², D. Laharie³, P. Bossuyt⁴, Y. Bouhnik⁵, A. Buissone⁶, G. Lambrecht⁷, E. Louis⁸, B. Oldenburg⁹, B. Pariente¹⁰, M. Pierik¹¹, C. J. van der Woude¹², G. D'Haens¹³, S. Vermeire^{14,15}, A. Gils¹ ¹University of Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²AZ Delta, Department of Gastroenterology, Roeselare, Belgium, ³Hôpital Haut-Lévêque, Service d'Hépatogastroentérologie et Oncologie Digestive, Bordeaux, France, ⁴Imelda General Hospital, IBD Clinic, Bonheiden, Belgium, ⁵Beaujon Hospital, APHP, Paris Diderot University, Department of Gastroenterology, Clichy, France, ⁶Estaing University Hospital, Department of Gastroenterology, Clermont-Ferrand, France, ⁷AZ Dambiaan, Department of Gastroenterology, Oostende, Belgium, ⁸Liège University Hospital, Department of Gastroenterology, Liège, Belgium, ⁹University Medical Centre, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ¹⁰Huriez Hospital, Lille ² University, Department of Gastroenterology and Hepatology, Lille, France, ¹¹University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ¹²Erasmus Medical Centre, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ¹³Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ¹⁴University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ¹⁵University of Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium
16:45 - 16:55	51: OP26: Long-term safety of vedolizumab in Ulcerative Colitis and Crohn's Disease: Final results from the GEMINI LTS study S. Vermeire¹, J.-F. Colombel², B. G. Feagan³, W. J. Sandborn⁴, B. E. Sands², S. Danese⁵, G. D'Haens⁶, R. Panaccione⁷, D. T. Rubin⁸, I. Shafraan⁹, A. Parfionovas¹⁰, R. Rogers¹⁰, R. A. Lirio¹⁰, E. V. Loftus, Jr¹¹ ¹University Hospitals Leuven, Leuven, Belgium, ²Icahn School of Medicine at Mount Sinai, New York, United States, ³Western University, London, Canada, ⁴University of California San Diego, La Jolla, United States, ⁵Humanitas University, Milan, Italy, ⁶Academic Medical Centre, Amsterdam, Netherlands, ⁷University of Calgary, Calgary, Canada, ⁸University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States, ⁹Shafraan Gastroenterology Research Center, Winter Park, United States, ¹⁰Takeda Pharmaceuticals, Cambridge, United States, ¹¹Mayo Clinic College of Medicine, Rochester, United States

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

C1-M4-5, Hall C, Bella Center (Session 9)

OR:

15:10 - 16:50	Scientific Session 9: Basic Science: Immune cells and microbes: A happy marriage? (C1-M4-5, Hall C, Bella Center) Tim Raine, Cambridge, United Kingdom Raja Atreya, Erlangen, Germany	
	15:10 - 15:30	52: Metabolic profiling – the new player in microbiome research Stefan Schreiber, Kiel, Germany
	15:30 - 15:40	53: OP27: High-dimensional mass cytometry reveals the immune cell landscape in Inflammatory Bowel Disease V. van Unen¹, N. Li¹, T. Abdelaal^{2,3}, Y. Kooy-Winkelaar¹, L. Ouboter^{1,4}, G. Beyrend¹, T. Höllt^{5,6}, L. Mearin⁷, A. Witte⁸, H. Escher⁹, B. Lelieveldt^{10,11}, A. van der Meulen - de Jong¹, F. Koning¹ ¹Leiden University Medical Center, Department of Immunohematology and Blood Transfusion, Leiden, Netherlands, ²Delft University of Technology, Delft Bioinformatics Lab, Delft, Netherlands, ³Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁴Leiden University Medical Center, Department of Gastroenterology, Leiden, Netherlands, ⁵Leiden University Medical Center, Leiden Computational Biology Center, Leiden, Netherlands, ⁶Delft University of Technology, Computer Graphics and Visualization, Delft, Netherlands, ⁷Leiden University Medical Center, Department of Paediatrics, Leiden, Netherlands, ⁸Alrijne Hospital, Department of Gastroenterology, Leiderdorp, Netherlands, ⁹Erasmus University Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ¹⁰Delft University of Technology, Pattern Recognition and Bioinformatics Group, Delft, Netherlands, ¹¹Leiden University Medical Center, Department of LKEB Radiology, Leiden, Netherlands
	15:40 - 15:50	54: OP28: Host-microbial crosstalk in the pathogenesis of inflammation and cancer in primary sclerosing cholangitis M. Neyazi¹, N. Ilott², Oxford IBD Cohort study investigators¹, S. Travis¹, C. Arancibia¹, F. Powrie², A. Geremia¹ ¹University of Oxford, Translational Gastroenterology Unit, Oxford, United Kingdom, ²University of Oxford, Kennedy Institute of Rheumatology, Oxford, United Kingdom
	15:50 - 16:10	55: Using mucosal immune pathways to predict disease outcome Ahmed Hegazy, Berlin, Germany
 Y-ECCO Abstract Award	16:10 - 16:20	56: OP29: ST2+/IL-33 responsive cells promote tumorigenesis in colitis-associated colorectal cancer L. R. Lopetuso¹, C. De Salvo², L. Di Martino², W. Goodman², F. Scaldaferrì³, A. Armuzzi³, A. Gasbarrini¹, T. T. Pizarro² ¹Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolic Sciences Department, Roma, Italy, ²Case Western Reserve University, Cleveland, United States, ³Fondazione Policlinico Universitario A. Gemelli IRCCS – Università Cattolica del Sacro Cuore, UOC Internal Medicine, Gastroenterology and Hepatology Gastroenterological and Oncological Area, Gastroenterological and Endocrino-Metabolic Sciences Department, Roma, Italy

OP = Oral presentation – Best abstracts

Friday, March 8, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

C1-M4-5, Hall C, Bella Center (Session 9)

16:20 - 16:30	57: OP30: Serum proteomic profiling predicts and diagnoses pouchitis in Ulcerative Colitis patients undergoing ileal pouch-anal anastomosis K. Machiels¹ , M. Ferrante ^{1,2} , N. Davani ¹ , A. Wolthuis ³ , A. D'Hoore ³ , S. Vermeire ^{1,2} ¹ KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ² University Hospitals Leuven, Department of gastroenterology and hepatology, Leuven, Belgium, ³ University Hospitals Leuven, Abdominal surgery, Leuven, Belgium
16:30 - 16:50	58: Resolution pathways: Next frontier to control intestinal inflammation Silvia D'Alessio, Milan, Italy
17:05 - 18:05	Digital Oral Presentations (Sessions 6 - 10) See pg. 41
18:35-19:35	Industry sponsored satellite symposia 4a & 4c & 4d See pg. 112

Saturday, March 9, 2019

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

 Y-ECCO Abstract Award	08:30 - 10:20		Scientific Session 10: The cycle of IBD life in clinical practice Glen Doherty, Dublin, Ireland Richard Russell, Glasgow, United Kingdom
	08:30 - 08:50		59: Challenges in managing the elderly Guillaume Savoye, Rouen, France
	08:50 - 09:00		60: OP31: TP53 mutation in human colonic organoids acquires resistance to in vitro long-term inflammation K. Tsuchiya , S. Watanabe, T. Shirasaki, R. Nishimura, N. Katsukura, S. Hibiya, R. Okamoto, T. Nakamura, M. Watanabe Tokyo Medical and Dental University and Tokyo Medical and Dental University, Tokyo, Japan
	09:00 - 09:10		61: OP32: A novel mechanism of colonic epithelial-T cell cross-talk is dysregulated in IBD R. J. Dart ^{1,2,3} , P. Vantourout ^{1,2} , P. M. Irving ³ , A. Hayday ^{1,2} ¹ King's College London, Peter Gorer Dept of Immunobiology, London, United Kingdom, ² Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom, ³ Guy's and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom
	09:10 - 09:30		62: The reproductive phase: Practical recommendations Ailsa Hart, London, United Kingdom
	09:30 - 09:40		63: OP33: Late-breaking Abstract
	09:40 - 09:50		64: OP34: Late-breaking abstract

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

09:50 - 10:00	65: OP35: Endoscopic and deep remission at 1 year prevents disease progression in early Crohn's Disease: Long-term data from CALM C. Yzet¹, R. Ungaro², P. Bossuyt³, F. Baert⁴, T. Vanasek⁵, G. D'Haens⁶, V. Joustra⁶, R. Panaccione⁷, G. Novacek⁸, A. Armuzzi⁹, O. Golovchenko¹⁰, O. Prymak¹⁰, A. Goldis¹¹, S. Travis¹², X. Hébuterne¹³, M. Ferrante¹⁴, G. Rogler¹⁵, M. Fumery¹, S. Danese¹⁶, G. Rydzewska¹⁷, B. Pariente¹⁸, E. Hertervig¹⁹, C. Stanciu²⁰, J.-C. Grimaud²¹, M.-M. Diculescu²², L. Peyrin-Biroulet²³, D. Laharie²⁴, J. P. Wright²⁵, F. Gomollón²⁶, I. Gubonina²⁷, S. Schreiber²⁸, S. Motoya²⁹, P. Hellström³⁰, J. Halfvarson³¹, J.-F. Colombel² ¹Amiens University Hospital, Amiens, France, ²Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, ³IBD Clinic, Department of Gastroenterology, Imelda General Hospital, Bonheiden, Belgium, ⁴AZ Delta Roeselare, Roeselare, Belgium, ⁵2nd Department of Internal Medicine, University Hospital Hradec Králové, Hradec Králové, Czech Republic, ⁶Department of Gastroenterology and Hepatology, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands, ⁷Cumming School of Medicine, University of Calgary, Calgary, Canada, ⁸Division of Gastroenterology and Hepatology, Medical University of Vienna, Vienna, Austria, ⁹Presidio Columbus Fondazione Policlinico A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ¹⁰Medical Clinical Investigational Center of Medical Center Health Clinic LLC, Vinnytsia, Ukraine, ¹¹Universitatea de Medicina si Farmacie, Timisoara, Romania, ¹²Translational Gastroenterology Unit, Nuffield Department of Experimental Medicine, University of Oxford, Oxford, United Kingdom, ¹³Gastro-Entérologie & Nutrition Clinique, Hôpital de l'Archet ², Nice, France, ¹⁴University Hospitals Leuven, Leuven, Belgium, ¹⁵Department of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland, ¹⁶Humanitas University, Istituto Clinico Humanitas, Milan, Italy, ¹⁷Central Clinical Hospital of the Ministry of Interior in Warsaw, Warsaw, Poland, ¹⁸Claude Huriez Hospital, Lille University, Lille, France, ¹⁹Skane University Hospital, Lund, Sweden, ²⁰Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania, ²¹Hepato-Gastroenterology Department, North Hospital, University of Mediterranean, Marseille, France, ²²University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania, ²³Hépatogastro-Entérologie, Hôpital de Brabois, Nancy, France, ²⁴Hépatogastro-entérologie et d'oncologie digestive, Hôpital Haut-Lévêque, Pessac, France, ²⁵Kingsbury Hospital, Cape Town, South Africa, ²⁶Hospital Clínico de Zaragoza, IIS Aragón, Zaragoza, Spain, ²⁷Military Medical Academy named after S.M.Kirov, Saint-Petersburg, Russian Federation, ²⁸Department of Internal Medicine I, Kiel University, Kiel, Germany, ²⁹IBD Center, Sapporo Kosei General Hospital, Sapporo, Japan, ³⁰Uppsala University Hospital, Uppsala, Sweden, ³¹Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden
10:00 - 10:20	66: Cancer risk in children with IBD, an under-recognised issue Arie Levine, Tel Aviv, Israel
10:20 - 10:50 Coffee break	

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

Scientific Session 11: Towards the future of IBD	
10:50 - 12:20	Nik Sheng Ding, Melbourne, Australia Marc Ferrante, Leuven, Belgium
10:50 - 11:10	67: Artificial intelligence augmenting medical management Vishal Nangalia, London, United Kingdom
11:10 - 11:20	68: OP36: A colonic gene expression signature predicts non-response to anti-inflammatory therapies in Inflammatory Bowel Disease T. Sato ¹ , K. Li ¹ , K. Hayden ¹ , L. Tomsho ¹ , F. Baribaud ¹ , C. Brodmerkel ¹ , L. E. Greenbaum ¹ , J. R. Friedman ¹ , M. Curran ¹ , Y. Imai ² , S. Plevy ¹ , S. E. Telesco ¹ ¹ Janssen Research & Development, LLC, Spring House, United States, ² Janssen Pharmaceutical K.K., Tokyo, Japan
11:20 - 11:40	69: Robot and surgeon: How will a partnership work? Antonino Spinelli, Milan, Italy
11:40 - 11:50	70: OP37: Efficacy and safety of ustekinumab as maintenance therapy in Ulcerative Colitis: Week 44 results from UNIFI W. J. Sandborn ¹ , B. E. Sands ² , R. Panaccione ³ , C. D. O'Brien ⁴ , H. Zhang ⁴ , J. Johannis ⁴ , L. Peyrin-Biroulet ⁵ , G. Van Assche ⁶ , S. Danese ⁷ , S. R. Targan ⁸ , M. T. Abreu ⁹ , T. Hisamatsu ¹⁰ , P. Szapary ⁴ , C. Marano ⁴ ¹ University of California San Diego, La Jolla, United States, ² Icahn School of Medicine at Mount Sinai, New York, United States, ³ University of Calgary, Calgary, Canada, ⁴ Janssen Research & Development, LLC, Spring House, United States, ⁵ Nancy University Hospital, Université de Lorraine, Nancy, France, ⁶ University of Leuven, Leuven, Belgium, ⁷ Humanitas Research Hospital, Milan, Italy, ⁸ Cedars-Sinai Medical Center, Los Angeles, United States, ⁹ University of Miami Miller School of Medicine, Miami, United States, ¹⁰ Kyorin University, Tokyo, Japan
11:50 - 12:00	71: OP38: Maintenance treatment with mirikizumab, a p19-directed IL-23 antibody: 52-week results in patients with Moderately to Severely Active Ulcerative Colitis G. R. D'Haens ¹ , W. J. Sandborn ² , M. Ferrante ³ , B. R. Bhandari ⁴ , E. Berliba ⁵ , T. Hibi ⁶ , J. Tuttle ⁷ , J. B. Canavan ⁸ , S. Friedrich ⁸ , M. Durante ⁸ , V. Arora ⁸ , B. Feagan ⁹ ¹ Amsterdam University Medical Centers, Amsterdam, Netherlands, ² University California San Diego, La Jolla, California, United States, ³ UZ Leuven, KU Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ⁴ Delta Research Partners, LLC, Bastrop, LA, United States, ⁵ Nicolae Testemitanu State University of Medicine and Pharmacy, Chisinau, Moldova, Republic of, ⁶ Kitasato Institute Hospital Center for Advanced IBD Research and Treatment, Minato-ku, Tokyo, Japan, ⁷ Eli Lilly and Company, Lilly Biotechnology Center, San Diego, California, United States, ⁸ Eli Lilly and Company, Indianapolis, Indiana, United States, ⁹ Western University, Robarts Clinical Trials Inc, London, Ontario, Canada
12:00 - 12:20	72: Big data: Potential for transforming IBD research and care Ignacio Hernandez-Medrano, Madrid, Spain

Saturday, March 9, 2019, cont.

Scientific programme day by day (as of February 1, 2019)

Plenary Hall, Hall A, Bella Center

12:20 - 12:50	Scientific Session 12: ECCO Lecture Silvio Danese, Milan, Italy Laurent Peyrin-Biroulet, Vandœuvre-Les-Nancy, France	
	12:20 - 12:50	73: ECCO Lecture: Inflammatory cytokines from discoveries to therapies Charles Dinarello, Denver, United States
12:50 - 12:55	74: Awards and closing remarks Silvio Danese, Milan, Italy	
12:55 - 13:00	75: The ECCO Film	

"Science improving patients' lives"

Thursday, February 15, 2018

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

11:00 - 12:00	Industry sponsored satellite symposia 1a & 1b Please refer to pages 104-105
12:15 - 12:20	1: Welcome Rainer Schöfl, Linz, Austria
12:20 - 12:30	2: Opening Julián Panés, Barcelona, Spain
12:30 - 14:00	Scientific session 1: Exploring IBD over time Axel Dignass, Frankfurt, Germany Charlotte Hedin, Stockholm, Sweden
12:30 - 12:50	3: Can we diagnose pre-symptomatic IBD? Joana Torres, Lisbon, Portugal
12:50 - 13:00	4: OP001: Gut barrier dysfunction – a primary defect in twins with Crohn's Disease predominantly caused by genetic predisposition Å. V. Keita ¹ , C.M. Lindqvist ² , Å. Öst ³ , C. DL Magana ¹ , I. Schoultz ² , J. Halfvarson ⁴ ¹ Linköping University, Department Of Clinical And Experimental Medicine, Linköping, Sweden, ² Örebro University, Department of Medical Sciences, Örebro, Sweden, ³ Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, ⁴ Örebro University, Department of Gastroenterology, Örebro, Sweden
13:00 - 13:20	5: Targeting early disease - lessons from rheumatoid arthritis Daniel Aletaha, Vienna, Austria
13:20 - 13:30	6: OP002: Assessment of disease activity patterns during the first 10 years after diagnosis in a population-based Crohn's Disease cohort shows a quiescent disease course for a substantial proportion of the population D. Wintjens ^{1,2} , F. Bergey ³ , E. Saccenti ⁴ , S. Jeuring ^{1,2} , M. Romberg-Camps ⁵ , L. Oostenbrug ⁵ , A. Masclee ^{1,2} , D. Jonkers ^{1,2} , V. Martins dos Santos ^{3,4} , M. Pierik ^{1,2} ¹ Maastricht University Medical Center +, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, The Netherlands, ² Maastricht University Medical Center +, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht, The Netherlands, ³ LifeGlimmer GmbH, Berlin, Germany, ⁴ Wageningen University & Research, Laboratory of Systems and Synthetic Biology, Wageningen, The Netherlands, ⁵ Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen/Heerlen, The Netherlands



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Thursday, February 15, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

13:30 - 13:40	7: OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics M. de Bruyn^{1,2}, V. Ballet³, S. Verstockt⁴, B. Verstockt^{1,3}, G. Van Assche^{1,3}, M. Ferrante^{1,3}, K. Machiels¹, S. Vermeire^{1,3} ¹Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, ²Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, ³University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, ⁴Laboratory of Complex Genetics, Human Genetics, Leuven, Belgium
13:40 - 14:00	8: Evolution of disease pathways over time in CD – early versus late disease Gerhard Rogler, Zurich, Switzerland
14:00 - 14:30 Coffee break	
Scientific session 2: Novel treatment strategies	
14:30 - 16:00 Matthieu Allez, Paris, France Tim Raine, Cambridge, United Kingdom	
14:30 - 14:50	9: Combining new drugs with different mechanisms Shomron Ben-Horin, Ramat Gan, Israel
14:50 - 15:00	10: OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis H. Schmitt¹, U. Billmeier¹, J. Ulmschneider¹, C. Admyre², T. Knittel², A. Zargari², M.F. Neurath¹, R. Atreya¹ ¹Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, ²InDex Pharmaceuticals AB, Stockholm, Sweden
15:00 - 15:20	11: Stem cell therapy for perianal CD – multidisciplinary management Silvio Danese, Milan, Italy Damián García-Olmo, Madrid, Spain
15:20 - 15:30	12: OP005: Higher anti-TNF serum levels are associated with perianal fistula closure in Crohn's Disease patients A. Strik¹, M. Löwenberg¹, C. Ponsioen¹, K. Gecse², C. Buskens³, W. Bemelman³, G. D'Haens¹ ¹Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, ²Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands, ³Academic Medical Center (AMC), Department of Surgery, Amsterdam, The Netherlands
15:30 - 15:40	13: OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study S. Danese¹, M. Neurath², A. Kopon³, S. Zakko⁴, T. Simmons⁵, R. Fogel⁶, J. Maccaroni⁷, X. Zhan⁷, K. Usiskin⁷, D. Chitkara⁷ ¹Istituto Clinico Humanitas, Milan, Italy, ²University Erlangen, Nurnberg, Germany, ³Torunskie Centrum Gastrologiczne Gastromed, Torun, Poland, ⁴Connecticut Clinical Research Foundation of Bristol Hospital, Bristol, United States, ⁵West Gastroenterology Medical Group, Los Angeles, United States, ⁶Clinical Research Institute of Michigan, Chesterfield, United States, ⁷Celgene Corporation, Summit, United States
15:40 - 16:00	14: Small molecules are back Laurent Peyrin-Biroulet, Vandoeuvre-Les-Nancy, France

Thursday, February 15, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

16:00 - 17:20		Scientific session 3: Returning to a normal life with IBD Barry Hall, Dublin, Ireland Paula Ministro, Viseu, Portugal
	16:00 - 16:20	15: Sexual dysfunction in IBD patients Eugeni Domènech, Badalona, Spain
	16:20 - 16:40	16: How to prevent disability Jean-Frédéric Colombel, New York City, United States
	16:40 - 16:50	17: OP007: Detection of mucosal healing with a serum marker panel in adalimumab treated patients with Ulcerative Colitis M. de Bruyn ^{1,2} , R. Ringold ³ , E. Martens ² , M. Ferrante ^{1,4} , G. Van Assche ^{1,4} , G. Opdenakker ² , A. Dukler ³ , S. Vermeire ^{1,4} 1Translational Research center for GastroIntestinal Disorders (TARGID), Chronic Diseases, Metabolism and Ageing (CHROMETA), Leuven, Belgium, 2Rega Institute for Medical Research, Microbiology and Immunology, Leuven, Belgium, 3Kepler Diagnostics, Inc., Simi Valley, United States, 4University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium
 Y-ECCO Abstract Award	16:50 - 17:00	18: OP008: α4β7 integrin-dependent gut homing of non-classical monocytes is essential for intestinal wound healing mediated by M2 macrophages L. Schleier ¹ , M. Wiendl ¹ , M.-T. Binder ¹ , R. Atreya ¹ , A. Watson ² , C. Neufert ¹ , I. Atreya ¹ , M.F. Neurath ¹ , S. Zundler ¹ ¹ University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, ² University of East Anglia, Norwich Medical School, Norwich, United Kingdom
	17:00 - 17:20	19: Patient perspective on treatment goals Corey Siegel, Lebanon, United States
17:30 - 18:30		Digital Oral Presentations (Sessions 1-5) Please refer to page 43
18:45 - 19:45		Industry sponsored satellite symposia 2a & 2b & 2c Please refer to pages 105-106

Friday, February 16, 2018

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

07:15 - 08:15	Industry sponsored satellite symposia, 3a & 3b & 3c Please refer to pages 106-107
08:30 - 10:30	Scientific session 4: The future of IBD diagnosis and disease prediction Iris Dotan, Petah Tikva, Israel Jonas Halfvarson, Örebro, Sweden
08:30 - 08:50	20: ECCO-ESGAR Guidelines: Present and future of diagnostic techniques for IBD Christian Maaser, Lueneburg, Germany Jaap Stoker, Amsterdam, The Netherlands
08:50 - 09:00	21: OP009: A combination of clinical, serological and genetic factors predicts complicated disease course in paediatric-onset Crohn's disease: results from a population-based study. H. Sarter ^{1,2} , G. Savoye ³ , D. Turck ^{2,4} , F. Vasseur ⁵ , G. Marot ^{6,7} , B. Pariente ^{2,8} , S. Singh ⁹ , J.F. Colombel ¹⁰ , C. Gower-Rousseau ^{1,2} , M. Fumery ¹¹ ¹ Lille Hospital and University, Public Health, Epidemiology and Economic Health, Epimad registry, Regional house of clinical research, Lille, France, ² Lille University, Lille Inflammation Research International Center LIRIC-UMR 995 Inserm, Lille, France, ³ Rouen Hospital and University, Gastroenterology Unit, Epimad registry, Rouen, France, ⁴ Lille University Jeanne de Flandre Children's Hospital and Faculty of Medicine, Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Lille, France, ⁵ Lille University and Hospital, Biostatistics Unit, EA 2694, Lille, France, ⁶ Lille University and Hospital, EA 2694 - Santé publique: épidémiologie et qualité des soins, Lille, France, ⁷ Inria Lille Nord Europe, Modal, Lille, France, ⁸ Gastroenterology Unit, Epimad registry, Lille Hospital and University, Lille, France, ⁹ Prometheus Laboratories Inc., San Diego, United States, ¹⁰ Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, ¹¹ Amiens Hospital and University, Gastroenterology Unit, EPIMAD Registry, Amiens, France
09:00 - 09:10	22: OP010: Shallow whole genome sequencing predicts the future cancer risk of low grade dysplastic lesions arising in Ulcerative Colitis I. Al Bakir ^{1,2} , K. Curtius ¹ , A.-M. Baker ¹ , T.S.O. Clarke ¹ , M. Moorghen ³ , M. Jansen ⁴ , M. Rodriguez-Justo ⁵ , S. Leedham ⁶ , T. Graham ^{*1} , A. Hart ^{*2} ¹ Queen Mary University of London, Barts Cancer Institute, London, United Kingdom, ² St. Mark's Hospital, Inflammatory Bowel Disease Unit, Harrow, United Kingdom, ³ St. Mark's Hospital, Pathology Department, Harrow, United Kingdom, ⁴ University College London Hospital, Pathology Department, London, United Kingdom, ⁵ Henry Wellcome Building of Genomic Medicine, Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom
09:10 - 09:20	23: OP011: Integration of whole exome sequencing and RNA sequencing of intestinal biopsies in Inflammatory Bowel Disease identifies inflammation dependent effects R. Barbieri ¹ , W. Uniken Venema ¹ , A. Vich Vila ¹ , Y. Li ¹ , L. Franke ¹ , F. van Dijk ¹ , N. De Klein ¹ , M. Swertz ¹ , S. Sanna ¹ , M.D. Voskuil ¹ , M. Rivas ² , R. Xavier ² , M. Daly ² , G. Dijkstra ¹ , E.A. Festen ¹ , R.K. Weersma ¹ ¹ UMCG, Groningen, The Netherlands, ² The Broad Institute of MIT and Harvard, Cambridge, United States
09:20 - 09:40	24: Molecular endoscopy for IBD Raja Atreya, Erlangen, Germany

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:40 - 09:50	25: OP012: IL-23 is centrally involved in mediating molecular resistance to anti-TNF therapy in Crohn's Disease patients H. Schmitt¹, U. Billmeier¹, W. Dieterich¹, T. Rath¹, S. Sonnenwald², S. Reid², S. Hirschmann¹, K. Hildner¹, M.J. Waldner¹, J. Mudter³, A. Hartmann⁴, R. Grützmann⁵, C. Neufert¹, T. Münster⁶, M.F. Neurath¹, R. Atreya¹ ¹Friedrich-Alexander-University Erlangen-Nürnberg, First Department of Medicine, Erlangen, Germany, ²Friedrich-Alexander-University Erlangen-Nürnberg, Department of Biology, Erlangen, Germany, ³Sana Kliniken Ostholstein, Eutin, Germany, ⁴Friedrich-Alexander-University Erlangen-Nürnberg, Department of Pathology, Erlangen, Germany, ⁵Friedrich-Alexander-University Erlangen-Nürnberg, Department of Surgery, Erlangen, Germany, ⁶Friedrich-Alexander-University Erlangen-Nürnberg, Department of Anesthesiology, Erlangen, Germany
09:50 - 10:00	26: OP013: HLA-DQA1 contributes to the development of antibodies to anti-TNF therapy in Crohn's Disease A. Sazonovs¹, N.A. Kennedy², C. Bewshea², L. Moutsianas¹, G.J. Walker², K. De Lange¹, J. Goodhand², C. Anderson¹, J. Barrett¹, PANTS Investigator Consortium, T. Ahmad² ¹Wellcome Trust Sanger Institute, Hinxton, United Kingdom, ²University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom
10:00 - 10:10	27: OP014: Analysis of 1792 gut metagenomes reveals microbial treatment targets for Inflammatory Bowel Disease and irritable bowel syndrome A. Vich Vila¹, F. Imhann¹, V. Collij¹, S.A. Jankipersadsing¹, T. Gurry², Z. Mujagic³, A. Kurilshikov¹, M.J. Bonder¹, J. Xiaofang², E. Tigchelaar¹, J. Dekens¹, V. Peters¹, M.D. Voskuil¹, M.C. Visschedijk¹, F. Eleonora A.M.¹, G. Dijkstra¹, A.A. Masclee³, M.H. Hofker¹, R. Xavier⁴, E.J. Alm², J. Fu¹, C. Wijmenga¹, D.M. Jonkers³, A. Zhernakova¹, R.K. Weersma¹ ¹University Medical Center Groningen, Groningen, The Netherlands, ²Massachusetts Institute of Technology, Boston, United States, ³Maastricht University Medical Center (MUMC), Maastricht, The Netherlands, ⁴Broad Institute, Boston, United States
10:10 - 10:30	28: Integration of "omics" and potential for clinical practice Claudio Fiocchi, Cleveland, United States
10:30 - 11:00 Coffee break	
Scientific session 5: New opportunities for IBD care and research 11:00 - 12:30 Dominik Bettenworth, Münster, Germany James Lindsay, London, United Kingdom	
11:00 - 11:20	29: Remote monitoring Daniel Baumgart, Berlin, Germany
11:20 - 11:40	30: Point of care tests Ann Gils, Leuven, Belgium
11:40 - 12:00	31: Web-based registries Pascal Juilliat, Bern, Switzerland

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

12:00 - 12:10	32: OP015: Biomarker correlation with endoscopic outcomes in patients with Crohn's Disease: Data from CALM W. Reinisch¹, R. Panaccione², P. Bossuyt³, F. Baert⁴, A. Armuzzi⁵, S. Travis⁶, S. Danese⁷, W.J. Sandborn⁸, G. D'Haens⁹, S. Berg¹⁰, J.-F. Maa¹¹, J. Petersson¹¹, E. Neimark¹¹, A.M. Robinson¹¹, J.-F. Colombel¹² ¹Medical University of Vienna, Vienna, Austria, ²University of Calgary, Calgary, Canada, ³Imelda General Hospital, Bonheiden, Belgium, ⁴AZ Delta Roeselare-Menen, Menen, Belgium, ⁵Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, ⁶Oxford University Hospitals, Oxford, United Kingdom, ⁷Istituto Clinico Humanitas, Milan, Italy, ⁸University of California San Diego, La Jolla, United States, ⁹Academic Medical Center, Amsterdam, The Netherlands, ¹⁰AbbVie AB, Solna, Sweden, ¹¹AbbVie Inc., North Chicago, United States, ¹²Icahn School of Medicine at Mount Sinai, New York, United States
12:10 - 12:30	33: Can the patient become an investigator? Germari Bianchi, Milan, Italy
12:30 - 13:30	Break / Guided Poster Session Please refer to page 74
12:40 - 13:20	Educational Lunchtime Satellite Symposia LS1 & LS2 & LS3 & LS4 Please refer to pages 107-108
13:30 - 15:00	Scientific session 6: Best perioperative management of IBD Yves Panis, Clichy, France Walter Reinisch, Vienna, Austria
13:30 - 13:50	34: Get your patient fit for surgery Peter Irving, London, United Kingdom Paulo Kotze, Curitiba, Brazil; Calgary, Canada
13:50 - 14:00	35: OP016: Need for primary abdominal surgery, but not repeated surgery, has decreased – a nationwide study of temporal trends in Crohn surgery in Sweden 1990-2014 D. Kalman¹, C. Nordenvall², A. Hallqvist Everhov³, J.F. Ludvigsson⁴, M.C. Sachs⁵, A. Ekbom⁶, O. Olén⁷, P. Myrelid¹ ¹Division of surgery, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University and Department of Surgery, County Council of Östergötland, Linköping, Sweden, ²Dept. of Molecular Medicine and Surgery, Karolinska Institutet; Center for Digestive Disease, Div. of Coloproctology, Karolinska University Hospital, Stockholm, Sweden, ³Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁴Department Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro, Sweden; Division of Epidemiology and Public Health, School of Medicine, University of Nottingham, Nottingham, UK; Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York, USA, Stockholm, Sweden, ⁵Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, ⁶Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, ⁷Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden; Clinical Epidemiology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden; Department of pediatric gastroenterology and nutrition, Sachs' Children and Youth Hospital, Stockholm, Sweden

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

14:00 - 14:20	36: Enhanced postoperative recovery pathways Gionata Fiorino, Milan, Italy Antonino Spinelli, Milan, Italy
14:20 - 14:30	37: OP017: Transanal minimally-invasive proctectomy with ileal pouch anal anastomosis (Ta-IPAA) in patients with Ulcerative Colitis: A cohort study from the TaTME international database G. Pellino ^{1,2} , K. Sahnan ^{2,3} , M. Penna ^{3,4} , S. Adegbola ^{2,3} , P. Chandrasinghe ^{2,3,5} , A. Spinelli ^{6,7} , R. Hompes ⁴ , J. Warusavitarne ^{2,3} , on behalf of the International TaTME Registry Collaborative. ¹ Università della Campania, Unit of Colorectal Surgery, Naples, Italy, ² St Mark's Hospital, Fistula Research Unit, London, United Kingdom, ³ Imperial College, Department of Surgery and Cancer, London, United Kingdom, ⁴ Oxford University Hospital NHS Trust - Churchill Hospital, Department of Colorectal Surgery, Oxford, United Kingdom, ⁵ Faculty of Medicine, University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, ⁶ Humanitas University, Colon and Rectal Surgery Unit, Department of General Surgery, Rozzano, Italy, ⁷ Humanitas University, Humanitas University, Department of Biomedical Sciences, Rozzano, Italy
14:30 - 14:40	38: OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling C. Mascaraque ¹ , S. Elangovan ² , L. Petti ¹ , A. Piontini ² , C. Correale ¹ , V. Arena ³ , B. Romano ¹ , F. Ungaro ² , V. Garlatti ² , S. D'Alessio ² , G. Fiorino ¹ , A. Spinelli ^{2,4} , S. Danese ^{1,2} , S. Vetrano ² ¹ Humanitas Research Institute, IBD Center Laboratory of Immunology in Gastroenterology, Rozzano, Italy, ² Humanitas University, Department of Biomedical Sciences, Rozzano, Italy, ³ Catholic University of Rome, Institute of Pathology, Rome, Italy, ⁴ Humanitas Research Institute, Colon and Rectal Surgery, Rozzano, Italy
14:40 - 15:00	39: Preventive strategy after resection surgery in CD Pierre Michetti, Lausanne, Switzerland
15:00 - 15:30 Coffee break	

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

EITHER:

15:30 - 16:10		Scientific session 7: ECCO Fellowships and Grants (Plenary Hall, Hall D, Messe Wien) Gerhard Rogler, Zurich, Switzerland Dino Tarabar, Belgrade, Serbia
 IIS Abstract Award	15:30 - 15:37	40: Outcomes from the ECCO-IOIBD Fellowship 2016 The interleukin-1 pathway as a putative new target in pediatric inflammatory bowel disease Sharon Veenbergen, Rotterdam, The Netherlands
	15:37 - 15:44	41: Outcomes from the ECCO-IOIBD Fellowship 2017 Precision Medicine for IBD using advanced machine learning Aria Zand, Los Angeles, United States
	15:44 - 15:50	42: Announcement of Fellowships and Grants 2018
	15:50 - 16:00	43: OP019: In Faecal Microbiota Transplantation (FMT) for Ulcerative Colitis, fusobacterium is associated with lack of remission, while metabolic shifts to starch degradation and short chain fatty acid production are associated with remission (FOCUS study) S. Paramsothy^{1,2} , M. Kamm ^{3,4} , S. Nielsen ¹ , N. Deshpande ¹ , J. Faith ² , J. Clemente ² , R. Paramsothy ⁵ , A. Walsh ⁶ , J. van den Bogaerde ⁷ , D. Samuel ⁸ , R. Leong ⁸ , S. Connor ² , W. Ng ⁵ , E. Lin ⁹ , M. Wilkins ¹ , J.-F. Colombel ² , T. Borody ⁹ , H. Mitchell ¹ , N. Kaakoush ¹ ¹ University of New South Wales, Sydney, Australia, ² Icahn School of Medicine at Mount Sinai, New York, United States, ³ St Vincent's Hospital, Melbourne, Australia, ⁴ University of Melbourne, Melbourne, Australia, ⁵ Liverpool Hospital, Sydney, Australia, ⁶ St Vincent's Hospital, Sydney, Australia, ⁷ Nambour General Hospital, Nambour, Australia, ⁸ Bankstown-Lidcombe Hospital, Sydney, Australia, ⁹ Centre for Digestive Diseases, Sydney, Australia
	16:00 - 16:10	44: OP020: The clinical determinants affect gut microbial profile of Inflammatory Bowel Disease patients P. Juillerat¹ , B. Yilmaz ² , R. Wiest ^{1,2} , G. Rogler ³ , A.J. Macpherson ¹ ¹ Clinic for Visceral Surgery and Medicine, Gastroenterology, Bern, Switzerland, ² University of Bern, Department of Biomedical Research, Bern, Switzerland, ³ University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

Scientific session 8: IBD Horizons (Plenary Hall, Hall D, Messe Wien) Filip Baert, Roeselare, Belgium Gerassimos Mantzaris, Athens, Greece	
16:10 - 17:10	
16:10 - 16:20	45: OP021: Autologous haematopoietic stem cell transplantation for Crohn's Disease: A retrospective study from the European Society for Blood & Marrow Transplantation (EBMT) Autoimmune Diseases Working Party C. Brierley¹, C. Castilla-Llorente², M. Labopin³, M. Badoglio³, M. Rovira⁴, E. Ricart⁵, D. Dierickx⁶, S. Vermeire⁷, P. Hasselblatt⁸, J. Finke⁹, F. Onida¹⁰, A. Cassinotti¹¹, J. Satsangi¹², M. Kazmi¹³, A. López-Sanromán¹⁴, D. Farge¹⁵, S. Travis¹⁶, C. Hawkey¹⁷, J. Snowden¹⁸ ¹Oxford University Hospitals, Department of Haematology, Oxford, United Kingdom, ²Département d'Hématologie Gustave Roussy, Programme de transplantation des cellules souches, Villejuif, France, ³Université Pierre et Marie Curie, Saint Antoine Hospital, EBMT Paris Study Office, Department of Haematology, Paris, France, ⁴Hospital Clínic of Barcelona, Haematology Department, Barcelona, Spain, ⁵Hospital Clínic of Barcelona, Gastroenterology Department, Barcelona, Spain, ⁶University Hospitals Leuven, Department of Haematology, Leuven, Belgium, ⁷University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ⁸Medical Faculty and University Hospital Freiburg, Department of Medicine II, Freiburg, Germany, ⁹University of Freiburg, Department of Gastroenterology, Freiburg, Germany, ¹⁰Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Università degli Studi di Milano, Haematology - BMT Centre, Milan, Spain, ¹¹Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy, ¹²Western General Hospital, University of Edinburgh, Gastro-intestinal Unit, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, ¹³Guy's and St Thomas' NHS Foundation Trust and King's College Hospital, Department of Haematology, London, United Kingdom, ¹⁴Ramon y Cajal Hospital, Gastroenterology and Hepatology Department, Madrid, Spain, ¹⁵AP-HP Hôpital Saint-Louis, Centre de Référence des Maladies auto-immunes systémiques Rares d'Ile-de-France (site constitutif), Filière FAI2R, Internal Medicine, Autoimmune and Vascular Diseases Unit, UF 04, Paris, France, ¹⁶Oxford University Hospitals, Translational Gastroenterology Unit, Oxford, United Kingdom, ¹⁷Queen's Medical Centre, Nottingham Digestive Diseases Centre, School of Clinical Sciences, Nottingham, United Kingdom, ¹⁸Sheffield Teaching Hospitals NHS Foundation Trust, Department of Haematology, Sheffield, United Kingdom
16:20 - 16:30	46: OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study S. Schreiber¹, L. Peyrin-Biroulet², B. Boland³, P.D. Higgins⁴, A. Armuzzi⁵, J. Terdiman⁶, W. Zhou⁷, G. Alperovich⁸, F. Cataldi⁹, S. Goteti¹⁰, A.P. Lacerda¹¹ ¹University Hospital Schleswig-Holstein, Kiel, Germany, ²University of Lorraine, Nancy, France, ³University of California, San Diego, San Diego, United States, ⁴University of Michigan, Ann Arbor, United States, ⁵Presidio Columbus, Fondazione Policlinico Gemelli Università Cattolica, Rome, Italy, ⁶University of California, San Francisco, Medical Center at Parnassus, San Francisco, United States, ⁷AbbVie Inc., North Chicago, United States, ⁸AbbVie Spain S.L.U., Madrid, Spain

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

16:30 - 16:40	47: OP023: A phase 3b open-label multicentre study (VERSIFY) of the efficacy of vedolizumab on endoscopic healing in Moderately to Severely active Crohn's Disease (CD) S. Danese¹, B. Feagan², W. Sandborn³, J.-F. Colombel⁴, S. Vermeire⁵, S. Jones⁶, K. Brennan⁶, J. Bornstein⁷ ¹Humanities University, IBD Center, Humanitas Clinical and Research Center, Rozzano, Milan, Italy, ²University of Western Ontario, Robarts Clinical Trials, London, Ontario, Canada, ³University of California, Inflammatory Bowel Disease Center, Division of Gastroenterology, San Diego, United States, ⁴Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, NY, United States, ⁵University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ⁶Europe Development Centre, Takeda R&D, London, United Kingdom, ⁷Takeda Pharmaceuticals International Co., Cambridge, MA, United States
16:40 - 16:50	48: OP024: Long-term safety and efficacy of the anti-MADCAM monoclonal antibody SHP647 for the treatment of Crohn's Disease: The OPERA II study G.R. D'Haens¹, W. Reinisch², S.D. Lee³, D. Tarabar⁴, E. Louis⁵, M. Klopocka⁶, J. Klaus⁷, S. Schreiber⁸, D.I. Park⁹, X. Hébuterne¹⁰, F. Cataldi¹¹, A. Banerjee¹², K. Gorelick¹³, W.J. Sandborn¹⁴ ¹Academic Medical Centre, Amsterdam, The Netherlands, ²Medical University of Vienna, Vienna, Austria, ³University of Washington, Seattle, United States, ⁴Clinic of Gastroenterology and Hepatology, Military Medical Academy, Belgrade, Serbia, ⁵University Hospital CHU of Liège, Liège, Belgium, ⁶Nicolaus Copernicus University, Collegium Medicum in Bydgoszcz, Bydgoszcz, Poland, ⁷Universitätsklinikum Ulm, Ulm, Germany, ⁸University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany, ⁹Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, South Korea, ¹⁰Université de Nice Sophia Antipolis, Hôpital de l'Archet, Nice, France, ¹¹Shire, Lexington, United States, ¹²Pfizer, Cambridge, United States, ¹³Zymo Consulting Group, Newtown Square, United States, ¹⁴University of California San Diego, La Jolla, United States
16:50 - 17:00	49: OP025: Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn's Disease: A multicentre consortium propensity score-matched analysis M. Bohm¹, S. V Sagi¹, M. Fischer¹, S. Kadire¹, G. Tran¹, M. Rahal¹, S. Aniwani², J. Meserve³, A. Weiss⁴, G. Kochhar⁵, P. Shashi⁶, D. Faleck⁶, A. Winters⁶, S. Chablaney⁶, J.L. Koliani-Pace⁷, B. Boland⁸, S. Singh⁸, R. Hirtten⁶, E. Shmidt⁶, K. Lasch⁸, M. Luo⁸, D. Hudesman⁹, S. Chang⁹, D. Lukin⁴, K. Sultan¹⁰, A. Swaminath¹¹, N. Gupta¹², C.A. Siegel⁷, S. Kane², É.V. Loftus², B.E. Sands⁶, W.J. Sandborn³, J.-F. Colombel⁶, B. Shen⁵, P.S. Dulai³ ¹Indiana University, Indianapolis, United States, ²Mayo Clinic, Rochester, United States, ³University of California - San Diego, La Jolla, United States, ⁴Montefiore Medical Center, New York, United States, ⁵Cleveland Clinic Foundation, Cleveland, United States, ⁶Icahn School of Medicine at Mount Sinai, New York, United States, ⁷Dartmouth-Hitchcock Medical Center, Lebanon, United States, ⁸Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, ⁹New York University (NYU), New York, United States, ¹⁰North Shore University Hospital, Manhasset, United States, ¹¹Lenox Hill Hospital, New York, United States, ¹²University of Mississippi, Jackson, United States

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

17:00 - 17:10	50: OP026: Comparative effectiveness of vedolizumab and TNF-antagonist therapy in Ulcerative Colitis: A multicentre consortium propensity score-matched analysis D. Faleck¹, P. Shashi², J. Meserve³, M. Rahal⁴, S. Kadire⁴, G. Tran⁴, A. Weiss⁵, A. Winters¹, S. Chablaney¹, S. Aniwani⁶, J.L. Koliani-Pace⁷, G. Kochhar², B. Boland³, S. Singh³, R. Hirten¹, E. Schmidt¹, K. Lasch⁸, M. Luo⁸, M. Bohm⁴, S. V. Sagi⁴, M. Fischer⁴, D. Hudesman⁹, S. Chang⁹, D. Lukin⁵, K. Sultan¹⁰, A. Swaminath¹¹, N. Gupta¹², C.A. Siegel⁷, B. Shen², W.J. Sandborn³, B.E. Sands¹, J.-F. Colombel¹, S. Kane⁶, E.V. Loftus⁶, P.S. Dulai³ ¹Icahn School of Medicine at Mount Sinai, New York, United States, ²Cleveland Clinic Foundation, Cleveland, United States, ³University of California - San Diego, La Jolla, United States, ⁴Indiana University, Indianapolis, United States, ⁵Montefiore Medical Center, New York, United States, ⁶Mayo Clinic, Rochester, United States, ⁷Dartmouth-Hitchcock Medical Center, Lebanon, United States, ⁸Takeda Pharmaceuticals U.S.A., Inc., Deerfield, United States, ⁹New York University (NYU), New York, United States, ¹⁰North Shore University Hospital, Manhasset, United States, ¹¹Lenox Hill Hospital, New York, United States, ¹²University of Mississippi, Jackson, United States
OR:	
15:30 - 17:10	Scientific session 9: Basic Science: Evolving concepts of IBD pathogenesis (Parallel Hall, Hall C, Messe Wien) Massimo Fantini, Rome, Italy Britta Siegmund, Berlin, Germany
15:30 - 15:50	51: Pathogenesis of fistulising IBD Michael Scharl, Zurich, Switzerland
15:50 - 16:00	52: OP027: SUCNR1 receptor mediates intestinal fibrosis J. Cosin-Roger^{1,2}, D. Ortiz-Masia², D.C. Macias-Ceja¹, L. Gisbert-Ferrandiz², P. Salvador², M. Hausmann³, G. Rogler³, S. Calatayud², M.D. Barrachina² ¹Fisabio, Hospital Dr Peset, Valencia, Spain, ²University of Valencia, Valencia, Spain, ³University of Zurich, Gastroenterology, Zurich, Switzerland
16:00 - 16:10	53: OP028: Single cell RNA sequencing of t-cells in Crohn's Disease identifies tissue specific drug targets E. Festen¹, R. Weersma¹, W.T. Uniken Venema¹, M.D. Voskuil¹, D. Graham² ¹University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands, ²The Broad Institute of MIT and Harvard, Cambridge, United States
16:10 - 16:30	54: Stress-induced controllers of intestinal inflammatory reactions Hermona Soreq, Jerusalem, Israel
16:30 - 16:40	55: OP029: Characterisation of Paneth cell dysfunction in XIAP-deficient mice M. Yabal¹, A. Wahida¹, B. Popper², K. Steiger³, P. Jost¹ ¹Technical University Munich, III. Medizinische Klinik, Munich, Germany, ²Ludwig-Maximilian University of Munich, Department for Cell Biology, Munich, Germany, ³Technical University Munich, Institut for Pathologie, Munich, Germany

Friday, February 16, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien (Session 7 & 8)

Parallel Hall, Hall C, Messe Wien (Session 9)

16:40 - 16:50	56: OP030: Loss of PTPN2 in dendritic cells promotes T cell activation and expression of co-stimulatory molecules L. Hering¹ , C. Gottier ¹ , S. Lang ¹ , B. Becher ² , G. Rogler ¹ , M. Scharl ¹ , M. Spalinger ¹ ¹ University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ² University of Zurich, Institute of Experimental Immunology, Zurich, Switzerland
16:50 - 17:10	57: How the gut speaks to the liver: Novel insights from PSC pathogenesis Herbert Tilg, Innsbruck, Austria
17:20 - 18:20	Digital oral presentations (Sessions 6 - 10) Please refer to pages 43-67
18:35-19:35	Industry sponsored satellite symposia 4a & 4c & 4d Please refer to pages 108-110

Saturday, February 17, 2018

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

Scientific session 10: Growing up with IBD safely	
08:30 - 10:20	Arie Levine, Tel Aviv, Israel Murat Toruner, Ankara, Turkey
08:30 - 08:50	58: Safe use of drugs in paediatric and elderly populations Pieter Hindryckx, Ghent, Belgium Gigi Veereman, Brussels, Belgium
08:50 - 09:00	59: OP031: Clinical effectiveness, safety and immunogenicity of anti-TNF therapy in Crohn's Disease: 12 month data from the PANTS study N.A. Kennedy¹ , G. Heap ^{1,2} , B. Hamilton ¹ , G.J. Walker ¹ , C. Bewshea ¹ , S. Bouris ³ , J. Goodhand ¹ , PANTS Investigator Consortium, T. Ahmad ¹ ¹ University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, ² Abbvie, Chicago, United States, ³ St Mark's Hospital, IBD Unit, London, United Kingdom
09:00 - 09:10	60: OP032: Outcome of pregnancies in female IBD patients treated with vedolizumab A. Moens^{1,2} , K. van Hoeve ^{2,3} , E. Humblet ⁴ , J.-F. Rahier ⁵ , P. Bossuyt ⁶ , S. Dewit ⁷ , D. Franchimont ⁸ , E. Macken ⁹ , J. Nijis ¹⁰ , A. Posen ¹¹ , A. Van Hootehem ¹² , W. Van Moerkercke ¹³ , S. Vermeire ^{1,2} , M. Ferrante ^{1,2} ¹ University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ² KU Leuven, Department of Chronic Diseases, Metabolism and Ageing, Leuven, Belgium, ³ University Hospitals Leuven, Department of Paediatric gastroenterology, Leuven, Belgium, ⁴ Ziekenhuis Oost-Limburg-Campus Sint-Jan, Department of Gastroenterology and Hepatology, Genk, Belgium, ⁵ CHU UCL Namur, Université catholique de Louvain, Yvoir, Belgium, ⁶ Imeldaziekenhuis, Department of Gastroenterology and Hepatology, Bonheiden, Belgium, ⁷ Mariaziekenhuis Noord-Limburg, Department of Gastroenterology and Hepatology, Overpelt, Belgium, ⁸ Hôpital Erasme, Université Libre de Bruxelles, Brussels, Belgium, ⁹ University Hospital Antwerp, Department of Gastroenterology and Hepatology, Antwerp, Belgium, ¹⁰ Sint-Trudo Ziekenhuis, Department of Gastroenterology and Hepatology, Sint-Truiden, Belgium, ¹¹ AZ Vesalius, Department of Gastroenterology and Hepatology, Tongeren, Belgium, ¹² AZ Klina, Department of Gastroenterology and Hepatology, Brasschaat, Belgium, ¹³ AZ Groeninge, Department of Gastroenterology and Hepatology, Kortrijk, Belgium
09:10 - 09:30	61: ESPGHAN-ECCO Guidelines: Update on Paediatric UC Treatment Richard Russell, Glasgow, United Kingdom Dan Turner, Jerusalem, Israel
09:30 - 09:40	62: OP033: The effect of tofacitinib on serum lipids and cardiovascular safety in patients with Ulcerative Colitis – results from the tofacitinib Ulcerative Colitis clinical programme B.E. Sands ¹ , P.R. Taub ² , B.G. Feagan³ , A. Armuzzi ⁴ , G.S. Friedman ⁵ , M. Moscarello ⁵ , N. Lawendy ⁵ , R.D. Pedersen ⁵ , G. Chan ⁵ , C.I. Nduaka ⁵ , D. Quirk ⁵ , L. Salese ⁵ , C. Su ⁵ ¹ Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, NY, United States, ² UC San Diego School of Medicine, Division of Cardiovascular Medicine, La Jolla, CA, United States, ³ Western University, Robarts Clinical Trials, London, ON, Canada, ⁴ Presidio Columbus Fondazione Policlinico Gemelli Università Cattolica, IBD Unit, Rome, Italy, ⁵ Pfizer Inc, Collegeville, PA, United States

Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:40 - 09:50

63: OP034: The initiation of thiopurines in elderly patients with Inflammatory Bowel Disease is associated with an increased risk of adverse effects: A case-control study of the enaida registry

M. Calafat^{1,2}, M. Mañosa^{3,4}, F. Cañete³, J. Panés^{4,5}, V. García Sánchez^{4,6}, M. Calvo⁷, F. Rodríguez-Moranta⁸, C. Taxonera⁹, P. Nos^{4,10}, A. López Sanromán¹¹, M.D. Martín Arranz¹², M. Mínguez¹³, J.P. Gisbert^{4,14}, S. García-López¹⁵, R. de Francisco¹⁶, F. Gomollón^{4,17}, X. Calvet^{4,18}, E. García-Planella¹⁹, M. Rivero²⁰, J. Martínez-Cadilla²¹, F. Argüelles²², L. Arias García²³, M. Cimavilla²⁴, Y. Zabana^{4,25}, L. Márquez²⁶, A. Gutiérrez^{4,27}, G. Alcáin²⁸, P. Martínez Montiel²⁹, J. Lázaro³⁰, D. Busquets³¹, M.F. García Sepulcre³², C. Verdejo³³, F. Bermejo³⁴, M. Mora³⁵, D. Monfort³⁶, P. Romero³⁷, B. Velayos³⁸, C. Rodríguez³⁹, A. Rodríguez⁴⁰, O. Merino⁴¹, A. Rodríguez-Pescador⁴², L. Bujanda^{4,43}, Y. Ber⁴⁴, M. Vela⁴⁵, O. Roncero⁴⁶, J.M. Huguet⁴⁷, O. García-Bosch⁴⁸, M. Barreiro-de-Acosta⁴⁹, R.E. Madrigal⁵⁰, L. Ramos⁵¹, M. Van Domselaar⁵², P. Almela⁵³, J. Llaó⁵⁴, A.J. Lucendo^{4,55}, C. Muñoz Vilafraña⁵⁶, A. Abad⁵⁷, M. Charro⁵⁸, J. Legido⁵⁹, J. Riera¹, S. Khorrami⁶⁰, E. Sesé⁶¹, A.M. Trapero⁶², E. Domènech^{3,4}

¹Hospital Son Llàtzer, Palma, Spain, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁴CIBERehd Instituto de Salud Carlos III, Madrid, Spain, ⁵Hospital Clínic, Barcelona, Spain, ⁶Hospital Reina Sofía, Córdoba, Spain, ⁷Hospital Puerta de Hierro, Majadahonda, Spain, ⁸Hospital Bellvitge, L'Hospitalet de Llobregat, Spain, ⁹Hospital Clínico San Carlos, Madrid, Spain, ¹⁰Hospital La Fe, Valencia, Spain, ¹¹Hospital Ramón y Cajal, Madrid, Spain, ¹²Hospital La Paz, Madrid, Spain, ¹³Hospital Clínico de Valencia, Valencia, Spain, ¹⁴Hospital La Princesa, Madrid, Spain, ¹⁵Hospital Universitario Miguel Servet, Zaragoza, Spain, ¹⁶Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁷Hospital Clínico Lozano Blesa, Zaragoza, Spain, ¹⁸Hospital Parc Taulí, Sabadell, Spain, ¹⁹Hospital Santa Creu i Sant Pau, Barcelona, Spain, ²⁰Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²¹Complejo Hospital Universitario de Vigo, Vigo, Spain, ²²Hospital Virgen de la Macarena, Sevilla, Spain, ²³Hospital Universitario Burgos, Burgos, Spain, ²⁴Hospital Río Hortega, Valladolid, Spain, ²⁵Hospital Mutua de Terrassa, Terrassa, Spain, ²⁶Hospital del mar, Barcelona, Spain, ²⁷Hospital General Universitario de Alicante, Alicante, Spain, ²⁸Hospital Clínico de Málaga, Málaga, Spain, ²⁹Hospital 12 de octubre, Madrid, Spain, ³⁰Hospital Universitario Fundación Alcorcón, Alcorcón, Spain, ³¹Hospital Dr Josep Trueta, Girona, Spain, ³²Hospital General Universitario de Elche, Elche, Spain, ³³Hospital General de Ciudad Real, Ciudad Real, Spain, ³⁴Hospital Universitario Fuenlabrada, Fuenlabrada, Spain, ³⁵Hospital Manises, Manises, Spain, ³⁶Consorci sanitari de Terrassa, Terrassa, Spain, ³⁷Hospital Santa Lucía, Cartagena, Spain, ³⁸Hospital Clínico Universitario Valladolid, Valladolid, Spain, ³⁹CH de Navarra, Pamplona, Spain, ⁴⁰Hospital Universitario de Salamanca, Salamanca, Spain, ⁴¹Hospital de Cruces, Barakaldo, Spain, ⁴²Hospital Galdakao, Galdakao, Spain, ⁴³Instituto Bionostia UPV/EHU, (Donostia, Spain, ⁴⁴Hospital San Jorge, Huesca, Spain, ⁴⁵Hospital Nuestra Sra Candelaria, Sta Cruz Tenerife, Spain, ⁴⁶Hospital Mancha Centro, Alcazar de San Juan, Spain, ⁴⁷Hospital General Universitario Valencia, Valencia, Spain, ⁴⁸Hospital Moisés Broggi, St Joan Despí, Spain, ⁴⁹CH Santiago, Santiago de Compostela, Spain, ⁵⁰CH de Palencia, Palencia, Spain, ⁵¹Hospital Universitario de Canarias, La Laguna, Spain, ⁵²Hospital Torrejón, Torrejón, Spain, ⁵³HG de Castelló, Castelló, Spain, ⁵⁴Hospital Sant Joan de Déu-Althaia, Manresa, Spain, ⁵⁵Hospital General de Tomelloso, Tomelloso, Spain, ⁵⁶Hospital Basurto, Bilbao, Spain, ⁵⁷Hospital Viladecans, Viladecans, Spain, ⁵⁸Hospital Rojo Vilanova, Zaragoza, Spain, ⁵⁹Hospital General, Segovia, Spain, ⁶⁰Hospital Son Espases, Palma, Spain, ⁶¹Hospital Arnau de Vilanova, Lleida, Spain, ⁶²Complejo Hospitalario de Jaén, Jaén, Spain

OP = Oral presentation – Best abstracts

Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

09:50 - 10:00	64: OP035: NUDT15 variants contribute to thiopurine-induced myelosuppression in European populations G. Walker^{1,2}, J. Harrison³, M. Voskuil⁴, G. Heap^{1,2}, N. Heerasing^{1,2}, P. Hendy^{1,2}, J. Koskela^{5,6}, M. Daly^{5,6}, H. Sokol⁷, D. McGovern⁸, R. Weersma⁴, C. Bewshea¹, M. Weedon³, J. Goodhand^{1,2}, N. Kennedy^{1,2}, T. Ahmad^{1,2}, IBD Pharmacogenetics Study Group ¹University of Exeter, IBD Pharmacogenetics, Exeter, United Kingdom, ²Royal Devon & Exeter NHS Foundation Trust, Department of Gastroenterology, Exeter, United Kingdom, ³University of Exeter, Exeter Medical School Bioinformatics Team, Exeter, United Kingdom, ⁴University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, The Netherlands, ⁵The Broad Institute of MIT and Harvard, Cambridge, United States, ⁶Massachusetts General Hospital, Analytical and Translational Genetics Unit, Boston, United States, ⁷Hôpital Saint-Antoine, Service de Gastroentérologie et Nutrition, Paris, France, ⁸Cedars-Sinai Medical Center, Inflammatory Bowel Disease Center, Division of Gastroenterology, Los Angeles, United States
10:00 - 10:20	65: Monitoring and improving safety of new agents Miguel Regueiro, Pittsburgh, United States
10:20 - 10:50 Coffee break	
Scientific session 11: Colorectal Cancer in IBD 10:50 - 12:20 Jessica de Bruyn, Amsterdam, The Netherlands Mircea Diculescu, Bucharest, Romania	
10:50 - 11:10	66: Molecular basis of dysplasia in IBD – clues for cancer prevention therapies? Laurence Egan, Galway, Ireland
11:10 - 11:20	67: OP036: Long-term risk of advanced neoplasia after colonic low-grade dysplasia in patients with Inflammatory Bowel Disease: A nationwide cohort study M. de Jong¹, S. van Tilburg^{1,2}, L. Nissen², W. Kievit¹, I. Nagtegaal³, F. Hoentjen¹, L. Derikx^{1,2} ¹Radboud University Nijmegen Medical Centre, Gastroenterology and Hepatology, Nijmegen, The Netherlands, ²Jeroen Bosch Hospital, Gastroenterology and hepatology, 'S Hertogenbosch, The Netherlands, ³Radboud University Nijmegen Medical Centre, Pathology, Nijmegen, The Netherlands
11:20 - 11:40	68: Serrated lesions in IBD Roger Feakins, London, United Kingdom Maria Pellise, Barcelona, Spain
11:40 - 11:50	69: OP037: Risk of cancer in Inflammatory Bowel Disease patients is associated with age and recent use of immunomodulators, while biologics and aminosalicylates are protective factors – a cross-sectional and follow-up analysis of the Swiss IBD cohort Study T. Greuter¹, S. Scharl¹, C. Barthel¹, J.-B. Rossel², L. Biedermann¹, B. Misselwitz¹, S. Vavricka¹, G. Rogler¹, M. Scharl¹, on behalf of the Swiss IBD Cohort Study Group ¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland, ²University Hospital Lausanne - CHUV, Institute of Social and Preventive Medicine, Lausanne, Switzerland



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Saturday, February 17, 2018, cont.

Scientific programme day by day (as of January 15, 2018)

Plenary Hall, Hall D, Messe Wien

11:50 - 12:00	70: OP038: Hobit- and Blimp1-driven tissue resident memory T cells critically control chronic intestinal inflammation S. Zundler¹ , E. Becker ¹ , M. Spocinska ¹ , L. Parga-Vidal ² , R. Stark ² , R. Atreya ¹ , T. Rath ¹ , M. Leppkes ¹ , C. Neufert ¹ , I. Atreya ¹ , K. van Gisbergen ² , M.F. Neurath ¹ ¹ University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany, ² Academic Medical Center, Department of Hematopoiesis, Sanquin Research and Landsteiner Laboratory, Amsterdam, The Netherlands
12:00 - 12:20	71: Endoscopic resection of dysplasia – mucosal and submucosal resection Raf Bisschops, Leuven, Belgium
12:20 - 12:50	Scientific session 12: ECCO Lecture Silvio Danese, Milan, Italy Julián Panés, Barcelona, Spain
12:20 - 12:50	72: Is translation the way to treatment personalisation? Yehuda Chowers, Haifa, Israel
12:50 - 12:55	73: Awards and closing remarks Julián Panés, Barcelona, Spain
12:55 - 13:00	74: The ECCO Film

"Advancing knowledge, improving care"

Thursday, February 16, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

10:45 - 11:15	Top Tips for chairs (closed session) Laurence Egan, Galway, Ireland
11:30 - 12:30	Industry sponsored satellite symposia 1a & 1b Please refer to pages 186-187
12:45 - 12:50	1: Welcome Javier Gisbert, Madrid, Spain
12:50 - 13:00	2: Opening Julían Panés, Barcelona, Spain
13:00 - 14:30	Scientific session 1: Pathways of environmental and genetic factors in IBD Stephan Vavricka, Zurich, Switzerland Nynne Nyboe Andersen, Copenhagen, Denmark
13:00 - 13:20	3: Nutrition and food additives Charlie Lees, Edinburgh, United Kingdom
13:20 - 13:30	4: OP001: Whole genome sequencing and imputation in Inflammatory Bowel Disease identifies 26 novel loci and offers therapeutically-relevant mechanistic insights L. Moutsianas¹ , K. De Lange ¹ , Y. Luo ^{1,2,3} , J. Lee ⁴ , L. Jostins ⁵ , C. Lamb ⁶ , N. Kennedy ⁷ , J. Mansfield ⁸ , M. Parkes ⁴ , J. Barrett ¹ , C. Anderson ¹ , UK Inflammatory Bowel Disease Genetics Consortium ⁹ ¹ Wellcome Trust Sanger Institute, Human Genetics, Hinxton, Cambridge, United Kingdom, ² Broad Institute of Harvard and MIT, Program in Medical and Population Genetics, Cambridge, United States, ³ Harvard Medical School, Division of Genetics and Rheumatology, Boston, United States, ⁴ Addenbrooke's Hospital, Inflammatory Bowel Disease Research Group, Cambridge, United Kingdom, ⁵ Wellcome Trust Centre for Human Genetics, Oxford, United Kingdom, ⁶ Newcastle University, Newcastle upon Tyne, United Kingdom, ⁷ University of Exeter, Precision Medicine Exeter, Exeter, United Kingdom, ⁸ University of Newcastle, Human Genetics, Newcastle upon Tyne, United Kingdom, ⁹ UK IBD Genetics Consortium, Various, United Kingdom
13:30 - 13:50	5: Everyday poisons: Smoking, pollution, stress, sedentary lifestyle Stephan Vavricka, Zurich, Switzerland
13:50 - 14:00	6: OP002: Epigenetic biomarkers to detect UC associated neoplasia: Results from phase I of the ENDCAP-C study T. Iqbal¹ , A. Beggs ¹ , P. Tanieri ² , Y. Wallis ³ , S. Mehta ⁴ , L. Magill ⁴ , J. Deeks ⁴ , G. Matthews ¹ , D. Morton ¹ , EndCAP-C Consortium ¹ University of Birmingham, Institute of Cancer & Genomic Sciences, Birmingham, United Kingdom, ² University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom, ³ West Midlands Regional Genetics Centre, Birmingham, United Kingdom, ⁴ University of Birmingham, Birmingham Clinical Trials Unit, Birmingham, United Kingdom



Y-ECCO
Abstract Award

OP = Oral presentation – Best abstracts

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

14:00 - 14:10	7: OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study J. Kirchgesner^{1,2}, L. Beaugerie¹, F. Carrat^{3,4}, N. Nyboe Andersen⁵, T. Jess^{5,6}, M. Schwarzwinger^{7,8}, For the BERENICE Study Group ¹Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, ²INSERM, University Paris 06, UMR S 1136, Paris, France, ³Hopital Saint Antoine, Department of Public Health, Paris, France, ⁴INSERM, University Paris 06, UMR S 1136, Paris, France, ⁵Statens Serum Institute, Department of Epidemiology Research, Copenhagen, Denmark, ⁶Frederiksberg Hospital, Institute of Preventive Medicine, Frederiksberg, Denmark, ⁷INSERM, UMR 1137, Paris, France, ⁸THEN, Translational Health Economics Network, Paris, France
14:10 - 14:30	8: Environmental factors as therapy (diet modification, EEN feeding) Pierre Ellul, Sliema, Malta Arie Levine, Tel Aviv, Israel
14:30 - 15:00	Coffee break
15:00 - 16:30	Scientific session 2: Evolving therapeutic algorithms in 2017 Jane Andrews, Adelaide, Australia Jarosław Kierkuś, Warsaw, Poland
15:00 - 15:20	9: Placing new molecules in the treatment pathway Gerhard Rogler, Zurich, Switzerland
15:20 - 15:30	10: OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's Disease L. Le Bourhis¹, A. Corraliza², C. Auzolle¹, E. Ricart², C. Hawkey³, J.O. Lindsay⁴, M. Clark³, G. Rogler⁵, J. Satsangi⁶, D. Haller⁷, J. Panes², A. Salas², M. Allez¹ ¹Hôpital Saint-Louis INSERM, U1160 - Intestinal Immunity in Inflammation and Cancer, Paris, France, ²IDIBAPS, Hospital Clínic, Gastroenterology, Barcelona, Spain, ³University of Nottingham, Gastroenterology, Nottingham, United Kingdom, ⁴Barts and The London, Queen Mary University of London, Centre for Immunology, The Blizard Institute, London, United Kingdom, ⁵University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, ⁶Western General Hospital, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, ⁷Technical University Munich, Department of Nutrition and Immunology, Freising, Germany
15:30 - 15:50	11: Maximising the bang for your buck: How to manage IBD on a minimum budget Peter Irving, London, United Kingdom

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

	15:50 - 16:00	12: OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy L. Guidi¹, G. Fiorino², A. Variola³, N. Manetti⁴, W. Fries⁵, G. Rizzuto⁶, F. Bossa⁷, M. Cappello⁸, L. Biancone⁹, R. D'Incà¹⁰, L. Cantoro¹¹, F. Castiglione¹², M. Principi¹³, M.L. Annunziata¹⁴, M. Di Girolamo¹⁵, M.M. Terpin¹⁶, C.C. Cortelezzi¹⁷, F. Costa¹⁸, A. Amato¹⁹, A. Di Sabatino²⁰, S. Saibeni²¹, G. Meucci²², C. Petruzzellis²³, R. Tari²⁴, F.W. Gugliemi²⁵, A. Armuzzi²⁶, S. Danese², A. Geccherle³, F. Rogai⁴, A. Ventra⁵, A. Orlando⁶, A. Andriulli⁷, B. Scirvo⁸, E. Troncone⁹, R. Caccaro¹⁰, A. Kohn¹¹, O. Nardone¹², V. Annese²⁷ ¹Complesso Integrato Columbus, Fondazione Policlinico Gemelli Università Cattolica, Internal Medicine and Gastroenterology, Rome, Italy, ²Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy, ³Sacro Cuore Don Calabria Hospital, Gastroenterology and Hepatology, Negrar, Italy, ⁴AOU Careggi, DEA, Gastroenterology, Florence, Italy, ⁵University of Messina, Clinical Unit for Chronic Bowel Disorders, Messina, Italy, ⁶Riuniti Villa Sofia - Cervello Hospital, Internal Medicine ², Palermo, Italy, ⁷IRCCS-CSS Hospital, Gastroenterology, San Giovanni Rotondo, Italy, ⁸University Hospital, Gastroenterology, Palermo, Italy, ⁹Tor Vergata, Gastroenterology, Roma, Italy, ¹⁰University of Padova, Gastroenterology, Padova, Italy, ¹¹S. Camillo-Forlanini Hospital, Gastroenterology, Rome, Italy, ¹²Federico II University, Gastroenterology, Naples, Italy, ¹³University Bari, Gastroenterology, Bari, Italy, ¹⁴IRCCS Policlinico, Gastroenterology & Digestive Endoscopy Unit, San Donato, Milano, Italy, ¹⁵University Hospital, Gastroenterology, Modena, Italy, ¹⁶AO Hospital, Gastroenterology and Endoscopy, Legnano, Italy, ¹⁷AOU di Circolo Fondazione Macchi, Gastroenterology, Varese, Italy, ¹⁸AOUP, Gastroenterology, Pisa, Italy, ¹⁹Ospedale Valduce, Gastroenterology, Como, Italy, ²⁰S. Matteo Hospital Foundation, University of Pavia, First Department of Medicine, Pavia, Italy, ²¹ASST Rhodense, Gastroenterology Unit, Rho, Italy, ²²S. Giuseppe Hospital, Gastroenterology, Milano, Italy, ²³Poliambulanza Hospital, Gastroenterology and Digestive Endoscopy, Brescia, Italy, ²⁴AOU Maggiore, Gastroenterology, Novara, Italy, ²⁵S. Pellegrino Hospital, Gastroenterology, Trani, Italy, ²⁶Complesso Integrato Columbus - Catholic University, Internal Medicine and Gastroenterology, Rome, Italy, ²⁷Valiant Clinic, Gastroenterology, Dubai, United Arab Emirates
 Y-ECCO Abstract Award	16:00 - 16:10	13: OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial L. Pouillon¹, M. Ferrante¹, G. Van Assche¹, P. Rutgeerts¹, M. Noman¹, N. Vande Castele², A. Gils³, S. Vermeire¹ ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University of California San Diego, Department of Medicine, La Jolla, CA, United States, ³University of Leuven, Department of Pharmaceutical Sciences, Leuven, Belgium
	16:10 - 16:30	14: Personalised medicine: Dream or reality? Iris Dotan, Tel Aviv, Israel
16:30 - 17:30	Scientific session 3: Vulnerable patients: 10 burning questions in IBD Pierre Michetti, Lausanne, Switzerland Triana Lobatón, Barcelona, Spain	
	16:30 - 16:42	15: The child with IBD: Should anti-TNF be used as a mono-therapy in children (safety risk)? Who should (be allowed to) operate on the children in IBD? Dan Turner, Jerusalem, Israel

Thursday, February 16, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

16:42 - 16:54	16: Treating the pregnant woman with IBD: Should anti-TNF be stopped during pregnancy? Should vedolizumab be stopped during pregnancy? Janneke van der Woude, Rotterdam, The Netherlands
16:54 - 17:06	17: The elderly patient with IBD: Should azathioprine ever be used in the elderly? Should the type of surgery be different in an elderly patient? Jean-Frédéric Colombel, New York, United States
17:06 - 17:18	18: The use of IBD medicine in patients with cancer: Which treatment should be stopped when cancer is diagnosed? Which treatment to use in a patient with a prior diagnosis with cancer? Laurent Beaugerie, Paris, France
17:18 - 17:30	19: The patient with psychological comorbidities: How to wean off opiates in these patients? Is there any preference in drugs? Jane Andrews, Adelaide, Australia
17:45 - 18:45	Industry sponsored satellite symposia 2a & 2b Please refer to pages 187
17:45 - 18:45	Digital oral presentations Please refer to page 43-67

Friday, February 17, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

07:15 - 08:15	Industry sponsored satellite symposia 3a & 3b Please refer to page 188
08:30 - 10:30	Scientific session 4: Clinical trials versus real life Janneke van der Woude, Rotterdam, The Netherlands Pascal Juillerat, Bern, Switzerland
08:30 - 08:50	20: Trial endpoints vs. therapeutic objectives Filip Baert, Roeselare, Belgium
08:50 - 09:00	21: OP007 A multi-centre double blind randomised placebo-controlled study of the use of rectal tacrolimus in the treatment of resistant ulcerative proctitis I.C. Lawrence^{1,2}, A. Baird¹, D. Lightowler², G. Radford-Smith³, J.M. Andrews⁴, S. Connor⁵ ¹ University of Western Australia, Medicine and Pharmacology, Perth, Australia, ² Saint John of God Hospital, Centre for Inflammatory Bowel Diseases, Subiaco, Australia, ³ University of Queensland School of Medicine, IBD Research Group, QIMR Berghofer Medical Research Institute, Brisbane, Australia, ⁴ University of Adelaide, School of Medicine, Adelaide, Australia, ⁵ University of NSW Medicine, South Western Sydney Clinical School, Sydney, Australia
09:00 - 09:10	22: OP008: An innovative treatment for refractory perianal fistulas in Crohn's Disease: Local micro reinjection of autologous fat and adipose derived stromal vascular fraction (ClinicalTrials.gov NCT02520843, Eudract: 2013-002602-31) M. Serrero¹, C. Philandrianos², C. Visee³, J. Veran², P. Orsoni³, F. Sabatier², J.C. Grimaud¹ ¹ Hopital Nord, Gastroenterology, Marseille, France, ² Aix-Marseille, Marseille, France, ³ Hopital Nord, Visceral Surgery, Marseille, France
09:10 - 09:20	23: OP009: Long-term efficacy and safety of Cx601, allogeneic expanded adipose-derived mesenchymal stem cells, for complex perianal fistulas in Crohn's Disease: 52-week results of a phase III randomised controlled trial J. Panes¹, D. García-Olmo², G. Van Assche³, J.F. Colombel⁴, W. Reinisch⁵, D.C. Baumgart⁶, M. Nachury⁷, M. Ferrante³, L. Kazemi-Shirazi⁵, J.C. Grimaud⁸, F. de la Portilla⁹, E. Goldin¹⁰, M.P. Richard¹¹, M.C. Diez¹, S. Danese¹² ¹ Hospital Clínic de Barcelona, Dept of Gastroenterology, Barcelona, Spain, ² Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³ University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Medical University of Vienna, Vienna, Austria, ⁶ Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷ CHU Lille, Lille, France, ⁸ Hôpital Nord, Marseille, France, ⁹ Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰ Sharee Zedek MC, Jerusalem, Israel, ¹¹ TiGenix, Madrid, Spain, ¹² Istituto Clinico Humanitas, Milano, Italy
09:20 - 09:40	24: The long-term efficacy outside clinical trials Stefan Schreiber, Kiel, Germany

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

09:40 - 09:50	25: OP010: Long term efficacy and safety of Ustekinumab for Crohn's Disease: Results from IM-UNITI long-term extension through 2 years W. Sandborn¹, P. Rutgeerts², C. Gasink³, D. Jacobstein³, L.-L. Gao³, J. Johannis³, B. Sands⁴, S.B. Hanauer⁵, S. Targan⁶, S. Ghosh⁷, D.V. Willem J.S.⁸, J.-F. Colombel⁴, B.G. Feagan⁹ ¹University of California San Diego, La Jolla, United States, ²University Hospital, Gasthuisberg, Leuven, Belgium, ³Janssen Research & Development, LLC, Spring House, United States, ⁴Icahn School of Medicine at Mt Sinai, New York, United States, ⁵Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶Cedars-Sinai Medical Center, Los Angeles, United States, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Stellenbosch, Stellenbosch, South Africa, ⁹Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada
09:50 - 10:00	26: OP011: Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study L. Peyrin-Biroulet¹, B.G. Feagan², J. Mansfield³, D.T. Rubin⁴, U. Arulmani⁵, R. Maciucă⁵, H. Tyrrell⁶, J. Thommes⁵, S. Tole⁶ ¹Université de Lorraine, Vandœuvre-lès-Nancy, France, ²University of Western Ontario, London, Canada, ³Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴University of Chicago Medicine, Chicago, United States, ⁵Genentech, South San Francisco, United States, ⁶Roche, Welwyn Garden City, United Kingdom
10:00 - 10:10	27: OP012: Perioperative use of vedolizumab is not associated with short-term postoperative infectious complications in patients with Ulcerative Colitis undergoing (procto)colectomy with ileal pouch-anal anastomosis M. Ferrante¹, N. Schils¹, A. de Buck van Overstraeten², S. Vermeire¹, G. Van Assche¹, A. Wolthuis², A. D'Hoore² ¹University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium, ²University Hospitals Leuven, Department of Abdominal Surgery, Leuven, Belgium
10:10 - 10:30	28: The long-term safety outside clinical trials Gert van Assche, Leuven, Belgium
10:30 - 11:00	Coffee break
11:00 - 12:30	Scientific session 5: Managing bowel damage in IBD: Surgical or medical treatment? Antonino Spinelli, Milan, Italy Edyta Zagórowicz, Warsaw, Poland
11:00 - 11:20	29: Are we truly changing disease course with current strategies? Yves Panis, Clichy, France

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

11:20 - 11:30	30: OP013: Disease management and outcomes of patients with Crohn's Disease at high risk of recurrence. Results from PRACTICROHN study M. Iborra¹, M.D. Martín Arranz², E. Domènech³, V. García⁴, A. Gutiérrez⁵, M. Barreiro-de Acosta⁶, L. Cea-Calvo⁷, C. Romero⁷, B. Juliá⁷ ¹Servicio de Gastroenterología, Hospital La Fe, Valencia, Spain, ²Hospital Universitario La Paz, Gastroenterology Unit, Madrid, Spain, ³Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain, ⁴Hospital Universitario Reina Sofía, Unidad Clínica de Aparato Digestivo, Córdoba, Spain, ⁵Hospital General Universitario Alicante, Gastroenterology unit, Alicante, Spain, ⁶Complejo Hospitalario Universitario de Santiago, Gastroenterology Unit, Santiago de Compostela, Spain, ⁷MSD Spain, Medical Department, Madrid, Spain
11:30 - 11:50	31: Combined approach for intestinal sparing in CD? Paulo Kotze, Curitiba, Brazil
11:50 - 12:00	32: OP014: Histological remission is predictive of improved clinical outcomes in patients with Ulcerative Colitis: Results from the TOUCHSTONE OLE W. Sandborn¹, B. Feagan², G. D'Haens³, B. Levesque², R. Pai⁴, S. Hanauer⁵, D. Wolf⁶, S. Vermeire⁷, S. Ghosh⁸, C. Li⁹, D. Penenberg⁹, R. Aranda⁹, A. Olson⁹ ¹University of California San Diego, San Diego, United States, ²Robarts Research, London, Canada, ³Academic Medical Center, Amsterdam, Netherlands, ⁴Mayo Clinic, Department of Laboratory Medicine and Pathology, Scottsdale, United States, ⁵Feinberg School of Medicine, Chicago, United States, ⁶Atlanta Gastroenterology Associates, Atlanta, United States, ⁷University of Leuven, Leuven, Belgium, ⁸University of Calgary, Calgary, Canada, ⁹Receptos, a wholly owned subsidiary of Celgene, San Diego, United States
12:00 - 12:10	33: OP015: Cost-effectiveness of laparoscopic ileocecal resection versus infliximab treatment of terminal ileitis in Crohn's Disease: THE LIRIC TRIAL J. de Groof^{1,2}, W. Bemelman¹, E. Eshuis², T. Gardenbroek¹, P. Bossuyt³, J. Bosmans⁴, H. van Dongen⁴, B. van Wagensveld⁵, M. Brink⁶, E. Consten⁷, C. Buskens¹, G. D'Haens², P. Stokkers⁸, C. Ponsioen², LIRIC study group ¹Academic Medical Center, Surgery, Amsterdam, Netherlands, ²Academic Medical Center, Gastroenterology, Amsterdam, Netherlands, ³Academic Medical Center, Epidemiology, Amsterdam, Netherlands, ⁴VU, Health Sciences, Amsterdam, Netherlands, ⁵OLVG West, Surgery, Amsterdam, Netherlands, ⁶Meander Medical Center, Gastroenterology, Amersfoort, Netherlands, ⁷Meander Medical Center, Surgery, Amersfoort, Netherlands, ⁸OLVG West, Gastroenterology, Amsterdam, Netherlands
12:10 - 12:30	34: The ileorectal anastomosis in UC: Time for a comeback? Oded Zmora, Tel Aviv, Israel
12:30 - 13:30	Lunch & Guided Poster Session Please refer to page 40
12:40 - 13:20	Educational Lunchtime Satellite Symposia Please refer to pages 188-189

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

13:30 - 15:00	Scientific session 6: Intestinal inflammation - not always IBD	
	Chairs: Eugeni Domènech, Badalona, Spain Dror Shouval, Tel Aviv, Israel	
	Carousel: Epidemiologist – Vito Annese, Florence, Italy Basic Science – Britta Siegmund, Berlin, Germany Pathologist – Roger Feakins, London, United Kingdom Physician – James Lindsay, London, United Kingdom	
	13:30 - 13:50	35: Microscopic colitis Carousel
	13:50 - 14:00	36: OP016: Potential role of bile acid receptor FXR in microscopic colitis C. Palmela¹ , J. Torres ¹ , P. Gomes de Sena ² , M.P. Costa Santos ¹ , C. Gouveia ¹ , M.H. Oliveira ² , C. M. P. Rodrigues ³ , M. Cravo ¹ , P. Borralho ^{4,5} ¹ Hospital Beatriz Ângelo, Gastroenterology Department, Loures, Portugal, ² Hospital Beatriz Ângelo, Pathology Department, Loures, Portugal, ³ Faculty of Pharmacy, Universidade de Lisboa, Research Institute for Medicines, Lisboa, Portugal, ⁴ Hospital Cuf Descobertas, Pathology Department, Lisboa, Portugal, ⁵ Universidade de Lisboa, Faculty of Medicine, Lisboa, Portugal
	14:00 - 14:20	37: IBDU Carousel
	14:20 - 14:30	38: OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach M. de Jong^{1,2} , A. van der Meulen-de Jong ³ , M. Romberg-Camps ⁴ , M. Becc ⁵ , M. Cilissen ¹ , J. Maljaars ³ , A. van Bodegraven ⁴ , N. Mahmood ⁵ , T. Markus ⁶ , W. Hameeteman ¹ , G. Dijkstra ⁷ , A. Masclee ^{1,2} , A. Boonen ^{8,9} , D. Jonkers ^{1,2} , A. van Tubergen ^{8,9} , M. Pierik ^{1,2} ¹ Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ² Maastricht University Medical Center (MUMC), NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³ Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁴ Zuyderland Medical Centre, Department of Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, ⁵ St. Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, Netherlands, ⁶ CCUVN, Woerden, Netherlands, ⁷ University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ⁸ Maastricht University Medical Center (MUMC), Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, ⁹ Maastricht University Medical Center (MUMC), CAPRI – School for Public Health and Primary Care, Maastricht, Netherlands
	14:30 - 14:40	39: OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type S. Kanis¹ , A. de Lima, C. van der Woude Erasmus University Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands
	14:40 - 15:00	40: Eosinophilic enteritis Carousel

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

EITHER:

15:00 - 15:40		Scientific session 7: ECCO Fellowships and Grants Britta Siegmund, Berlin, Germany Gionata Fiorino, Milan, Italy Plenary Hall, Ground level, CCIB
15:00 - 15:07		41: Outcomes from the 2015-2016 Fellowships: Post-genomic application in general, and the establishment of computational approaches relevant to translational medicine Ferdinando Bonfiglio, Stockholm, Sweden
15:07 - 15:14		42: Outcomes from the 2015-2016 Fellowships: Hypoxia, antophagy and inflammasome Jesús Cosín, Valencia, Spain
15:14 - 15:20		43: Announcement of ECCO Fellowships & Grants 2017
15:20 - 15:30		44: OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn's Disease treated with mongersen (GED-0301) B. Feagan¹ , J.-F. Colombel ² , G. Rossiter ³ , X. Li ³ , K. Usiskin ³ , X. Zhan ³ , B. Sands ² ¹ Robarts Clinical Trials and University of Western Ontario, London, Canada, ² Icahn School of Medicine at Mount Sinai, New York, United States, ³ Celgene Corporation, Summit, United States
15:30 - 15:40		45: OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease A. Gils¹ , E. Dreesen ¹ , G. Compernelle ¹ , M. Peeters ¹ , E. Brouwers ¹ , S. Tops ¹ , V. Ballet ¹ , M. Noman ² , M. Ferrante ² , G. Van Assche ² , S. Vermeire ² ¹ KU Leuven, P.O. Box 820 Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ² UZ Leuven, Campus Gasthuisberg, Department of Gastroenterology and Hepatology, Leuven, Belgium
15:40 - 16:10		Coffee break
16:10 - 17:10		Scientific session 8: IBD Horizons Bruce Sands, New York, United States Herbert Tilg, Innsbruck, Austria Plenary Hall, Ground level, CCIB
16:10 - 16:20		46: OP021: Hyperbaric oxygen therapy is safe and effective for hospitalised Ulcerative Colitis patients suffering from moderate-severe flares: A multi-center, randomised, double-blind, sham-controlled trial P. Dulai^{1,2} , J. Buckley Jr. ² , L. Raffals ³ , J. Swoger ⁴ , P. Claus ³ , K. O'Toole ⁴ , J. Ptak ² , M. Gleeson ² , C. Widjaja ¹ , J. Adler ² , N. Patel ² , L. Skinner ² , S. Haren ³ , K. Goldby-Reffner ⁴ , K. Thompson ² , R. Knight ¹ , J. Chang ¹ , C. Siegel ² ¹ University of California San Diego, La Jolla, CA, United States, ² Dartmouth Hitchcock Medical Center, Lebanon, NH, United States, ³ Mayo Clinic, Rochester, MN, United States, ⁴ University of Pittsburgh Medical Center, Pittsburgh, PA, United States

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

16:20 - 16:30	47: OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study R. Kalla¹, A. Adams¹, S. Vatn², D. Bergemalm³, P. Ricanek⁴, J. Lindstrom², A. Ocklind⁵, N. Nordberg⁵, N. Kennedy¹, N. Venham¹, IBD Character Consortium⁶, M. Vatn⁴, J. Söderholm⁷, M. Pierik⁸, L. Törkvist⁹, F. Gomollón¹⁰, J. Jahnsen², J. Halfvarson³, J. Satsangi¹ ¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²Akershus University Hospital, Department of Gastroenterology, Lørenskog, Norway, ³Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ⁴University of Oslo, Institute of Clinical Medicine, Oslo, Norway, ⁵Linköping Proteomics, Uppsala, Sweden, ⁶IBD Character Consortium, Edinburgh, United Kingdom, ⁷Linköping University, Gastroenterology, Linköping, Sweden, ⁸Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁹Karolinska Institutet, Department of Clinical Science, Intervention and Technology, Karolinska, Sweden, ¹⁰HCU "Lozano Blesa", IIS Aragón, CIBEREHD, Zaragoza, Spain
16:30 - 16:40	48: OP023: Maintenance of clinical effect in patients with Moderate-to-Severe Crohn's Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study S. Vermeire¹, S. Schreiber², R. Petryka³, T. Kuehbach⁴, X. Hebuterne⁵, X. Roblin⁶, M. Klopocka⁷, A. Goldis⁸, M. Wisniewska-Jarosinska⁹, A. Baranovsky¹⁰, R. Sike¹¹, K. Stoyanova¹², L. Meuleners¹³, C. Tasset¹³, A. Van der Aa¹³, P. Harrison¹³ ¹University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ²University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³Vivamed, Warsaw, Poland, ⁴Asklepios Hospital West Hamburg, Department of Gastroenterology, Hamburg, Germany, ⁵CHU Nice Hopital l'Archet, Department of Gastroenterology and Nutrition, Nice Cedex 3, France, ⁶North Hospital, Department of Gastroenterology, Saint Priez en Jarez, France, ⁷NC University in Toruń, Collegium Medicum, Bydgoszcz, Poland, ⁸Dr. Goldis Center for Gastroenterology, Ltd., Timisoara, Romania, ⁹Santa LLC, Santa Familia Research, Prevention and Treatment Centre, Lodz, Poland, ¹⁰City Clinical Hospital #31, St. Petersburg, Russian Federation, ¹¹Szent Margit Hospital, Budapest, Hungary, ¹²PSI Pharma Support EOOD, Sofia, Bulgaria, ¹³Galapagos NV, Mechelen, Belgium
16:40 - 16:50	49: OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014 O. Olén^{1,2}, J. Askling¹, P. Frumento³, M.C. Sachs⁴, M. Neovius⁵, J. Eriksson¹, K.E. Smedby¹, A. Ekboom¹, P. Malmberg^{1,2}, J.F. Ludvigsson^{4,5,6,7} ¹Karolinska Institutet, Department of Medicine Solna, Clinical Epidemiology Unit, Stockholm, Sweden, ²Sachs' Children's Hospital, Department of Pediatric Gastroenterology and Nutrition, Stockholm, Sweden, ³Karolinska Institutet, Institute of Environmental Medicine, Stockholm, Sweden, ⁴Karolinska Institutet, Department of Medical Epidemiology and Biostatistics, Stockholm, Sweden, ⁵Örebro University Hospital, Department of pediatrics, Örebro, Sweden, ⁶University of Nottingham, Division of Epidemiology and Public Health, School of Medicine, Nottingham, United Kingdom, ⁷Columbia University College of Physicians and Surgeons, Department of Medicine, New York, Sweden

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

16:50 - 17:00	50: OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn's Disease in clinical practice S. Steiner¹ , E. King ² , K. Park ³ , D. Pashankar ⁴ , H. Shashidhar ⁵ , B. Sudel ⁶ , S. Eichner ⁷ , S. Chen ² , J. Pratt ² , R. Colletti ⁸ , ImproveCareNow Network ⁹ ¹ Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, United States, ² Cincinnati Children's Hospital Medical Center, Cincinnati, United States, ³ Lucile Salter Packard Children's Hospital, Stanford University, Palo Alto, United States, ⁴ Yale-New Haven Children's Hospital, New Haven, United States, ⁵ New Hampshire's Hospital for Children, Manchester, United States, ⁶ University of Minnesota Masonic Children's Hospital, Minneapolis, United States, ⁷ AbbVie, North Chicago, United States, ⁸ University of Vermont Children's Hospital, Burlington, United States, ⁹ ImproveCareNow, Burlington, United States
17:00 - 17:10	51: OP026: Zero diagnostic yield of dysplasia in polyp adjacent biopsies for patients with Inflammatory Bowel Disease C. Lahiff¹ , L.M. Wang ² , S.P.L. Travis ¹ , J.E. East ¹ ¹ Nuffield Department of Clinical Medicine, University of Oxford, John Radcliffe Hospital, Translational Gastroenterology Unit, Experimental Medicine Division, Oxford, United Kingdom, ² John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust, Department of Cellular Pathology, Oxford, United Kingdom

OR:

15:00 - 17:10	Scientific session 9: Basic Science meets the clinic Arthur Kaser, Cambridge, United Kingdom Azucena Salas, Barcelona, Spain Room 111, Level 1, CCIB
----------------------	--



Y-ECCO
Abstract Award

15:00 - 15:20	52: IL-23 and beyond Fiona Powrie, Oxford, United Kingdom
15:20 - 15:30	53: OP027: IL-33/ST2 axis sustains gut mucosal wound healing and cancerogenesis in Colitis-associated colorectal cancer L.R. Lopetuso^{1,2} , C. De Salvo ³ , L. Di Martino ³ , W. Goodman ³ , F. Scalfaferrri ⁴ , A. Gasbarrini ⁴ , T.T. Pizarro ³ ¹ Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy, ² Case Western Reserve University, Pathology, Cleveland, United States, ³ Case Western Reserve University, Pathology, Cleveland, United States, ⁴ Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy
15:30 - 15:40	54: OP028: Gut specific regulatory T cells – a new frontier for Crohn's Disease therapy R. Goldberg^{1,2,3,4} , C. Scotta ^{3,4,5} , D. Cooper ⁶ , E. Eliraz ⁷ , E. Nir ⁷ , P. Irving ^{1,8} , J. Sanderson ^{1,8} , N. Shpigiel ⁷ , F. Marelli-Berg ⁹ , G. Lombardi ^{3,4,5} , G. Lord ^{2,3,4} ¹ Guy's and St Thomas' NHS Trust, Gastroenterology, London, United Kingdom, ² King's College London, Experimental Immunobiology, London, United Kingdom, ³ King's College London, Medical Research Council Centre for Transplantation, London, United Kingdom, ⁴ Guy's and St Thomas' NHS Trust, National Institute for Health Research Biomedical Research Centre, London, United Kingdom, ⁵ King's College London, Immunoregulation and Immune Intervention, London, United Kingdom, ⁶ Bart's and the London Queen Mary School of Medicine and Dentistry, William Harvey Research Institute, London, United Kingdom, ⁷ Hebrew University of Jerusalem, Koret School of Veterinary Medicine, Rehovot, Israel, ⁸ King's College London, Diabetes and Nutritional Sciences, London, United Kingdom

OP = Oral presentation – Best abstracts

Friday, February 17, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB (Scientific sessions 7 & 8)

Room 111, Level 1, CCIB (Scientific session 9)

15:40 - 16:10 Coffee break	
16:10 - 16:30	55: Genetics and function in IBD: The missing link? Sebastian Zeissig, Dresden, Germany
16:30 - 16:40	56: OP029: Hypoacetylation of histone-3 is a hallmark of intestinal fibrosis in Crohn's Disease A. Lewis¹ , C. Felice ^{1,2} , A. Nihhuis ¹ , S. Iqbal ¹ , S. Mehta ¹ , R. Feakins ³ , A. Armuzzi ² , A. Silver ¹ , J. Lindsay ⁴ ¹ Queen Mary's University London, Centre for Genomics and Child Health, Blizard Institute, London, United Kingdom, ² Gemelli Hospital Catholic University Foundation, IBD Unit, Presidio Columbus, Rome, Italy, ³ The Royal London Hospital, Department of pathology, London, United Kingdom, ⁴ Queen Mary's University
16:40 - 16:50	57: OP030: Identification of disease-relevant bacterial signatures in gnotobiotic IL-10 deficient mice using fecal samples from IBD patients undergoing hematopoietic stem cell transplantation A. Metwaly¹ , L. F. Buttó ¹ , N. Waldschmitt ¹ , I. Lagkouravdos ² , A.M. Corraliza ³ , A. Mayorgas ³ , M. Martinez-Medina ⁴ , M. Allez ⁵ , J. Panes ³ , A. Salas ³ , D. Haller ^{1,2} ¹ Technical University Munich, Chair of Nutrition and Immunology, Freising, Germany, ² ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany, ³ Instituto de Investigaciones Biomédicas de Barcelona CSIC, IDIBAPS, CIBERehd, Department of Experimental Pathology, Barcelona, Spain, ⁴ Laboratory of Molecular Microbiology, Universitat de Girona, Biology Department, Girona, Spain, ⁵ APHP, Hôpital Saint Louis, INSERM UMR5 1160, Paris Diderot, Sorbonne Paris-Cité University, Department of Gastroenterology, Paris, France
16:50 - 17:10	58: Epigenetics in complex diseases Manel Esteller, Barcelona, Spain
17:20 - 18:20	Digital oral presentations Please refer to pages 43-67
18:30 - 19:30	Industry sponsored satellite symposia 4a & 4b Please refer to page 190
20:30	ECCO Interaction: Hearts & Minds Please refer to page 207

Saturday, February 18, 2017

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

07:15 - 08:15	Industry sponsored satellite symposia 5a & 5b Please refer to page 192
08:30 - 10:20	Scientific session 10: New compounds in the treatment of IBD John Mansfield, Newcastle upon Tyne, United Kingdom Pieter Hindryckx, Ghent, Belgium
08:30 - 08:50	59: JAK-inhibitors Séverine Vermeire, Leuven, Belgium
08:50 - 09:00	60: OP032: Long-term safety and tolerability of oral tofacitinib in patients with Crohn's Disease: Results from a phase 2 open-label 48-week extension study J. Panés¹ , G.R. D'Haens ² , P.D.R. Higgins ³ , L. Mele ⁴ , M. Moscarello ⁴ , G. Chan ⁴ , W. Wang ⁴ , W. Niezychowski ² , C. Su ⁴ , E. Maller ⁴ ¹ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ² Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ³ University of Michigan, Ann Arbor, MI, United States, ⁴ Pfizer Inc, Collegeville, PA, United States
09:00 - 09:10	61: OP032: Efficacy and safety of oral tofacitinib as maintenance therapy in patients with Moderate to Severe Ulcerative Colitis: Results from a phase 3 randomised controlled trial W.J. Sandborn ¹ , B.E. Sands ² , S. Danese ³ , G.R. D'Haens ⁴ , S. Vermeire ⁵ , S. Schreiber ⁶ , B. Feagan ⁷ , W. Reinisch ^{8,9} , G. Friedman ¹⁰ , D. Woodworth ¹⁰ , H. Zhang ¹⁰ , N. Lawendy ¹⁰ , W. Niezychowski ¹⁰ , C. Su ¹⁰ , J. Panés¹¹ ¹ Division of Gastroenterology, University of California, San Diego, La Jolla, CA, United States, ² Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, NY, United States, ³ IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁴ Department of Gastroenterology, Academic Medical Centre, Amsterdam, Netherlands, ⁵ Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium, ⁶ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁷ Robarts Clinical Trials, Inc., Robarts Research Institute, Western University, London, ON, Canada, ⁸ McMaster University, Hamilton, ON, Canada, ⁹ Medical University of Vienna, Vienna, Austria, ¹⁰ Pfizer Inc, Collegeville, PA, United States, ¹¹ Hospital Clinic de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain
09:10 - 09:20	62: OP033: Reduction of tissue pSTAT3 in Crohn's Disease patients treated with filgotinib (GLPG0634, GS-6034), a JAK1-selective inhibitor S. Vermeire ¹ , G. De Hertogh² , G. Chen ³ , D. French ⁴ , E. Huntzicker ⁴ , A. Van der Aa ⁵ , T. Van Kaem ⁵ , P. Harrison ⁵ , C. Tasset ⁵ , R. Galien ⁶ , Y. Pan ⁴ , B. Feagan ⁷ , W. Sandborn ⁸ ¹ University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ² University Hospitals Leuven, Department of Pathology, Leuven, Belgium, ³ Gilead Sciences, Department of Biostatistics, Foster City, United States, ⁴ Gilead Sciences, Biomarker Sciences, Foster City, United States, ⁵ Galapagos NV, Mechelen, Belgium, ⁶ Galapagos SASU, Romainville, France, ⁷ Robarts Research Institute, Ontario, Canada, ⁸ University of California, Division of Gastroenterology, San Diego, United States
09:20 - 09:40	63: S1P modulators Arthur Kaser, Cambridge, United Kingdom

Saturday, February 18, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

09:40 - 09:50	64: OP034: Efficacy and safety of abrilumab in subjects with Moderate to Severe Ulcerative Colitis: Results of a phase 2b, randomised, double-blind, multiple-dose, placebo-controlled study W.J. Sandborn¹, M. Cyrille², M.B. Hansen³, B.G. Feagan⁴, E.V. Loftus Jr⁵, G. Rogler⁶, S. Vermeire⁷, M.L. Cruz², J. Yang², B.A. Sullivan², W. Reinisch⁸ ¹University of California San Diego, Department of Gastroenterology, La Jolla, United States, ²Amgen, Thousand Oaks, United States, ³University of Copenhagen, Copenhagen, Denmark, ⁴Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, ⁵Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁶Universitätsspital Zurich, Zurich, Switzerland, ⁷University Hospital Gasthuisberg, Leuven, Netherlands, ⁸Medical University of Vienna, Vienna, Austria
09:50 - 10:00	65: OP035: Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for Moderate to Severe Crohn's Disease W.J. Sandborn¹, M. Cyrille², M. Berner Hansen³, B.G. Feagan⁴, E.V. Loftus Jr⁵, S. Vermeire⁶, M.L. Cruz², M. Mo², B.A. Sullivan², W. Reinisch⁷ ¹University of California San Diego, La Jolla, United States, ²Amgen Inc., Thousand Oaks, United States, ³University of Copenhagen, Copenhagen, Denmark, ⁴Robarts Research Institute, University of Western Ontario, London, Canada, ⁵Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁶University Hospitals Leuven, Leuven, Belgium, ⁷Medical University Vienna, Vienna, Austria
10:00 - 10:20	66: Anti IL12/IL23 compounds Bruce Sands, New York, United States
10:20 - 10:50	Coffee break
10:50 - 12:20	Scientific session 11: Gut luminal content – more than just bacteria Isabelle Cleynen, Leuven, Belgium Miquel Gassull, Barcelona, Spain
10:50 - 11:10	67: The forgotten populations in the gut Patricia Lepage, Jouy-En-Josas, France
11:10 - 11:20	68: OP036: Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active Ulcerative Colitis: A randomised controlled trial S. Costello^{1,2,3}, O. Waters⁴, R. Bryant^{2,3}, R. Katsikeros³, J. Makanyanga⁴, M. Schoeman^{2,3}, R. Mountfield⁵, D. Tee⁶, S. Howell⁷, P. Hughes⁷, M. Conlon⁷, I. Roberts-Thomson^{1,2}, J. Andrews^{2,3} ¹The Queen Elizabeth Hospital, Gastroenterology, Woodville, Australia, ²University of Adelaide, School of Medicine, Adelaide, Australia, ³The Royal Adelaide Hospital, Gastroenterology and Hepatology, Adelaide, Australia, ⁴Fiona Stanley Hospital, Gastroenterology, Murdoch, Australia, ⁵Flinders Medical Centre, Gastroenterology, Bedford Park, Australia, ⁶Lyell McEwin Hospital, Gastroenterology, Elizabeth Vale, Australia, ⁷CSIRO, Health and Biosecurity, Adelaide, Australia
11:20 - 11:40	69: Metabolic activity Dirk Haller, Freising, Germany



IIS
Abstract Award

Saturday, February 18, 2017, cont.

Scientific programme day by day (as of January 16, 2017)

Plenary Hall, Ground level, CCIB

11:40 - 11:50	70: OP037: Infants born to mothers with Inflammatory Bowel Disease exhibit distinct microbiome features that persist up to 3 months of life J. Torres¹, J. Hu², C. Eisele², N. Nair², H. Panchal², X. Bao², X. Niu², J. Coté-Daigneault¹, B. Jharap¹, E. Maser¹, A. Kornbluth¹, P. Legnani¹, J. George¹, M. Dubinsky³, J. Stone⁴, C.-L. Chen⁴, J. Clemente^{2,5}, J.-F. Colombel¹, I. Peter² ¹Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, ²Icahn School of Medicine at Mount Sinai, Genetics and Genomic Sciences, New York, United States, ³Icahn School of Medicine at Mount Sinai, Department of Pediatrics, New York, United States, ⁴Icahn School of Medicine at Mount Sinai, Obstetrics, Gynecology and Reproductive Science, New York, United States, ⁵Icahn School of Medicine at Mount Sinai, Immunology, New York, United States
11:50 - 12:00	71: OP038: Impact of ileocecal resection in Crohn's Disease patients on mucosal microbiota K. Machiels¹, M. Pozuelo del Río², J. Sabino¹, A. Santiago², D. Campos², A. Wolthuis³, A. De Buck Van Overstraeten³, A. D'Hooze², G. Van Assche¹, M. Ferrante¹, P. Rutgeerts¹, G. De Hertogh³, S. Vermeire¹, C. Manichanh² ¹University Hospitals Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ²Vall d'Hebron Research Institute, Barcelona, Spain, ³University Hospitals Leuven, KU Leuven, Leuven, Belgium
12:00 - 12:20	72: Microbiome reality check – looking beyond the hype Jeroen Raes, Ghent, Belgium
12:20 - 12:50	Scientific session 12: ECCO Lecture Julián Panés, Barcelona, Spain Silvio Danese, Milan, Italy
12:20 - 12:50	73: Best individualised IBD care – optimising drugs, psychology, diet and microbes Michael Kamm, Melbourne, Australia
12:50 - 12:55	74: Awards and closing remarks Julián Panés, Barcelona, Spain
12:55 - 13:00	75: The ECCO Film

"IBD innovations driving clinical decisions"

Thursday, March 17, 2016

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

	10:45 - 11:15	Top tips for chairs (closed session) Laurence Egan, Galway, Ireland
11:30 - 12:30	Industry sponsored satellite symposia 1a & 1b Please refer to pages 188-189	
12:45 - 12:50	1: Welcome Janneke van der Woude, Rotterdam, The Netherlands Bas Oldenburg, Utrecht, The Netherlands	
12:50 - 13:00	2: Opening Séverine Vermeire, Leuven, Belgium	
13:00 - 14:30	Scientific session 1: Cell therapy: Ready for clinical practice? Pierre Desreumaux, Lille, France Dominik Bettenworth, Munster, Germany	
	13:00 - 13:20	3: Haematopoietic stem cell transplantation Azucena Salas, Barcelona, Spain Elena Ricart, Barcelona, Spain
	13:20 - 13:30	4: Best abstract: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulae in Crohn's Disease J. Panés¹ , D. García-Olmo ² , G. van Assche ³ , J.F. Colombel ⁴ , W. Reinisch ⁵ , D.C. Baumgart ⁶ , M. Nachury ⁷ , M. Ferrante ³ , L. Kazemi-Shirazi ⁸ , J.C. Grimaud ⁹ , F. de la Portilla ⁹ , E. Goldin ¹⁰ , A. Leselbaum ¹¹ , M.C. Diez ¹¹ , S. Danese ¹² ¹ Hospital Clínic Barcelona, Barcelona, Spain, ² Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³ University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Medical University of Vienna, Vienna, Austria, ⁶ Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷ CHU Lille, Lille, France, ⁸ Hôpital Nord, Marseille, France, ⁹ Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰ Sharee Zedek MC, Jerusalem, Israel, ¹¹ TiGenix, Madrid, Spain, ¹² Istituto Clinico Humanitas, Milano, Italy
	13:30 - 13:50	5: Immune cell manipulation Graham Lord, London, United Kingdom Matthieu Allez, Paris, France
	13:50 - 14:00	6: Best abstract: Histopathological response and remission after dual topical application of the toll-like-receptor 9 agonist DIMS0150 in patients with moderate to severe Ulcerative Colitis R. Atreya¹ , A. Öst ² , C. Admyre ³ , A. Karlsson ³ , T. Knittel ³ , J. Kowalski ³ , F. Scaldaferri ⁴ , M. Neurath ¹ , C. Hawkey ⁵ ¹ University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ² Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, ³ Index Pharmaceuticals, Stockholm, Sweden, ⁴ Catholic University of Rome, Internal Medicine Department, Gastroenterology Division, Rome, Italy, ⁵ Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

14:00 - 14:20	7: Mesenchymal stem cells Tandem talk: Stefania Vetrano, Milan, Italy Laurence Egan, Galway, Ireland
14:20 - 14:30	8: Best abstract: Predicting short and medium-term efficacy of the biosimilar infliximab: Trough levels/ADAs or clinical/biochemical markers play a more important role? P.A. Golovics¹ , Z. Vegh ¹ , M. Rutka ² , K. Gecse ¹ , A. Balint ² , K. Farkas ² , J. Banai ³ , L. Bene ⁴ , B. Gasztonyi ⁵ , T. Kristof ⁶ , L. Lakatos ⁷ , P. Miheller ⁸ , K. Palatka ⁹ , A. Patai ¹⁰ , A. Salamon ¹¹ , T. Szamosi ³ , Z. Szepes ¹² , G.T. Toth ¹³ , A. Vincze ¹⁴ , E. Biro ¹⁵ , B. Lovasz ¹ , Z. Kurti ¹ , F. Nagy ¹² , T. Molnar ² , P. Lakatos ¹ ¹ Semmelweis University, ^{1st} Department of Medicine, Budapest, Hungary, ² University of Szeged, ^{1st} Department of Medicine, Szeged, Hungary, ³ Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴ Peterfy Hospital, ^{1st} Department of Medicine, Budapest, Hungary, ⁵ Zala County Hospital, ^{2nd} Department of Medicine, Zalaegerszeg, Hungary, ⁶ B-A-Z County and University Teaching Hospital, ^{2nd} Department of Medicine, Miskolc, Hungary, ⁷ Csolnok F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸ Semmelweis University, ^{2nd} Department of Medicine, Budapest, Hungary, ⁹ University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰ Markusovszky Hospital, ^{1st} Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹¹ Tolna County Teaching Hospital, ^{1st} Department of Gastroenterology, Szekszard, Hungary, ¹² University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³ Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴ University of Pecs, ^{1st} Department of Medicine, Pecs, Hungary, ¹⁵ Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary
14:30 - 15:00	Coffee break

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

15:00 - 17:00 Scientific session 2: Application of genetic testing in understanding and managing IBD Andre Franke, Kiel, Germany Thomas Billiet, Heverlee, Belgium	
15:00 - 15:20	9: Very early onset IBD – from research to bedside Holm Uhlig, Oxford, United Kingdom
15:20 - 15:30	10: Best abstract: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn's Disease A. Stojmirovic, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman Janssen R & D, LLC, Spring House, United States
15:30 - 15:50	11: Genetics in predicting drug response Tariq Ahmad, Exeter, United Kingdom
15:50 - 16:00	12: Best abstract: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-TNF serum levels in IBD T. Billiet ¹ , I. Cleynen ¹ , M. Ferrante ² , G. van Assche ² , A. Gils ³ , S. Vermeire ² ¹ Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Leuven, Belgium, ² University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³ KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium
16:00 - 16:10	13: Best abstract: Autophagy regulates dendritic cell migration through Rac1 – implications for thiopurine therapy M. Wildenberg ¹ , P. Koelink ² , K. Diederens ² , A. te Velde ² , V. Nuij ³ , M. Peppelenbosch ³ , M. Nobis ⁴ , O. Sansom ⁴ , C.J. van der Woude ³ , G. D'Haens ¹ , G. van den Brink ¹ ¹ Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, ² Academic Medical Center, Tytgat Institute, Amsterdam, Netherlands, ³ Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ⁴ Beatson Institute for Cancer Research, Glasgow, United Kingdom
16:10 - 16:30	14: The future of genetics in clinical medicine Rinse Weersma, Groningen, The Netherlands
16:30 - 16:40	15: Best abstract: Comprehensive epigenome-wide DNA methylation profiling in Inflammatory Bowel Disease N. Ventham ¹ , N. Kennedy ¹ , A. Adams ¹ , R. Kalla ¹ , S. Heath ² , K. O'Leary ¹ , H. Drummond ¹ , D. Wilson ³ , on behalf of the IBD-BIOM Consortium ¹ , on behalf of the IBD-CHARACTER Consortium ¹ , I. Gut ² , E.R. Nimmo ¹ , J. Satsangi ¹ ¹ University of Edinburgh, CGEM, Edinburgh, United Kingdom, ² Centro Nacional de Análisis Genómico, Barcelona, Spain, ³ University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom



Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:40 - 16:50

16: Best abstract: Genotype-phenotype analysis across 130,422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis

R. Alberts¹, E.M. de Vries², G. Alexander³, D. Alvaro⁴, A. Bergquist⁵, U. Beuers², E. Björnsson⁶, K.M. Boberg⁷, C.L. Bowlus⁸, R.W. Chapman⁹, O. Chazouillères¹⁰, A. Cheung¹¹, G. Dalekos¹², B. Eksteen¹³, D. Ellinghaus¹⁴, M. Färkkilä¹⁵, E.A. Festen¹, A. Floreani¹⁶, T. Folseraas⁷, E. Goode¹⁷, D.N. Gotthardt¹⁸, G.M. Hirschfield¹⁹, B. van Hoek²⁰, K. Holm⁷, S. Hohenester²¹, J.R. Hov⁷, F. Imhann¹, P. Invernizzi²², X. Jiang⁷, J. Eaton²³, B.D. Juran²⁴, K.N. Lazaridis²⁴, V. Leppa²⁵, J.Z. Liu²⁶, J. Löfberg²⁷, M.P. Manns²⁸, H.-U. Marschall²⁹, M. Marziona³⁰, A.L. Mason³¹, E. Melum⁷, P. Milkiewicz³², T. Müller³³, A. Pares³⁴, C. Rupp³⁵, S.M. Rushbrook³⁶, C. Rust³⁷, F. Sampaziotis³⁸, R.N. Sandford³⁹, C. Schramm⁴⁰, S. Schreiber¹⁴, E. Schrumpf⁷, M. Silverberg⁴¹, B. Srivastava³⁹, M. Sterneck⁴², A. Teufel⁴³, L. Tittmann⁴⁴, L. Vallier³⁸, A.V. Vila¹, B. de Vries¹, T.J. Weismüller²⁸, C. Wijmenga⁴⁵, K. Zachou⁴⁶, A. Franke¹⁴, C.A. Anderson²⁶, T.H. Karlsen⁷, C.Y. Ponsioen², R.K. Weersma¹

¹University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ³University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, ⁴Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, ⁵Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, ⁶Landspitli University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, ⁷Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Center, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, ⁸University of California Davis, Division of Gastroenterology and Hepatology, Davis, United States, ⁹John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, ¹⁰Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, ¹¹University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, ¹²Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, ¹³University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, ¹⁴Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, ¹⁵Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, ¹⁶University of Padova, Department of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, ¹⁷Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, ¹⁸University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, ¹⁹University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, ²⁰Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ²¹University of Munich, Department of Medicine II, Munich, Germany, ²²Humanitas Clinical and Research Center, Center for Autoimmune Liver Diseases, Rozzano, Italy, ²³Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ²⁴Mayo Clinic, College of Medicine, Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, United States,

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:40 - 16:50 cont.	²⁵Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, ²⁶Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, ²⁷Karolinska Institute, Stockholm, Sweden, ²⁸Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, ²⁹Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, ³⁰Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, ³¹University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Canada, ³²Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, ³³Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, ³⁴University of Barcelona, Liver Unit, Hospital Clínic, I.D.I.B.A.P.S., C.I.B.E.R.ehd, Barcelona, Spain, ³⁵University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, ³⁶University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, ³⁷University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, ³⁸Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, ³⁹University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, ⁴⁰University Medical Center Hamburg-Eppendorf, ¹st Department of Medicine, Hamburg, Germany, ⁴¹Mount Sinai Hospital Toronto, Inflammatory Bowel Disease (IBD) Group, Zane Cohen Centre for Digestive Diseases, Toronto, Canada, ⁴²University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, ⁴³University of Mainz, ¹st Department of Medicine, Mainz, Germany, ⁴⁴Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, ⁴⁵University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, ⁴⁶University of Thessaly, Department of Internal Medicine, Larissa, Greece
16:50 - 17:00	17: Best abstract: Gene-microbiome interactions underlying the onset and the clinical phenotypes of Inflammatory Bowel Disease F. Imhann¹, A. Vich Vila¹, M.J. Bonder², D. Gevers³, J. Fu², M.C. Visschedijk¹, L.M. Spekhorst¹, L. Franke⁴, H. van Dullemen¹, R.W.F. Ter Steege¹, C. Huttenhower⁵, G. Dijkstra¹, R.J. Xavier⁶, C. Wijmenga², E.A.M. Festen¹, A. Zhernakova², R.K. Weersma¹ ¹University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²University of Groningen and University Medical Center Groningen, Department of Genetics, Groningen, Netherlands, ³The Broad Institute of MIT and Harvard, Cambridge, United States, ⁴Harvard School of Public Health, Biostatistics Department, Boston, United States
17:15 - 18:15	Digital oral presentations (Sessions 1-5) Please refer to pages 42-54
17:15 - 18:15	Industry sponsored satellite symposia 2a & 2b Please refer to pages 189-190

Friday, March 18, 2016

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

07:15 - 08:15	Industry sponsored satellite symposia 3a & 3b Please refer to pages 190-191
08:30 - 09:30	Scientific session 3: Resolution of inflammation Javier Gisbert, Madrid, Spain Giovanni Monteleone, Rome, Italy
08:30 - 08:50	18: Mechanisms by which inflammation resolves Silvio Danese, Milan, Italy
08:50 - 09:10	19: Stopping drugs Charlie Lees, Edinburgh, United Kingdom
09:10 - 09:20	20: Best abstract: Azathioprine dose reduction in Inflammatory Bowel Disease patients on combination therapy: A prospective study E. Del Tedesco ¹ , S. Paul ² , H. Marotte ³ , C. Jarlot ¹ , N. Williet ⁴ , J.M. Phelip ⁴ , L. Peyrin-Biroulet ⁵ , J.F. Colombel ⁶ , X. Roblin⁴ ¹ University Hospital, Gastroenterology, Saint Etienne, France, ² University of Saint Etienne, Immunology, Saint Etienne, France, ³ University Hospital, Rheumatology, Saint Etienne, France, ⁴ CHU Saint Etienne, Saint Etienne, France, ⁵ CHU de Nancy, Department of Gastroenterology, Vandoeuvre-Lès-Nancy, France, ⁶ Mount Sinai Hospital, New York, United States
09:20 - 09:30	21: Best abstract: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn's Disease: A prospective, multicentre, open-labeled clinical trial (DIAMOND study) T. Matsumoto¹ , S. Motoya ² , K. Watanabe ³ , T. Hisamatsu ⁴ , H. Nakase ⁵ , N. Yoshimura ⁶ , T. Ishida ⁷ , S. Kato ⁸ , T. Nakagawa ⁹ , M. Esaki ¹⁰ , M. Nagahori ¹¹ , T. Matsui ¹² , Y. Naito ¹³ , T. Kanai ¹⁴ , Y. Suzuki ¹⁵ , M. Nojima ¹⁶ , M. Watanabe ¹¹ , T. Hibi ¹⁷ ¹ Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, ² Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, ³ Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, ⁴ Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, ⁵ Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, ⁶ Tokyo Yamate Medical Center, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, ⁷ Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ⁸ Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, ⁹ Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, ¹⁰ Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, ¹¹ Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ¹² Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ¹³ Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, ¹⁴ Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, ¹⁵ Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ¹⁶ The Institute of Medical Science Hospital, The University of Tokyo, Center for Translational Research, Tokyo, Japan, ¹⁷ Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

09:30 - 10:30		Scientific session 4: Viruses and IBD Laurent Beaugerie, Paris, France Marina Shapina, Moscow, Russia
 Y-ECCO Abstract Award  Y-ECCO Abstract Award	09:30 - 09:50	22: Should we treat CMV in patients with UC? Britta Siegmund, Berlin, Germany
	09:50 - 10:00	23: Best abstract: Risk factors for colorectal neoplasia in Ulcerative Colitis: Results from the largest and longest-running colonoscopic surveillance programme C.H.R. Choi^{1,2} , I. Al Bakir ^{1,2} , N.S.J. Ding ¹ , M. Moorghen ¹ , S. Thomas-Gibson ¹ , J. Warusavitarne ¹ , B. Saunders ¹ , M. Rutter ³ , T. Graham ² , A. Hart ¹ ¹ St. Mark's Hospital, London, United Kingdom, ² Barts Cancer Institute, Tumour Biology, London, United Kingdom, ³ University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom
	10:00 - 10:10	24: Best abstract: Evolution of corticosteroid use in Crohn's Disease patients between 1991 and 2014: Results from the Dutch population-based IBDSL cohort S. Jeuring^{1,2} , V. Biemans ¹ , L. Liu ¹ , T. van den Heuvel ^{1,2} , M. Zeegers ^{3,4} , W. Hameeteman ¹ , M. Romberg-Camps ⁵ , L. Oostenbrug ⁶ , A. Masclee ^{1,2} , D. Jonkers ^{1,2} , M. Pierik ^{1,2} ¹ Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ² Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³ Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴ Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵ Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶ Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands
	10:10 - 10:30	25: Other viral complications in clinical practice Jonas Halfvarsson, Örebro, Sweden
10:30 - 11:00		Coffee break

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:00 - 12:20		Scientific session 5: Challenging dogmas – from clinical trials to clinical practice Torsten Kucharzik, Lüneburg, Germany Maria Chaparro, Madrid, Spain
	11:00 - 11:20	26: Mucosal healing – Is it the holy grail? Geert D'Haens, Amsterdam, The Netherlands
	11:20 - 11:30	27: Best abstract: A multicentre, double-blind, placebo-controlled phase3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn's Disease refractory to anti-TNFα: UNITI-1 P. Rutgeerts¹ , C. Gasink ² , M. Blank ³ , Y. Lang ² , J. Johanns ² , L.-L. Gao ² , B. Sands ² , S. Hanauer ² , B. Feagan ⁶ , S. Targan ⁷ , S. Ghosh ⁸ , W. de Villiers ⁹ , J.-F. Colombel ¹⁰ , S. Lee ¹¹ , P. Desreumaux ¹² , E.V. Loftus Jr ¹³ , S. Vermeire ¹⁴ , W.J. Sandborn ¹⁵ ¹ University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, ² Janssen R & D, LLC, Spring House, United States, ³ Janssen Scientific Affairs, LLC., Horsham, United States, ⁴ Mount Sinai Medical Center, New York, United States, ⁵ Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶ Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, ⁷ Cedars-Sinai Medical Center, Division of Gastroenterology, Los Angeles, United States, ⁸ University of Calgary, Department of Gastroenterology, Calgary, Canada, ⁹ Universiteit Stellenbosch University, Stellenbosch, South Africa, ¹⁰ Mount Sinai, Icahn School of Medicine, New York, United States, ¹¹ University of Washington, Seattle, United States, ¹² University of Lille, Lille, France, ¹³ Mayo Clinic Rochester, Department of Gastroenterology, Rochester, United States, ¹⁴ University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ¹⁵ University of California San Diego, Division of Gastroenterology, La Jolla, United States
	11:30 - 11:40	28: Best abstract: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's Disease who are anti-TNF inadequate responders S. Danese¹ , S. Vermeire ² , P. Hellstern ³ , R. Panaccione ⁴ , G. Rogler ⁵ , G. Fraser ⁶ , A. Kohn ⁷ , P. Desreumaux ⁸ , R.W. Leong ⁹ , G.M. Comer ¹⁰ , F. Cataldi ¹⁰ , A. Banerjee ¹⁰ , M.K. Maguire ¹¹ , C. Li ¹⁰ , N. Rath ¹¹ , J. Beebe ¹⁰ , S. Schreiber ¹² ¹ Humanitas University Clinical and Research Hospital, Rozzano, Milan, Italy, ² University Hospitals Leuven, Leuven, Belgium, ³ Nature Coast Clinical Research, Inverness, United States, ⁴ University of Calgary, Calgary, Canada, ⁵ University of Zürich, Zürich, Switzerland, ⁶ Rabin Medical Centre and University of Tel-Aviv, Petah Tikva, Israel, ⁷ AO San Camillo Forlanini, Rome, Italy, ⁸ University of Lille, Inserm U995, Lille, France, ⁹ Concord Hospital, Sydney, New South Wales, Australia, ¹⁰ Pfizer Inc, Cambridge, United States, ¹¹ Pfizer Inc, Collegeville, United States, ¹² Christian-Albrechts University, Kiel, Germany
	11:40 - 12:00	29: Patient-reported outcomes William Sandborn, San Diego, United States
	12:00 - 12:20	30: Should clinical trials in children be different? Dan Turner, Jerusalem, Israel
12:20 - 13:20		Lunch break and guided poster session in the exhibition hall Please refer to pages 38-39
12:30 - 13:10		Industry sponsored educational lunchtime satellite symposia LS1-4 Please refer to pages 191-192

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

13:20 - 14:50	Scientific session 6: Bugs and drugs in IBD Philippe Seksik, Paris, France Barry Hall, Dublin, Ireland
13:20 - 13:40	31: The microbiome and geographical spread of IBD Philip Rosenstiel, Kiel, Germany
13:40 - 13:50	32: Best abstract: Development and validation of diagnostic criteria for IBD-Unclassified (IBDU) in children: A multicentre longitudinal study from the Paediatric IBD Porto group of ESPGHAN L. Birmberg Schwartz ¹ , D. Zucker ² , A. Akriv ² , C. Salvatore ³ , F. Cameron ⁴ , I. Lazowska ⁵ , L. Yianni ⁶ , P. Siba ⁷ , S. Kolacek ⁸ , C. Romano ⁹ , S. Buderus ¹⁰ , A. Pærregaard ¹¹ , J. C. Escher ¹² , D. Turner ¹³ ¹ Shaare Zedek Medical Center, Paediatrics, Jerusalem, Israel, ² The Hebrew University, Jerusalem, Israel, ³ Sapienza University of Rome, Rome, Italy, ⁴ Yorkhill Children's Hospital, Glasgow, United Kingdom, ⁵ Medical University of Warsaw, Warsaw, Poland, ⁶ University Hospital Southampton, Hampshire, United Kingdom, ⁷ University of Dundee, Scotland, United Kingdom, ⁸ Zagreb University Medical School, Zagreb, Croatia, ⁹ University of Messina, Messina, Italy, ¹⁰ St. Marien Hospital, Bonn, Germany, ¹¹ Hvidovre University Hospital, Copenhagen, Denmark, ¹² Erasmus Medical Center, Netherlands, ¹³ Shaare Zedek Medical Center, Jerusalem, Israel
13:50 - 14:10	33: Manipulating the microbiota in everyday practice Francisco Guarner, Barcelona, Spain
14:10 - 14:20	34: Best abstract: Multi donor intense faecal microbiota transplantation is an effective treatment for resistant Ulcerative Colitis: A randomised placebo-controlled trial S. Paramsothy ¹ , M. Kamm ^{2,3} , A. Walsh ⁴ , J. van den Bogaerde ⁵ , D. Samuel ⁶ , R. Leong ⁶ , S. Connor ⁷ , W. Ng ⁷ , R. Paramsothy ⁷ , N. Kaakoush ⁸ , H. Mitchell ⁹ , W. Xuan ³ , E. Lin ¹⁰ , T. Borody ¹⁰ ¹ University of New South Wales, St Vincent's Clinical School, Sydney, Australia, ² St Vincent's Hospital, Melbourne, Australia, ³ Imperial College London, London, United Kingdom, ⁴ St Vincent's Hospital, Sydney, Australia, ⁵ Nambour General Hospital, Nambour, Australia, ⁶ Bankstown-Lidcombe Hospital, Sydney, Australia, ⁷ Liverpool Hospital, Sydney, Australia, ⁸ University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia, ⁹ Ingham Institute, Sydney, Australia, ¹⁰ Centre for Digestive Diseases, Sydney, Australia
14:20 - 14:30	35: Best abstract: The impact of "Crohn's Disease-Treatment-with-EATing" diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism V. Svols ¹ , R. Hansen ² , K. Hughes ¹ , U.Z. Ijaz ³ , C. Quince ⁴ , D. Gaya ⁵ , R. Russell ¹ , K. Gerasimidis ¹ ¹ Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, ² Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, ³ School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁴ Warwick Medical School, University of Warwick, Warwick, United Kingdom, ⁵ Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom
14:30 - 14:50	36: Future strategies to change the flora Harry Sokol, Paris, France
14:50 - 15:20	Coffee break

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

15:20 - 16:00	Scientific session 7: ECCO Fellowships & Grants Gerhard Rogler, Zürich, Switzerland Noortje Fester, Groningen, The Netherlands
15:20 - 15:27	37: Outcomes from the 2015 Fellowships – Part 1 <i>Selective histone deacetylase inhibitors: A potential new treatment of Inflammatory Bowel Diseases</i> Carla Felice, Rome, Italy
15:27 - 15:34	38: Outcomes from the 2015 Fellowships – Part 2 <i>Sphingosine 1-phosphate (S1P)/S1PR3 axis a novel therapeutic target for intestinal fibrosis in Crohn's Disease</i> Cristina Mascaraque, Granada, Spain
15:34 - 15:40	39: Announcement of ECCO Fellowships & Grants 2016 Gerhard Rogler, Zürich, Switzerland
15:40 - 15:50	40: Best abstract: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe Ulcerative Colitis: Results from two phase 3 randomised controlled trials W.J. Sandborn ¹ , B.E. Sands ² , G. D'Haens ³ , S. Vermeire ⁴ , S. Schreiber ⁵ , S. Danese ⁶ , J. Panés ⁷ , B.G. Feagan ⁸ , W. Reinisch ⁹ , W. Niezychowski ¹⁰ , G. Friedman ¹⁰ , N. Lawendy ¹⁰ , D. Yu ¹⁰ , D. Woodworth ¹⁰ , A. Mukherjee ¹¹ , P. Healey ¹¹ , H. Zhang ¹⁰ , C. Su ¹⁰ ¹ Division of Gastroenterology, University of California, San Diego, United States, ² Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ³ Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ⁴ Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁵ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁶ IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁷ Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ⁸ Robarts Research Institute, London, Canada, ⁹ McMaster University, Hamilton, Canada, ¹⁰ Pfizer Inc, Collegeville, United States, ¹¹ Pfizer Inc, Groton, United States
15:50 - 16:00	41: Best abstract: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's Disease: Interim analysis from the phase 2 FITZROY study S. Vermeire ¹ , S. Schreiber ² , R. Petryka ³ , T. Kuehbach ⁴ , X. Hebuterne ⁵ , X. Roblin ⁶ , M. Klopocka ⁷ , E. Goldis ⁸ , M. Wisniewska-Jarosinska ⁹ , A. Baranovsky ¹⁰ , R. Sike ¹¹ , C. Tasset ¹² , A. van der Aa ¹² , P. Harrison ¹² ¹ UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, ² University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³ Vivamed, Warsaw, Poland, ⁴ Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, ⁵ Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁶ Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, ⁷ University Hospital Nr. 2 im. Bizuela, Department of Gastroenterology, Bydgoszcz, Poland, ⁸ Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, ⁹ Saint Family Hospital Medical Center, Department of Gastroenterology and Endoscopy, Lodz, Poland, ¹⁰ City Clinical Hospital #31, St Petersburg, Russian Federation, ¹¹ Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, ¹² Galapagos NV, Department of Development, Mechelen, Belgium

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:00 - 17:00	Scientific session 8: Challenging Cases Peter Irving, London, United Kingdom Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France
16:00 - 16:20	42: Case 1: Challenges during pregnancy: Anti-TNF treatment during pregnancy Shannon Kanis, Rotterdam, The Netherlands
16:20 - 16:40	43: Case 2: Refractory upper gut Crohn's Disease: Refractory upper gut Crohn's Disease with fatal outcome Miquel Cusachs, Barcelona, Spain
16:40 - 17:00	44: Case 3: When extra-intestinal symptoms dominate: Severe arthralgia in Crohn's Disease – disease or drug-related? Donata Lissner, Berlin, Germany
17:00 - 17:50	Scientific session 9: What's new on the Guidelines front? Oded Zmora, Tel Aviv, Israel Loris Lopetuso, Rome, Italy
17:00 - 17:10	45: ECCO Guidelines: Surgical CD Willem Bemelman, Amsterdam, The Netherlands
17:10 - 17:20	46: Best abstract: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's Disease: Results of a Phase 2b randomised placebo-controlled trial G. D'Haens ¹ , R. Pannaccione ² , P.D.R. Higgins ³ , J.-F. Colombel ³ , B.G. Feagan ⁴ , M. Mosciariello ⁵ , G. Chan ⁵ , P. Healey ⁶ , W. Niezychowski ⁵ , W. Wang ⁵ , A. Marren ⁵ , E. Maller ⁵ ¹ Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ² University of Calgary, Calgary, Canada, ³ University of Michigan, Ann Arbor, United States, ⁴ Robarts Research Institute, London, Canada, ⁵ Pfizer Inc, Collegeville, United States, ⁶ Pfizer Inc, Groton, United States
17:20 - 17:30	47: Best abstract: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn's Disease: Results of a Phase 2b randomised placebo-controlled trial J. Panés ¹ , W.J. Sandborn ² , S. Schreiber ³ , B.E. Sands ⁴ , S. Vermeire ⁵ , G. Chan ⁶ , M. Mosciariello ⁶ , W. Wang ⁶ , W. Niezychowski ⁶ , A. Marren ⁶ , P. Healey ⁷ , E. Maller ⁶ ¹ Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ² Division of Gastroenterology, University of California, San Diego, United States, ³ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁴ Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁶ Pfizer Inc, Collegeville, United States, ⁷ Pfizer Inc, Groton, United States
17:30 - 17:40	48: ECCO Guidelines: UC Update Rami Eliakim, Tel Hashomer, Israel Marcus Harbord, London, United Kingdom
17:40 - 17:45	49: ECCO Topical Review: Fibrosis Florian Rieder, Cleveland, United States
17:45 - 17:50	50: ECCO Topical Review: Elderly in IBD Paolo Gionchetti, Bologna, Italy
18:05 - 19:05	Digital oral presentations (Sessions 6-10) Please refer to pages 56-66
18:05 - 19:05	Industry sponsored satellite symposia 4a & 4b Please refer to page 193
20:00	ECCO Interaction: Hearts & Minds Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam (Please refer to page 207)

Saturday, March 19, 2016

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

07:15 - 08:15	Industry sponsored satellite symposia 5a & 5b Please refer to page 194
08:30 - 10:20	Scientific session 10: Surgical and endoscopic FAQs in IBD André D'Hoore, Leuven, Belgium Zuzana Serclova, Prague, Czech Republic
08:30 - 08:50	51: Case 1 – Preparing your patient for optimal surgery Richard Fedorak, Edmonton, Canada
 IIS Abstract Award	52: Best abstract: Comparison between newly-developed NBI and panchromoendoscopy for surveillance colonoscopy in patients with Ulcerative Colitis: A prospective multicentre randomised controlled trial, Navigator Study K. Watanabe¹ , M. Nishishita ² , F. Shimamoto ³ , T. Fukuchi ⁴ , M. Esaki ⁵ , Y. Okamoto ⁵ , Y. Maehata ⁵ , S. Oka ⁶ , S. Nishiyama ⁶ , S. Fujii ⁷ , F. Hirai ⁸ , T. Inoue ⁹ , N. Hida ¹⁰ , R. Nozaki ¹¹ , T. Sakurai ¹² , K. Takeuchi ¹³ , M. Saruta ¹⁴ , S. Saito ¹⁵ , Y. Saito ¹⁶ , N. Ohmiya ¹⁷ , H. Kashida ¹² , S. Tanaka ⁶ , T. Matsui ⁸ , Y. Suzuki ¹³ , Y. Ajioka ¹⁸ , H. Tajiri ¹⁹ ¹ Osaka City General Hospital, Gastroenterology, Osaka, Japan, ² Nishishita Gastrointestinal Hospital, Osaka, Japan, ³ Faculty of Human Culture and Science Prefectural University of Hiroshima, Hiroshima, Japan, ⁴ Osakafu Saiseikai Nakatsu Hospital, Gastroenterology and Hepatology, Osaka, Japan, ⁵ Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, ⁶ Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan, ⁷ Kyoto Katsura Hospital, Digestive Disease Centre, Department of Gastroenterology, Kyoto, Japan, ⁸ Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, ⁹ Osaka Medical College, Second Department of Internal Medicine, Osaka, Japan, ¹⁰ Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, ¹¹ Takano Hospital, Division of Gastroenterology, Coloproctology Center, Kumamoto, Japan, ¹² Kinki University, Department of Gastroenterology, Osaka, Japan, ¹³ Toho University Sakura Medical Center, Department of Internal Medicine, Chiba, Japan, ¹⁴ The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, ¹⁵ The Jikei University School of Medicine, Department of Endoscopy, Tokyo, Japan, ¹⁶ National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan, ¹⁷ School of Medicine, Fujita Health University, Department of Gastroenterology, Aichi, Japan, ¹⁸ Graduate School of Medical and Dental Sciences, Niigata University, Division of Molecular and Diagnostic Pathology, Niigata, Japan, ¹⁹ The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan
09:00 - 09:10	53: Best abstract: Mucosal healing and dysplasia surveillance in a large referral centre cohort of patients with Crohn's Disease and Ulcerative Colitis treated with vedolizumab M. Noman ¹ , M. Ferrante ¹ , R. Bisschops ¹ , G. De Hertogh ² , K. van den Broeck ¹ , K. Rans ¹ , P. Rutgeerts ¹ , S. Vermeire ¹ , G. van Assche¹ ¹ UZ Leuven, Gastroenterology, Leuven, Belgium, ² UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

09:10 - 09:20	54: Best abstract: Escalation of medical therapy decreases need for repeat dilatation in Crohn's anastomatic strictures N.S. Ding^{1,2}, W. Yip¹, R. Choi¹, B. Saunders³, S. Thomas-Gibson³, N. Arebi¹, A. Humphries³, A. Hart¹ ¹St Mark's Hospital, IBD, London, United Kingdom, ²Imperial College London, Department of Surgery and Cancer, London, United Kingdom, ³St Mark's Hospital, Wolfson Unit For Endoscopy, Department of Gastroenterology, Harrow, United Kingdom
09:20 - 09:40	55: Case 2 – Post-surgery prevention Marc Ferrante, Leuven, Belgium
09:40 - 09:50	56: Best abstract: The TOPPIC trial: A randomised, double-blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's Disease following surgical resection in 240 patients I. Arnett¹, C. Mowat², H. Ennis³, C. Keerie³, S. Lewis³, N. Kennedy⁴, A. Cahill⁵, A. Morris⁵, M. Dunlop⁶, S. Bloom⁷, J. Lindsay⁸, S. Subramanian⁹, J. Satsangi¹, on behalf of the Toppic Trial Study Group¹⁰ ¹NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, ²NHS Tayside, Gastroenterology, Dundee, United Kingdom, ³University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, ⁴University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ⁵NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, ⁶University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, ⁷University College Hospital, Department of Gastroenterology, London, United Kingdom, ⁸Bart's Health NHS Trust, Newham University Hospital, Department of Gastroenterology, London, United Kingdom, ⁹Royal Liverpool University Hospital, Gastroenterology, Liverpool, United Kingdom, ¹⁰Toppic Trial Study Group, UK, United Kingdom
09:50 - 10:00	57: Best abstract: Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn's Disease: Outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group A. Brouquet¹, L. Maggiori², P. Zerbib³, J. Lefèvre⁴, Q. Denost⁵, A. Germain⁶, E. Cotte⁷, L. Beyer-Berjot⁸, N. Munoz-Bongrand⁹, V. Desfourneaux¹⁰, A. Rahili¹¹, J.-P. Duffas¹², K. Pautrat¹³, C. Denet¹⁴, V. Bridoux¹⁵, G. Meurette¹⁶, J.-L. Faucheron¹⁷, J. Loriau¹⁸, F. Guillon¹⁹, E. Vicaut²⁰, S. Benoist¹, Y. Panis² ¹Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France, ²Beaumont Hospital, Colorectal Surgery, Clichy, France, ³CHU Lille, Digestive Surgery, Lille, France, ⁴Saint Antoine Hospital, Digestive Surgery, Paris, France, ⁵CHU Bordeaux, Digestive Surgery, Bordeaux, France, ⁶CHU Nancy, Digestive Surgery, Nancy, France, ⁷CHU Lyon-Sud, Digestive Surgery, Lyon, France, ⁸CHU Marseille, Digestive Surgery, Marseille, France, ⁹Saint Louis Hospital, Digestive Surgery, Paris, France, ¹⁰CHU Rennes, Digestive Surgery, Rennes, France, ¹¹CHU Nice, Digestive Surgery, Nice, France, ¹²CHU Toulouse, Digestive Surgery, Toulouse, France, ¹³Lariboisière Hospital, Digestive Surgery, Paris, France, ¹⁴Montsouris Institute, Digestive Surgery, Paris, France, ¹⁵CHU Rouen, Digestive Surgery, Rouen, France, ¹⁶CHU Nantes, Digestive Surgery, Nantes, France, ¹⁷CHU Grenoble, Digestive Surgery, Grenoble, France, ¹⁸Saint-Joseph Hospital, Digestive Surgery, Paris, France, ¹⁹CHU Montpellier, Digestive Surgery, Montpellier, France, ²⁰Fernand Widai Hospital, Clinical Research, Paris, France

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

10:00 - 10:20	58: Case 3 – Dealing with a problematic pouch Michael Kamm, Melbourne, Australia
10:20 - 10:50	Coffee break
10:50 - 12:20	Scientific session 11: Right time, right drug, right strategy Marieke Pierik, Maastricht, The Netherlands Nik Ding, London, United Kingdom
10:50 - 11:10	59: Molecular stratification of the patient Miles Parkes, Cambridge, United Kingdom
11:10 - 11:20	60: Best abstract: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's Disease: Results from the UNITI-1 and UNITI-2 studies O.J. Adedokun¹ , Z. Xu ¹ , C. Gasink ¹ , J. Friedman ¹ , P. Szapary ¹ , Y. Lang ¹ , J. Johanss ¹ , L.-L. Gao ¹ , Y. Miao ¹ , H. Davis ¹ , S. Hanauer ² , B. Feagan ³ , W. Sandborn ⁴ ¹ Janssen R & D, LLC, Spring House, United States, ² Northwestern University Feinberg School of Medicine, Chicago, United States, ³ Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Canada, ⁴ UCSD, Medicine, La Jolla, United States
11:20 - 11:40	61: Choosing the right drug Iris Dotan, Tel Aviv, Israel
11:40 - 11:50	62: Best abstract: Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn's Disease: A prospective, randomised, multicentre trial (Tailorix) G. D'Haens¹ , S. Vermeire ² , G. Lambrecht ³ , F. Baert ⁴ , P. Bossuyt ⁵ , M. Nachury ⁶ , A. Buisson ⁷ , Y. Bouhnik ⁸ , J. Filippi ⁹ , J. van der Woude ¹⁰ , P. van Hooitegem ¹¹ , J. Moreau ¹² , E. Louis ¹³ , D. Franchimont ¹⁴ , M. De Vos ¹⁵ , F. Mana ¹⁶ , L. Peyrin-Biroulet ¹⁷ , H. Brix ¹⁸ , M. Allez ¹⁹ , P. Caenepeel ²⁰ , A. Aubourg ²¹ , B. Oldenburg ²² , M. Pierik ²³ , A. Gils ²⁴ , S. Chevre ²⁵ , D. Laharie ²⁶ ¹ Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands, ² University Hospitals Gasthuisberg, Gastroenterology, Leuven, Belgium, ³ AZ Damiaan, Oostende, Belgium, ⁴ AZ Delta, Roeselare, Belgium, ⁵ Imelda GI Clinical Research Centre, Bonheiden, Belgium, ⁶ Hopital Claude Hurriez, Lille, France, ⁷ Hopital Estaing, Clermont-Ferrand, France, ⁸ Hopital Beaujon, Clichy, France, ⁹ Hopital Archet, Nice, France, ¹⁰ Erasmus Medical Centre, Rotterdam, Netherlands, ¹¹ St Lukas Hospital, Bruges, Belgium, ¹² Hopital Rangueil, Toulouse, France, ¹³ Hopital Sart Tilman, Liège, Belgium, ¹⁴ Hopital Erasme, Brussels, Belgium, ¹⁵ University of Ghent, Ghent, Belgium, ¹⁶ Free University of Brussels, Brussels, Belgium, ¹⁷ Hopital Brabois, Nancy, France, ¹⁸ Hopital Robert Debre, Reims, France, ¹⁹ Hopital St Louis, Paris, France, ²⁰ Ziekenhuis Oost Limburg, Genk, Belgium, ²¹ Hopital Trousseau, Tours, France, ²² University of Utrecht, Utrecht, Netherlands, ²³ University Hospital Maastricht, Maastricht, Netherlands, ²⁴ University of Leuven, Leuven, Belgium, ²⁵ Department Biostatistique St Louis, Paris, France, ²⁶ Haut-Leveque, Pessac, France

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:50 - 12:00	63: Best abstract: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in Ulcerative Colitis T. Kobayashi¹, Y. Suzuki², S. Motoya³, F. Hirai⁴, H. Ogata⁵, H. Ito⁶, N. Sato⁷, K. Ozaki⁷, M. Watanabe⁸, T. Hibi¹ ¹Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, ²Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ³Sapporo-kosei General Hospital, Inflammatory Bowel Diseases Center, Sapporo, Japan, ⁴Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ⁵Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, ⁶Kitano Hospital The Tazuke Kofukai Medical Research Institute, Digestive Disease Center, Osaka, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, ⁸Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan
12:00 - 12:20	64: Care or action plans for patients Jane Andrews, Adelaide, Australia Karen Kemp, Manchester, United Kingdom
12:20 - 12:50	Scientific session 12: ECCO Lecture Séverine Vermeire, Leuven, Belgium Julián Panés, Barcelona, Spain
12:20 - 12:50	65: Future of IBD healthcare in Europe Daniel Hommes, Los Angeles, United States
12:50 - 12:55	66: Awards and closing remarks Julián Panés, Barcelona, Spain on behalf of the Organising Committee
12:55 - 13:00	The ECCO Film 2016

"Bringing science, therapy & quality to patients"

February 18-21, 2015, Barcelona, Spain

Opening & welcome:

Eugení Domènech (ES) and Séverine Vermeire (BE)

12:45 – 13:00

Scientific session 1: The exposome in the pathogenesis of IBD

13:00 – 14:30

Arie Levine (IL) and Isabelle Cleynen (BE)

- How food triggers inflammation: Marc Veldhoen (UK)
- Best abstract: Transmissive Crohn's disease-like ileitis is caused by functional dysbiosis in the intestinal microbiota independent of inflammation-driven Paneth cell failure: Monika Schaubek (DE)
- Impact of lifestyle changes on disease course: Gerhard Rogler (CH)
- Best abstract: UK IBD twin and multiplex registry: Concordance and environmental risk factors of twins with IBD: Hannah Gordon (UK)
- Best abstract: Faecal microbiota transplantation in Ulcerative Colitis: A randomised controlled trial: N.G.M. Rossen (NL)
- Epigenetics of IBD: Jack Satsangi (UK)

Scientific session 2: Pharmacokinetics in clinical practice: Does it matter?

15:00-17:00

Geert D'Haens (NL) and Eugení Domènech (ES)

- Influence of the inflammatory burden on pharmacokinetics of biologicals: Diane Mould, (US)
- Best abstract: Adalimumab and infliximab levels in neonates (ERA study): Mette Julsgaard (DK)
- Understanding pharmacokinetics and immunogenicity of anti-TNFs: Ann Gils (BE)
- Best abstract: Infliximab trough level thresholds vary depending on the efficacy criterion chosen in IBD patients: Xavier Roblin (FR)
- Best abstract: Disease burden outweighs the impact of drug concentrations and antibodies to infliximab in primary non-response to infliximab in Crohn's Disease patients: Thomas Billiet (BE)
- Applying pharmacokinetics in the daily care of patients: from combination therapy to therapeutic drug monitoring: Barrett Levesque (US)
- Best abstract: Deep remission in Crohn's Disease does not prevent disease relapse after withdrawal of anti-TNF α therapy: Martin Bortlik (CZ)
- Applying the lessons learnt from anti-TNF strategies to novel biologics: Yehuda Chowers (IL)

Friday, February 20, 2015

Scientific session 3: Optimal use of resources

08:30-09:30

Anna Kohn (IT) and John Mansfield (UK)

- The true cost of IBD care: Keith Bodger (UK)
- Best abstract: The first prospective Australian population-based study of newly diagnosed IBD identifies frequent use of immunomodulators, low surgery rates and high cost from medications and investigations: Olga Niewiadomski (AUS)

- Best abstract: Unchanged surgery and hospitalization rates in an East-West European inception cohort despite differences in use of biologicals - 3-year follow-up of the ECCO-EpiCom cohort: Johan Burisch (DK)
- Surgical alternatives to biological therapy: Omar Faiz (UK)

Scientific session 4: The gut barrier under attack: Therapeutic implications 09:30-10:30

Silvio Danese (IT) and Philippe Marteau (FR)

- Mechanisms of damage and repair: Gijs van den Brink (NL)
- Best abstract: Medication-induced microscopic colitis: Do recency and duration of use matter? Bas P.M. Verhaegh (NL)
- Best abstract: Budesonide MMX® 9 mg for Inducing Remission in Patients with Mild-to-Moderate Ulcerative Colitis Not Adequately Controlled with Oral 5-ASAs: David T. Rubin (US)
- The microbiome in the pathogenesis and therapy of IBD: Ailsa Hart (UK)

Scientific session 5: Delivering quality to the patients

11:00-12:20

Simon Travis (UK) and Philippe Marteau (FR)

- The central role of the IBD nurse in the multidisciplinary management: Marian O'Connor (UK)
- Best abstract: Information needs and concerns of patients with Inflammatory Bowel Disease: What can we learn from participants of a national clinical cohort? Valérie Pittet (CH)
- Measuring the quality performance of your centre: Xavier Calvet Calvo (ES)
- Best abstract: Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years? Andreas Stallmach (DE)
- Panel discussion: Simon Travis (UK) and Ronan O'Connell (IE) and Zuzana Zelinkova (SK) and Hankje Escher (NL) and Marian O'Connor (UK)

Scientific session 6: Anti-TNF: Originators & Biosimilars

13:30-15:00

Gerassimos Mantzaris (GR) and Gionata Fiorino (IT)

- The science behind biosimilars: Gonzalo Calvo (ES)
- Best abstract: Use of anti-TNF- α agents in relation to first-time surgery for ulcerative colitis and Crohn's disease during childhood: Michael Due Larsen (DK)
- Experience with biosimilars from rheumatology: Ulf Müller-Ladner (DE)
- Best abstract: Multicentre clinical trial with topical administration of the Toll-Like receptor 9 agonist DIMS0150 shows evidence for efficacy in moderate to severe Ulcerative Colitis: Raja Atreya (DE)
- Best abstract: Treatment strategy during the first year after diagnosis in patients with inflammatory bowel diseases from the 2011 ECCO-EpiCom inception cohort: Zsuzsanna Vegh (HU)
- Unanswered questions on biosimilars in IBD: Stefan Schreiber (DE)

Scientific session 7: ECCO Fellowships & Grants

15:30-16:10

Edouard Louis (BE) and Pieter Hindryckx (BE)

- Outcomes from the 2013-14 Fellowships: The effect of vitamin D on the intestinal microbiome in patients with Ulcerative Colitis: Mayur Garg (AUS)
- Outcomes from the 2013-14 Fellowships: Mechanisms of primary non response to anti-TNF α therapy in Inflammatory Bowel Disease: Konstantinos Papamichael (GR)
- Announcement of ECCO Fellowships and Grants 2015: Edouard Louis (BE)

- Best abstract: Long-term outcomes in a cohort of patients with acute severe ulcerative colitis refractory to intravenous steroids treated with cyclosporine or infliximab: David Laharie (FR)
- Best abstract: Prolonged Deep Remission of Ileocolonic Crohn's Disease following Autologous Haemopoietic Stem Cell Transplantation, presented on behalf of all the ASTIC Trialists: Chris Hawkey (UK)

Scientific session 8: Challenging Cases

16:10-17:10

Edouard Louis (BE) and Pierre Michetti (CH) and Frank Ruemmele (FR)

- Case 1: Risk of cancer in chronic perianal disease: Stephan Vavricka (CH)
- Case 2: Risk of infection occurring under biological treatment: Thomas Billet (BE)
- Case 3: Loss of response to anti-TNF in paediatrics: Malgorzata Sladek (PL)

Scientific session 9: What's new on the Guidelines front?

17:10-17:50

Vito Annese (IT) and Tiago Nunes (DE/BR)

- Malignancy: Rami Eliakim (IL)
- Best abstract: Forty-Year Analysis of Colonoscopic Surveillance for Ulcerative Colitis Reveals Decreasing Risk of Interval and Advanced Cancer and Reducing Colectomy Rate for Dysplasia: Chang Ho Ryan Choi (UK)
- Best abstract: Patients with Inflammatory Bowel Disease and a history of cancer: The risk of cancer following exposure to immunosuppression: Jordan Axelrad (US)
- Extra-intestinal manifestations: Franck Carbonnel (FR) & Marcus Harbord (UK)

Saturday, February 21, 2015

Scientific session 10: New therapies and strategies

08:30-10:20

Laurent Peyrin-Biroulet (FR) and Krisztina Gecse (HU)

- New algorithms for treating IBD: Gert van Assche (BE)
- Best abstract: TURANDOT: a randomized, multicenter double-blind, placebo-controlled study of the safety and efficacy of Anti-MAdCAM Antibody PF-00547659 (PF) in patients with moderate to severe Ulcerative Colitis (UC): Séverine Vermeire (BE)
- Best abstract: Anti-MAdCAM-1 Antibody (PF-00547659) for Active Refractory Crohn's Disease: Results of the OPERA study: Geert D'Haens (NL)
- Best abstract: Methotrexate for corticosteroid-dependent ulcerative colitis: results of a placebo randomized controlled trial: Franck Carbonnel (FR)
- Positioning of the new molecules in practice: Brian Feagan (CA)
- Best abstract: A randomized, double-blind, placebo-controlled induction trial of an oral S1P receptor modulator (RPC 1063) in moderate to severe Ulcerative Colitis: Results of the TOUCHSTONE study: William Sandborn (US)
- Best abstract: A randomized, double-blind placebo-controlled phase 2a induction study of MEDI2070 (anti-p19 antibody) in patients with active Crohn's disease who have failed anti-TNF antibody therapy: Bruce E. Sands (US)
- New surgical techniques: Willem Bemelman (NL)

Scientific session 11: Managing the manageable: Chronic pain and fatigue

10:50-12:20

Eduard Cabré (ES) and Igor Khalif (RU)

- Joint pain: arthritis and arthralgias: Juan Jesús Gómez Reinó (ES)
- Algorithm for abdominal pain management: Andreas Sturm (DE)
- Algorithm for the management of fatigue: Janneke van der Woude (NL)
- Best abstract: Post-operative use of anti-TNF α agents in patients with Crohn's disease and risk of re-operation - a nationwide cohort study: Jens Kjeldsen (DK)

- Best abstract: The rising incidence of early-onset paediatric inflammatory bowel disease (Paris A1a) in Scotland since 1981: a national, population-based, cohort study: Paul Henderson (UK)
- Best abstract: Oral delivery of a new class of non-antibody protein scaffold Nanofitins targeting TNF-alpha shows a strong preventive and curative anti-inflammatory effect in models of inflammatory bowel disease: Mathieu Cinier (FR)

Scientific session 12: ECCO Lecture

12:20-12:50

Séverine Vermeire (BE) and Julián Panés (ES)

- The science which will impact our IBD clinic: María Abreu (US)
- Awards and closing remarks: Séverine Vermeire (BE)
- The ECCO Film 2015

“The causes, consequences and quality of care for IBD”

February 20-22, 2014, Copenhagen, Denmark

Thursday, February 20, 2014

Top tips for chairs (closed session):

10:45 – 11:15

Geert D’Haens (NL)

Opening & welcome:

12:45 – 13:00

Simon Travis (UK) and Ole Hamberg (DK)

Scientific session 1: Neglected cells as potential target Eduard Stange

13:00 – 14:30

(DE) and James Lee (UK)

- Lymphatic endothelial cells as mediators and targets: Silvio Danese (IT)
- Best abstract: Innate lymphoid cells accumulate in IBD: Geremia, A. (UK)
- Mast cells at the leading edge: Guy Boeckxstaens (BE)
- Best abstract: The GCN2/elf2alpha/ATF4 signaling pathway is necessary for autophagy response to infection with Crohn’s Disease-associated adherent invasive *Escherichia coli*: Nguyen, H. (FR)
- Best abstract: Circadian clock function maintains mucosal architecture and protects against intestinal inflammation in mice: Sina, C. (DE)
- Stromal cells: Innocent bystanders or regulators? Ben Owens (UK)

Scientific session 2: Optimisation of therapy

15:00 – 17:00

Jean-Frédéric Colombel (US) and Dirk van Asseldonk (NL)

- Defining quality: Gil Melmed (US)
- Best abstract: Early combined immunosuppression for the management of Crohn’s Disease: A community-based cluster randomized trial: Feagan, B.G. (CA)
- Maintaining quality when choice is limited: Vineet Ahuja (IN)
- Best abstract: Is elderly-onset Ulcerative Colitis a different entity? Natural disease course and treatment response compared to adult-onset disease in the population-based IBDSL cohort: Jeuring, S. (NL)
- Best abstract: Personalised thiopurine dosing based on TPMT genotyping reduces leucopenia occurrence and results in cost-savings in IBD patients; Results from a randomized trial in the Netherlands: Coenen, M. (NL)
- Biological drug levels in practice: Shomron Ben-Horin (IL)
- Best abstract: Anti-MAdCAM monoclonal antibody PF-00547659 does not affect immune surveillance in the central nervous system of anti-TNF and immunosuppressant experienced Crohn’s Disease patients who are anti-TNF inadequate responders: Results from the TOSCA study: D’Haens, G. (NL)
- Travel with IBD: Climb high, dive deep: Stephan Vavricka (CH)

Friday, February 21, 2014

Scientific session 3: Cost of therapy, burden of care

08:30 – 09:30

Pia Munkholm (DK) and Iril Monstad (NO)

- Biosimilars – straight ahead or off at a tangent? Pierre Michetti (CH)
- Best abstract: The cost of investigations and medical treatment including biological therapy in a European inception cohort from the biological era – An ECCO-EpiCom study: Burisch, J. (DK)
- Best abstract: Long-term safety and efficacy of golimumab in patients with moderately to severely active Ulcerative Colitis: Results from the PURSUIT-SC maintenance study extension: Reinisch, W. (CA)
- Exit strategies: James Lindsay (UK)

Scientific session 4: Tomorrow's therapy

09:30 – 10:30

Herbert Tilg (AT) and Pär Myreliid (SE)

- It's decision time: Anti-TNF vs anti-intergrin therapy: Julian Panés (ES)
- Best abstract: AlphaE integrin expression as a predictive biomarker for induction of clinical remission by etrolizumab: Analysis of a phase II trial in moderate-to-severely active Ulcerative Colitis: Keir, M. (US)
- Best abstract: Tralokinumab (CAT-354), an interleukin 13 antibody, in moderate to severe Ulcerative Colitis: A phase 2 randomized placebo-controlled study: Berner Hansen, M. (SE)
- Tomorrow's surgery: Antonio Spinelli (IT)

Scientific session 5: Fibrosis as a complication

11:00 – 12:20

Gerhard Rogler (CH) and Tim Raine (UK)

- ECCO-DigestScience Research funding 2014 – Award ceremony
- Intestinal fibrogenesis: Claudio Fiocchi (US)
- Best abstract: Epigenetic control of colonic inflammation via the methyl-binding protein MBD2: Jones, G. –R. (UK)
- Imaging: inflammation vs. Fibrosis: Andrea Laghi (IT)
- Best abstract: Status of ER stress and autophagy in Crohn's Disease: From genetics to functional read-outs: Nys, K. (BE)
- Tandem Talk: Stricturolysis: potential and practice: Iris Dotan (IL) and Willem Bemelman (NL)

Scientific session 6: Intestinal failure

13:30 – 14:50

Laurence Egan (IRE) and Aurelien Amiot (FR)

- Physiology and consequences of short bowel syndrome: Palle Jeppesen (DK)
- Best abstract: Early endoscopic, laboratory and clinical predictors of poor disease course in paediatric Ulcerative Colitis (UC): Turner, D. (IL)
- Surgical quality: timing of decision-making: Iain Anderson (UK)
- Best abstract: Gut homing markers in perianal Crohn's fistulae: Yassin, N.A. (UK)
- Intestinal transplantation: Just the end, or the end of the beginning? Peter Friend (UK)

Scientific session 7: ECCO Fellowships and Grants

15:20 – 16:05

Michael Kamm (AUS) and Pierre Michetti (CH)

- Outcomes from 2012 - 13 Fellowships: Nathalie Aoun (LEB) and Markus Tschurtschenthaler (AT)
- Announcement of ECCO Fellowships and Grants 2014: Edouard Louis (BE)
- Best abstract: Transethnic association study of IBD identifies 14 new disease loci and demonstrates pervasive sharing of genetic risk factors and phenotypic features between five seronegative autoimmune inflammatory disease: Weersma, R.K. (NL)
- Best abstract: Cross-disease study determines extent of sharing of associated loci between five seronegative autoimmune inflammatory disease: Ellinghaus, D. (DE)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary care: R. P. H. Logan (UK)

Scientific session 8: Challenging Cases

16:00 – 17:00

Michael Kamm (AUS) and Pierre Michetti (CH) and Yves Panis (FR)

- Case 1: Ileal Crohn's disease (is therapeutic choice making decisions more complex?): Marc Ferrante (BE)
- Case 2: Acute severe colitis (the stakes are high!): Maria Nachury (FR)
- Case 3: Dealing active Crohn's in pregnancy: Jacqueline Paterson (UK)

Scientific session 9: What's new on the guideline front

17:00 – 17:45

Axel Dignass (DE) and Rami Eliakim (IL)

- ECCO Guidelines: Reproduction and IBD: Janneke van der Woude (NL)
- ECCO Guidelines: P-ECCO/ESGPHAN Guidelines in Paediatric CD: Frank Ruemmele (FR)
- ECCO Guidelines: The Crohn's Disease Consensus: Axel Dignass (DE)

Saturday, February 22, 2014

Scientific session 10: Colitis under the microscope

08:30 – 10:20

Gerassimos Mantzaris (GR) and Signe Wildt (DK)

- Is microscopic colitis IBD? Cord Langner (AT)
- Best abstract: Identification of an anti-inflammatory protein from *Faecalibacterium prausnitzii*, a deficient commensal bacteria implicated in Crohn's Disease: Seksik, P. (FR)
- Best abstract: Hypoxia responsive elements methylation status governs adherent-invasive *Escherichia coli*-receptor CEACAM6 expression in Crohn's Disease: Barnich, N. (FR)
- Best abstract: 16S rRNA gene pyrosequencing indicate that siblings of Crohn's Disease patients exhibit a biologically relevant dysbiosis in the mucosal microbiota communities: Hedin, C. (UK)
- Treatment-refractory microscopic colitis: Andreas Munch (SE)
- ECCO Guidelines on Anaemia in IBD: Konstantinos Katsanos (GR)
- Best abstract: Steroid-free remission in adalimumab-treated paediatric patients with moderately to severely active Crohn's Disease in the IMAGINE 1 trial: Griffiths, A. (CA)
- ECCO Guidelines on Surgery in Ulcerative Colitis: André D'Hoore (BE)

Scientific session 11: Challenging current practice: Value-based healthcare for IBD

10:50 – 12:20

Zuzana Serclova (CZ) and Marilia Cravo (PT)

- What triggers relapse? Charles Bernstein (CA)
- Best abstract: Low microbial gene diversity and depletion of Akkermansia muciniphila is associated with a relapsing course of Ulcerative Colitis: Casellas, F.(ES)
- Post-operative prevention - offence or defence? Paul Rutgeerts (BE)
- Best abstract: Optimising post-operative Crohn's Disease management: Best drug therapy alone versus endoscopic monitoring, disease evolution, and faecal calprotectin monitoring. The POCER study: Kamm, M.A. (AU)
- Best abstract: Agreement among central readers in the evaluation of endoscopic disease activity in Crohn's Disease: Khanna, R. (CA)
- Challenging conventional pathways of care: Daan Hommes (US)

Scientific session 12: ECCO Lecture

12:20 – 12:50

Séverine Vermeire (BE) and Simon Travis (UK)

- The causes of Crohn's Disease? Tony Segal FRS (UK)
- Awards and closing remarks: Séverine Vermeire (BE)
- The ECCO Film 2014

“New concepts and current challenges in IBD”

February 14-16, 2013, Vienna, Austria

Thursday, February 14, 2013

Top tips for chairs (closed session): Geert D'Haens (NL)

10:15 – 10:45

Join the fight against IBD 2013: “Crohn’s and Colitis in Europe: The burden of disease in young people:

Helmut Brand (NL)

12:15 – 12:45

Opening & welcome:

Simon Travis (UK) and Wolfgang Petritsch (AT)

12:45 – 13:00

Scientific session 1: Early stage IBD Oliver Brain (UK) and

13:00 – 14:30

Silvio Danese (IT)

- Does the pathogenesis change over the course of the disease?: Matthieu Allez (FR)
- Best abstract: Functional consequences of a novel IL-10 receptor alpha mutation on innate and adaptive immunity in early-onset Inflammatory Bowel Disease: J. N. Samsom (NL)
- Is there a therapeutic window of opportunity?: Gert van Assche (BE)
- Best abstract: A novel FOXO3-driven pathway determines prognosis in Crohn’s Disease, rheumatoid arthritis and malaria: J. Lee (UK)
- Best abstract: Anti-TNF in patients with an early course of Crohn’s Disease – a prospective observational study in Germany: B. Bokemeyer (GER)

Scientific session 2: Preventing progression in IBD

15:00 – 17:00

Arthur Kaser (UK) and Alexander Moschen (AT)

- Fat and inflammation: Britta Siegmund (GER)
- Best abstract: Caspase 8 maintains epithelial cell adhesion and intestinal homeostasis in vivo through regulation of clathrin-dependent endocytosis and autophagy: G. Pineton de Chambrun (FR)
- Inflammation in IBD: Tissue repair or despair: Florian Rieder (US)
- Best abstract: Prep 1: A new player in the development of IBD-associated fibrosis: S. D’Alessio (IT)
- Best abstract: Development of the Crohn’s Disease (CD) digestive damage score: The Lémann score: B. Pariente (FR)
- Best abstract: ER stress transcription factor Xbp1 suppresses intestinal tumorigenesis: L. Niederreiter (UK)
- Preventing cancer: Ian Lawrance (AU)
- ECCO: ESP Histopathology Guidelines in IBD: Arzu Ensari (TR) and Fernando Magro (PT)

Friday, February 15, 2013

Scientific session 3: What is on the horizon?

08:30 – 09:30

Siew Ng (CN) and Herbert Tilg (AT)

- Genomics in IBD: Who gets what and when?: Stefan Schreiber (GER)
- Best abstract: Characterization of the ~40,000 patient cohort of the International Inflammatory Bowel Disease Genetics Consortium (IIBDGC): C. W. Lees (UK)
- Best abstract: Clinical and endoscopic improvement following haemopoietic stem cell transplantation in the ASTIC trial: C. Hawkey (UK)
- Therapeutic targets to hit or miss: Jean-Frédéric Colombel (US)

Scientific session 4: Clinical trials in Ulcerative Colitis

09:30 – 10:30

Franck Carbonnel (FR) and Alexander Eser (AT)

- Pitfalls in design and practice: Brian Feagan (CA)
- Best abstract: Indigenous Australians (IA) have a distinctive gut microbial profile compared to patients with Inflammatory Bowel Disease (IBD) and non Indigenous control: G. lyngkaran (AU)
- Best abstract: Vedolizumab induction therapy for patients with Crohn's Disease and prior anti-tumour necrosis factor antagonist failure: A randomised, placebo-controlled, double-blind, multicentre trial: P. Rutgeerts (BE)
- Long-term outcomes: Sandro Ardizzone (IT)

Scientific session 5: Reproduction and IBD

11:00 – 12:20

Monica Cesarini (IT) and Sanja Kolacek (HR)

- Pharmacokinetics in pregnancy and location: Implications for drug efficacy & safety: Zuzana Zelinkova (SK)
- Best abstract: Pre-existing IgG antibodies to the Fab region of infliximab predict efficacy and safety in IBD patients naïve to anti-TNF agents: C. Steenholdt (DK)
- Care from conception to delivery: Janneke van der Woude (NL)
- Best abstract: Prevalence of anemia in patients with Inflammatory Bowel Disease during the first ten years from diagnosis-results from a population-based inception cohort, the IBSEN Study: M. L. Hoivik (NO)
- Neonatal safety: Saskia de Wildt (NL)

Scientific session 6: Adolescents with IBD

13:30 – 14:50

Kaija-Leena Kolho (FN) and Frank Ruemmele (FR)

- The adolescent phenotype: Gabor Veres (HU)
- Best abstract: Incidence and phenotype at diagnosis in paediatric IBD patients –An ECCO-EpiCom study: J. Burisch (DK)
- Organising care: Hankje Escher (NL)
- Best abstract: Serious infections and associated risk factors in patients receiving infliximab and immunotherapies for children with Inflammatory Bowel Disease: DEVELOP registry data: J. Escher (NL)
- Therapeutic strategies: Richard Russell (UK)

Scientific session 7: ECCO Fellowships and Grants

15:20 – 16:05

Marie Joossens (BE) and Andreas Sturm (GER)

- Outcomes from 2011/12 Fellowships: Timon Erik Adolph (AT) and Jessica Claire Wilson (IE)
- Announcement of ECCO Fellowships and Grants 2013: Andreas Sturm (GER)
- Best abstract: Relationships between clinical remission, C-reactive protein normalization and mucosal healing in Crohn's Disease: Analyses from the SONIC trial: L. Peyrin-Biroulet (FR)
- Best abstract: Optimising the use of faecal calprotectin for early diagnosis of IBD in primary Crohn's Disease: P. H. Logan (UK)

Saturday, February 16, 2013

Scientific session 9: Course and treatment of IBD in the elderly

08:30 – 10:30

Mircea Diculescu (RO) and Konstantinos Papadakis (GR)

- The natural history of IBD in the elderly: Corinne Gower-Rousseau (FR)
- Best abstract: The quality of care for inpatients with Inflammatory Bowel Disease in the UK over a six year period: L. Alrubaiy (UK)
- Medical management of IBD in the elderly: David Binion (US)
- Best abstract: Tumour necrosis factor-alpha antagonists and cardiovascular disease in Inflammatory Bowel Disease: N. Nyboe Andersen (DK)
- Best abstract: Mortality and causes of death in Ulcerative Colitis: Results from a Norwegian population based study during a twenty years period of follow-up (the IBSEN study): I. L. K. Monstad (NO)
- Minimising damage: Single incision surgery and enhanced recovery: Tonia Young-Fadok (US)
- First N-ECCO Consensus on caring for patients with IBD: Marian O'Connor (UK)
- Opportunistic Infection Guidelines: The update: Jean-François Rahier (BE)

Scientific session 10: Treating IBD in patients with past or current malignancy

11:00 – 12:20

Dino Tarabar (RS) and Ricardo Veloso (PT)

- The risk of extra-intestinal cancer in IBD: Tine Jess (DK)
- Best abstract: Risk of cervical dysplasia and cancer in patients with Inflammatory Bowel Disease: C. Rungø (DK)
- Lessons from rheumatology: Georg Schett (GER)
- Best abstract: When to stop therapy in Crohn's Disease? Results of the EPACT-2 Update panel: V. Pittet (SH)
- Practical management of IBD with past or current malignancy: David Laharie (FR) and Jean-Frédéric Blanc (FR)

Scientific session 11: ECCO Lecture

12:20 – 12:50

Simon Travis (UK) and Séverine Vermeire (BE)

- Where it all started and where it's going to: Biological therapy for IBD: Sander van Deventer (NL)

Closing remarks

12:50 – 13:00

Organising Committee Members and Simon Travis (UK)

"Breaking down barriers in IBD"

February 16-18, 2012, Barcelona, Spain

Thursday, February 16, 2012

Top tips for chairs (closed session): Geert D'Haens (NL) 10:45 – 11:15

Opening & welcome:
Miquel Gassull (ES) and Daniel Hommes (US) 12:45 – 13:00

Scientific session 1: Common ground across inflammatory disorders 13:00 – 14:20

Miquel Sans (ES) and Jan Wehkamp (GER)

- Tandem talk: Shared pathways in inflammation: Maria Abreu (US) and Fiona Powrie (UK)
- Best abstract: Card9 is a crucial adapter protein for gastro-intestinal immune response: Harry Sokol (FR)
- Best abstract: Identification of Glycoprotein 2 as an immunomodulator of innate and adaptive immune responses: Lael Werner (GER)
- Best abstract: Induction of autophagy upon DC-T cell contact is mediated by LKB1-AMPK-mTOR signaling: Manon Wildenberg (NL)
- Inflammatory side-effects of biological therapy: François Aubin (FR)

Scientific session 2: Measuring success and failure in IBD Dana Duricova (CZ) 14:50 – 16:10

and Pierre Michetti (CH)

- Predicting disease outcome: Siew Ng (HK)
- Best abstract: Mortality and cancer in paediatric Inflammatory Bowel Disease: A population-based study: Guillaume Savoye (FR)
- Tandem talk: Scoring disease damage and disability: Benjamin Pariente (FR) and Laurent Peyrin-Biroulet (FR)
- Best abstract: Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's Disease: Edouard Louis (BE)
- Assessing endoscopic and disease activity in practice: Gert van Assche (BE)

Scientific session 3: Preliminary results from the 3rd Scientific Workshop 16:10 – 16:30

Dana Duricova (CZ) and Pierre Michetti (CH)

- Malignancy in IBD: Laurent Beaugerie (FR), Silvio Danese (IT) and Laurence Egan (IRE)

Mini-session 3: ECCO-ESPGHAN Paediatric Guidelines on UC Dan Turner (IL) 16:30 – 17:00

Friday, February 17, 2012

Scientific session 4: Imaging in IBD

08:30 – 09:30

Simon Jackson (UK), André D'Hoore (BE) and Janneke van der Woude (NL)

- Medical or surgical therapy for obstruction: Is imaging the key? Casper Gijbert Noomen (NL)
- IBDU facing surgery - Are you sure the small bowel is normal? Ailsa Hart (UK)
- ECCO-ESGAR Imaging Guidelines: Julián Panés (ES)
- Case resolution
- Best abstract: Endocytoscopy allows accurate in vivo differentiation of mucosal inflammatory cells in IBD - A pilot study: Helmut Neumann (GER)
- Best abstract: Use of fecal calprotectin as marker of disease activity in patients under maintenance treatment with Infliximab for ulcerative colitis: Martine De Vos (BE)

Scientific session 5: Complications carousel: Management tips and tricks

09:30 – 10:30

Simon Jackson (UK), André D'Hoore (BE) and Janneke van der Woude (NL)

- Anaemia: Christoph Gasche (AT)
- Osteoporosis: Ad Van Bodegraven (NL)
- Renal: Satish Keshav (UK)
- Ocular: Luis Pablo (ES)
- Pulmonary: Franck Carbonnel (FR)
- Thromboembolism: Gerassimos Mantzaris (GR)
- Discussion

Scientific session 6: Impact of IBD on daily life

11:00 – 12:20

Fermin Mearin (ES) and Fernando Magro (PT)

- Debate: IBD and IBS - Marriage or divorce? Giovanni Barbara (IT) and Michael Kamm (AUS)
- Best abstract: SPARC modifies colonic tissue healing and inflammation by regulating collagen and MMP expression: Ian Lawrance (AUS)
- Best abstract: Anti TNF- alpha; Therapy is a major cost driver in Inflammatory Bowel Disease: Results from the COIN study: Mirthe Van der Valk (NL)
- The patient perspective: Ben Wilson (UK)

Guided poster session
Poster award ceremony

Scientific session 7: Organising care in IBD Mircea

13:30 – 14:30

Diculescu (RO) and Francesc Casellas (PT)

- E-Health and home-testing: Ready for prime time? Pia Munkholm (DK)
- Best abstract: Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in Ulcerative Colitis: Maria Teresa Arias Santander (ES)
- Best abstract: Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled trough level adapted Infliximab treatment (TAXIT) trial: Niels Vande Casteele (BE)
- The IBD care pathway: Daniel Hommes (US)

Scientific session 8: ECCO Fellowships and Grants

15:00 – 15:50

Andreas Sturm (GER)

- Fellowship 1: Bénédicte Brounais-Le Royer (CH)
- Fellowship 2: Lael Werner (GER)
- Announcement of ECCO Fellowships and Grants 2012: Andreas Sturm (GER)
- The role of proteases in IBD: Daniel Lottaz (CH)
- Best abstract: Multiple functional variants at the 3p21 locus contribute to ulcerative colitis: Results from a European consortium: Isabelle Cleynen (BE)
- Best abstract: TLR4 signaling activates the WNT pathway in a mouse model of colitis-associated neoplasia: Rebeca Santaolalla (US)

Scientific session 9: Challenging Cases

15:50-17:25 Jürgen

Schölmerich (GER), Peter Irving (UK), Manuel Barreiro (ES) and Antonino Spinelli (IT)

- Life-threatening restrictive TBC – Pericarditis affecting a Crohn's patient while on treatment with an anti-TNF 42: Xavier Aldegue (ES)
- The troubled journey of a young colitis patient: Shaji Sebastian (UK)
- Crohn's Disease, Anti-TNF & surgery: Paulo Kotze (BRA)
- Best abstract: Adenomas in patients with Inflammatory Bowel Disease: Increased risk of advanced neoplasia: Fiona van Schaik (NL)
- Best abstract: Immunosuppressive co-treatment with adalimumab (ADA) may be more effective than ADA monotherapy for maintaining remission in Crohn's disease (CD): Catherine Reenaers (BE)
- How I manage abnormal LFTs in IBD: Maria Esteve (ES)

Saturday, February 18, 2012

Scientific session 10: Surgery in IBD

08:30 – 10:00

Daniel Hommes (US) and Bjorn Moum (NOR)

- Perianal CD: Bruce George (UK)
- Best abstract: Adding ciprofloxacin to adalimumab results in a higher fistula closure rate in perianal fistulizing Crohn's disease: Peter Dewint (NL)
- Tandem talk: Find the best timing for surgery: Sandro Ardizzone (IT) and Antonino Spinelli (IT)
- Best abstract: Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. Study of prevalence and predictive factors: ENEIDA project: Alex Cañas-Ventura (ES)
- Best abstract: Long-term outcome after first intestinal resection in paediatric-onset Crohn's disease: A population-based study: Medina Boualit (FR)
- Managing complications: Emmanuel Tiret (FR)

Scientific session 11: Where are we heading?

10:30 – 11:50

Antonio Lopez San Roman (ES) and Simon Travis (UK)

- Are gene hunting days over? Miles Parkes (UK)
- Best abstract: Genetic and functional evidence for a role for CYLD in Crohn's disease: Results from a European consortium: Isabelle Cleynen (BE)
- Are stem cells ready for clinical practice? Gijs van den Brink (NL)
- Best abstract: TNF and MDP induce epithelial-to-mesenchymal transition in human intestinal cells: Implications for the pathogenesis of Crohn's disease-associated fistulae and the use of anti-TNF antibodies: Michael Scharl (CH)
- Are we ready to manage the microbiome? Arlette Darfeuille-Michaud (FR)

Scientific session 12: ECCO Lecture

11:50 – 12:20

Antonio Lopez San Roman (ES) and Simon Travis (UK)

- Translating evidence from clinical trials into personalised medicine: Stephen Hanauer (US)

Closing remarks:

12:20 – 12:30

Simon Travis (UK)

“Embracing diversity in IBD”

February 24-26, 2011, Dublin, Ireland

Thursday, February 24, 2011

Top tips for chairs (closed session):

10:45 – 11:15

Geert D’Haens (NL)

Opening & welcome:

12:45 – 13:00

Daniel Hommes (NL) and Colm O’Morain

Scientific session 1: Where are we heading?

13:00 – 14:40

Jean-Frédéric Colombel (FR) and Laurence Egan (IRE)

- Concept and importance of mucosa-associated bacteria: Arlette Darfeuille-Michaud (FR)
- Best abstract: Autophagy contributes to immune regulation through destabilization of the immunological synapse: Manon Wildenberg (NL)
- Metabolic functions as sensor for the microbiome: Dirk Haller (GER)
- Best abstract: Gene expression profiling in CD8 T cells predicts disease course in Crohn’s Disease and Ulcerative Colitis: James Lee (UK)
- Stressed out! Arthur Kaser (AT)
- Best abstract: Crohn’s Disease-associated dysbiosis as a predictive factor of clinical relapse: A microbiological substudy of the GETAID-STORI cohort: Sylvie Rajca (FR)
- Microbial manipulation for IBD in practice: Eamonn Quigley (IRE)

Scientific session 2: Intestinal Healing: 2nd ECCO Pathogenesis Workshop

15:10 – 16:40

Florian Rieder (US) and Gigi Veereman (BE)

- Overview: Andreas Sturm (GER)
- Mechanisms of intestinal healing: Miquel Sans (ES)
- Measures and markers for monitoring intestinal healing: Marco Daperno (IT)
- Impact of intestinal healing on the course of IBD: Laurent Peyrin-Biroulet (FR)
- Therapeutic strategies to enhance intestinal healing: Geert D’Haens (NL)
- Best abstract: Pro-fibrogenic action of Toll-like receptor and NOD-like receptor ligands on human intestinal myofibroblasts: Florian Rieder
- Best abstract: Depth of remission may not predict outcome of UC over 2 year: Daniel Burger (UK)

Mini-session 2: ECCO Guidelines 1: The ECCO Consensus process and future prospects

16:40 – 17:00

Gert van Assche (BE)

Friday, February 25, 2011

Scientific session 3: The age of innocence: IBD in children

08:30 – 10:00

Sanja Kolacek (CRO) and Tom Øresland (NO)

- IBD in the very young - insights into pathogenesis: Frank Ruemmele (FR)

- Best abstract: Paediatric modification of the Montréal Classification for Inflammatory Bowel Disease - the Paris classification: Arie Levine (IL)
- IBD Surgery in children: indications and outcome: Paolo Lionetti (IT)
- Best abstract: Induction and maintenance Adalimumab therapy for the treatment of Moderate to Severe Crohn's Disease in children: Anne Griffiths (CAN)
- Best abstract: Bronchopulmonary manifestations in Inflammatory Bowel Diseases: a retrospective study from the GETAID: Matthieu Allez (FR)
- Management of IBD in adolescence: Robert Heuschkel (UK)

Mini-session 3: ECCO Guidelines 2: Paediatric acute severe colitis

10:00 – 10:20

Dan Turner (IL)

Scientific session 4: Targets in IBD: Lost and Found

10:50 – 12:20

Silvio Danese (IT) and Charlie Lees (UK)

- TLRs as therapeutic targets: Luke O'Neill (IRE)
- Best abstract: Phase I-II safety, immunogenicity and clinical results Of TNFa-kinoid immunotherapeutic immunization in Crohn's Disease patients: Pierre Vandepapeliere (FR)
- Past and future of T cell-directed therapies: Yehuda Chowers (IL)
- Best abstract: Inhibition of IL 17A by Secukinumab is ineffective for Crohn's Disease (CD): Simon Travis (UK)
- Best abstract: NKG2D activation drives Th17 response in Crohn's Disease: Benjamin Pariente (FR)
- Therapeutic implications of autophagy and apoptosis: Stefan Schreiber (GER)

Guided poster session

Poster award ceremony

Scientific session 5: Optimising surgical outcomes in IBD

13:30 – 15:00

Johan D. Söderholm (Linköping (SWE) and Antonino Spinelli (IT)

- Nutrition and medication: preparation for surgery: John Hyland
- Best abstract: Ciclosporin versus Infliximab In acute severe ulcerative colitis refractory to intravenous steroids: A randomized study: David Laharie
- Tandem Talk: Treating ileocaecal Crohn's disease: resect or medicate? Julian Panes (ES) and André D'Hoore (BE)
- Best abstract: Infliximab, Azathioprine, or Infliximab + Azathioprine for treatment of Moderate to Severe Ulcerative Colitis: the UC SUCCESS trial: Remo Panaccione (CAN)
- Best abstract: Infliximab for Severe IV steroid-refractory Ulcerative Colitis: Can Infliximab trough levels guide our management? Marc Ferrante (BE)
- Improving outcomes of pouch surgery: raising the bar: John Nicholls (UK)

Scientific session 6: Daily challenges in IBD

15:30 – 17:00

Hülya Över-Hamzaoglu (TR), Martine De Vos (BE)

- Report of the ECCO Consensus on reproduction and IBD37: Janneke van der Woude (NL)
- Best abstract: Risk of squamous and basal cell carcinomas in patients with Inflammatory Bowel Disorders exposed to thiopurines: The Cesame National Cohort Study: Laurent Peyrin-Biroulet (FR)
- Optimising conventional therapies for IBD: Peter Irving (UK)

- Best abstract: 52-week clinical efficacy with Adalimumab in patients with Moderately to Severely Active Ulcerative Colitis who failed corticosteroids and/or immunosuppressants: Walter Reinisch (AT)
- Best abstract: Long term evolution and impact of immunomodulator co-treatment and withdrawal on Infliximab on trough levels in 223 patients with Crohn's Disease: David Drobne (BE)
- Tailoring anti-TNF therapy in CD: Edouard Louis (BE)

Mini-session 6:

17:00 – 17:20

Hülya Över-Hamzaoglu (TR)

- Imaging in IBD: Simon Jackson (UK)

Saturday, February 26, 2012

Scientific Session 7: Challenging Cases

08:30 – 10:00 Willem

Bemelman (NL), Eugene Domenech (ES), Michael Kamm (AT), Joseph Keane (IE), Siew Ng (CN)

- Challenging Case 1: Tuberculosis: Séverine Vermeire (BE)
- Challenging Case 2: Transplantation: Elena Ricart (ES)
- Challenging Case 3: Hermann Schulze (DE)

Scientific Session 8: Cancer and IBD Dino Tarabar

10:30 – 12:00

(RS), Gijs van den Brink (NL)

- Inflammation and Cancer: Partners in crime: Florian Greten (DE)
- Best abstract: Junctional adhesion molecule-a is a new key regulator in Colitis associated colon cancer: Stefania Vetrano (IT)
- Needle in a haystack: strategies to detect cancer: Ralf Kiesslich (DE)
- Best abstract: Incidence of dysplasia and colorectal cancer in patients with Ulcerative Colitis included in the Spanish ENEIDA registry: Jordi Gordillo (ES)
- Best abstract: Risk factors for Inflammatory Bowel Disease associated colorectal carcinoma: Maurice Lutgens (NL)
- Extraintestinal cancer in IBD: Corey Siegel (USA)

Scientific Session 9: ECCO Lecture Daan

12:00 – 13:10

Hommes (NL), Simon Travis (UK)

- ECCO Fellowships 2010: Presentation 1: Emanuela Sala (IT)
- ECCO Fellowships 2010: Presentation 2: Caterina Strisciuglio (IT)
- Announcement of ECCO Fellowships & Grants 2011: Matthieu Allez (FR)
- Marc Lémann Lecture: Understanding clinical trials in IBD: Jean-Frédéric Colombel (FR)

Closing remarks Daan

13:00 – 13:10

Hommes (NL)

"Cause and consequence in IBD"

February 25-27, 2010, Prague, Czech Republic

Thursday, February 25, 2010

Opening and welcome

13:00 – 13:10

Petr Dite (CZ), Jean-Fred Colombel (FR)

Scientific Session 1: Fibrogenesis and its consequences Franco Scaldaferrri

13:00 – 14:40

(IT), Martin Zeitz (DE)

- Mechanisms of intestinal fibrogenesis: Miquel Sans (ES)
- Best abstract: Smad7 expression in T cells protects from colitis-associated colorectal cancer: Massimo Fantini (IT)
- Markers of fibrosis in practice: Is this stricture inflammatory?: Gerhard Rogler (CH)
- Best abstract: IRF-4 drives experimental colitis through direct activation of IL-17 promoter: Jonas Mudter (DE)
- Best abstract: Oxygen sensor inhibition attenuates TNF- α -induced intestinal epithelial damage by hypoxia-inducible factor (HIF)-1-dependent repression of fas-associated death domain protein (FADD): Pieter Hindryckx (BE)
- Therapeutic opportunities for modifying fibrosis: lessons from the liver: Massimo Pinzani (IT)

Scientific Session 2: Extraintestinal manifestations

15:10 – 16:50

Martin Bortlik (CZ), Republic Gerard Dijkstra (NL)

- Communication between the gut and liver: Pierre Desreumaux (FR)
- Best abstract: Modulation of gut immune homeostasis via the Toll-interacting protein: Michel H Maillard (CH)
- PSC and prognosis: Roger Chapman (UK)
- Best abstract: Genetic variants that predispose to early complications in Crohn's disease identified by re-analysing genome-wide association study data from 3 consortia: James Lee (UK)
- Best abstract: Decreased expression of ATG16L1 and IRGM results in pro-inflammatory dendritic cells: Manon Wildenberg (NL)
- Best abstract: Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: Walter Reinisch (AT)
- When the skin causes problems in IBD: Emmanuel Laffitte (CH)

Scientific Session 3: Therapeutic opportunity: Leukocyte Trafficking

08:30 – 10:00

Maria Papp (HU), Andreas Sturm (DE)

- Mechanisms in intestinal Inflammation: Jesús Rivera Nieves (USA)
- Best abstract: Phase I results of intravenous autologous bone marrow derived mesenchymal stromal cell treatment in refractory Crohn's disease: Marjolijn Duijvestein (NL)
- Policing the traffic - safety first?: Brian Feagan (CA)

- Best abstract: The pharmacologic and toxicologic profile of the gastrointestinal-selective, anti-inflammatory drug vedolizumab in cynomolgus macaques: Eric Fedyk (USA)
- Best abstract: Oral treatment using Parabacteroides distasonis components attenuates dextran sodium sulphate induced colitis by modulation of immunity and microbiota composition: Miloslav Kverka (CZ)
- Future present: traffic control:Konstantinos Papadakis (GR)

Scientific Session 4: Endpoints and outcomes of therapy

10:30 – 12:00

Milan Lukas (CZ), Gottfried Novacek (AT)

- Predicting the course of disease: Andreas Stallmach (DE)
- Best abstract: Predictors of poor outcome in paediatric Crohn's disease: Guillaume Savoye (FR)
- Mucosal healing and its relevance: Gert van Assche (BE)
- Best abstract: Mucosal healing in Crohn's disease is associated with high infliximab trough levels: Wouter Van Moerkercke (BE)
- Best abstract: Pharmaco-economic impact of mucosal healing in early Crohn's disease: an analysis of the step-up-top-down prospective follow-up study: Filip Baert (BE)
- Future perfect-endpoints and damage scores: Laurent Peyrin-Biroulet (FR)

Guided poster session

Award ceremony

Scientific Session 5: It's not always IBD

13:30 – 15:00

Andrea Cassinotti (IT), Denis Franchimont (BE)

- Chronic granulomatous disease: Edward Loftus (USA)
- Best abstract: Clinical and biological efficacy to anti-TNF therapy relates to reciprocally modulating blood and intestinal mucosa Foxp3 expression: Zhe Li (BE)
- TB or not TB? Gerassimos Mantzaris (GR)
- Best abstract: Endoscopic response to placebo therapy in Crohn's disease: Marc Ferrante (BE)
- Best abstract: Deep remission for adalimumab-treated patients with moderate to severe ileocolonic Crohn's disease: Results from EXTEND: Jean-Fédéric Colombel (FR)
- Intestinal Behçet's disease: Aykut Ferhat Celik (TR)

Scientific Session 6: Safety in IBD therapy

15:30 – 17:00

Iris Dotan (IL), Zusana Zelinkova (SK)

- Immunomodulation and lymphomas: Laurent Beaugerie (FR)
- Best abstract: Liver histology of IBD patients who are treated with 6-thioguanine due to failure of conventional thiopurines: Dirk van Asseldonk (NL)
- Pregnancy: Janneke van der Woude (NL)
- Best abstract: Severe auto-immune driven arthralgia as a new side effect in anti-TNFα treated IBD patients? Wouter Van Moerkercke (BE)
- Best abstract: Long-term outcome of treatment with infliximab in paediatric Crohn's disease: a population-based study: Jean-Frédéric Colombel (FR)
- Travelling with IBD: Shomron Ben-Horin (IL)

Saturday, February 27, 2010

Scientific Session 7: Intestinal failure

08:30 – 10:00

Ana-Maria Catuneanu (RO), Miquel Gassull (ES)

- Physiology of short bowel syndrome: Palle Bekker Jeppesen (DK)
- Best abstract: Animal protein intake and risk of inflammatory bowel disease: The E3N prospective study: Prevost Jantchou (FR)
- Managing high output stomas and enterocutaneous fistulae: Simon Gabe (UK)
- Best abstract: Effects of dietary and systemic iron on chronic ileitis targeting endoplasmic reticulum stress responses and apoptosis in the epithelium : Stefan Wagner (DE)
- Best abstract: Predictors of intestinal failure in inflammatory bowel disease: Richard Geary (NZ)
- Intestinal transplantation: Olivier Goulet (FR)

Scientific Session 8: Challenging Cases

10:00 – 11:00

Francisco (PT), Grazyna Rydzewska (PL), Severine Vermeire (BE), Alastair Windsor (UK)

- Case 1: Hide and seek - CMV in IBD: Johannes Meier (DE)
- Case 2: An unusual mediastinal complication during anti-TNF treatment: Harald Peeters (BE)
- Case 3: Severe hypoalbuminemia in a patient with long duration Crohn's disease treated with Infliximab: Catarina Andrade Fidalgo (PT)

Scientific Session 9:

Pathogenesis Workshop: Loss of response to anti-TNF monoclonal antibodies

11:30 – 12:15

Matthieu Allez (FR), Yehuda Chowers (IL)

Scientific Session 10: ECCO Lecture

12:15 – 13:00

Jean-Frederic Colombel (FR), Daan Hommes (NL)

- ECCO Fellowship 2009: The impact of anti-TNF therapy of the faecal microbiota in inflammatory bowel disease: Francesca Fava (IT)
- Announcement of ECCO Fellowships & Grants 2010: Matthieu Allez (FR)
- Science at the bench - what will impact on clinical practice? Claudio Fiocchi (USA)
- ECCO's road 2010-2012: Daan Hommes (NL)

“Unmet therapeutic needs in IBD”

February 5-7, 2009, Hamburg, Germany

Thursday, February 5, 2009

Scientific Session 1

13:10 – 14:30

Axel Dignass (DE), Tibor Hlavaty (SK)

- Welcome: Jean – Frederic Colombel (FR)
- IBD: An inflammatory barrier disease? (Tandem talk part 1): Pierre Michetti (CH)
- IBD: An inflammatory barrier disease? (Tandem talk part 2): Stefan Schreiber (DE)
- Best Abstract: Colonic mucosal expression of barrier genes in patients with inflammatory bowel disease before and after first infliximab treatment: Ingrid Arijis (BE)
- Best abstract: targeting gut T cell Ca²⁺ release-activated Ca²⁺ channels inhibits Th1 cytokine production and T-bet in inflammatory bowel disease: Antonio Di Sabatino (IT)
- The unmet therapeutic need in IBD: the Japanese perspective: Toshifumi Hibi (JP)

Scientific Session 2

15:00 – 17:00

Charlie Lees (UK), Giovanni Monteleone (IT)

- How do anti-inflammatory therapies work? – Back from the bedside to the bench (Tandem Talk part 1: Clinical): Julian Panes (ES)
- How do anti-inflammatory therapies work? – Back from the bedside to the bench (Tandem Talk part 2: Science): Britta Siegmund (DE)
- Best abstract: Azathioprine modulates human monocyte function via the pak-2 signalling pathway: Lu Zhou (NL)
- Best Abstract: The lymphatic system controls interstitial inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6: Stefania Vetrano (IT)
- Changing gut flora: aetiologic & therapeutic implications (Tandem talk part1): Patricia Lepage (AT)
- Changing gut flora: aetiologic & therapeutic implications (Tandem talk part2): Herbert Tilg (AT)
- Best abstract: neutrophil accumulation and bacterial clearance are delayed in patients with crohn's disease: Buhussain Hayee (UK)
- Best abstract: Temporal stability of faecal microbiota by inter spacer rDNA bacterial profiling (IS-pro): Matthijs Grasman (NL)

Friday, February 6, 2009

Scientific Session 3

08:30 – 10:30

Laurence Egan (IE), marc Lemann (FR), Markus Neurath (DE), Tom Öresland (NO), Stefan Schreiber (DE)

- Live Endoscopy: Live Demonstration via Satellite from Kiel to Hamburg: Marco Deparno (IT), Stephan Hellmig (DE), Tanja Kühbacher (DE), Susanna Nikolaus (DE), Marcus Seeger (DE), Andrea Sturm (DE)

Scientific Session 4

11:00 – 14:00

Jean-Frederic Colombel (FR), Andre van Gossum (BE)

- OMED-ECCO consensus report: small bowel endoscopy in IBD (Part 1): Arnaud Bourrille (FR)
- OMED-ECCO consensus report: small bowel endoscopy in IBD (Part 2): Ana Ingjatovic (UK), Chairs: Matthieu Allez (FR), Willem Bemelman (NL), Lloyd Mayer (USA), Simon Travis (UK)
- Difficult cases in IBD: Yehuda Chowers (IL)
- State of the art lecture (endoscopy): Optimal endoscopic techniques in 2009: Ralf Kiesslich (DE)

Guided poster Session

Scientific Session 5

14:00 – 15:20

Elena Belousova (RU), Konstantinos Papadakis (GR)

- Immunomodulators in IBD: is there a price to pay?: Gert van Assche (BE)
- Best abstract: Thiopurine therapy is associated with a three-fold decrease in the incidence of advanced colorectal neoplasia in IBD patients with longstanding extensive colitis: The cesame prospective data: Laurent Beaugerie (FR)
- Best abstract: Azathioprine/biological therapy does prevent surgery but not reoperation in smokers with crohn's disease: Tamas Szamosi (HU)
- Stress in IBD: the overlooked villain: David Rampton (UK)
- Best abstract: Geograohic distribution of inflammatory bowel disease (IBD) in France is influenced by sunlight exposure: V. Nerich (FR)
- Best abstract: Patterns and predictors of dosage increase in patients treated with adalimumab for crohn's disease in the United States: Jingdong Chao (USA)

Scientific Session 6

15:50 – 17:00

Simon Travis (UK)

- ECCO Fellowship 2008: Alessia R. Grillo (IT)
- Announcement of ECCO Fellowship & Grants 2009: Simon Travis (UK), Chairs: Jens Dahlerup (DK), Laurent Payrin-Biroulet (FR)
- The right use of diagnostics: How not to harm patient: Edouard Louis (BE)

- Best Abstract: Lack of usefulness of systematic determination of azathioprine (AZA) metabolites during follow-up of inflammatory bowel disease (IBD) patients under thiopurinic therapy: Final results of the metasa study: Y. Gonzalez-Lama (ES)
- Best abstract: Immunosuppressive (IS) therapy impacts the results of quantiferon® and tuberculin skin in routine screening for latent tuberculosis (LTB) in patients with inflammatory bowel disease (IBD): Palov Papay (AT)

Saturday, February 7, 2009

Scientific Session 7

08:30 – 09:40

Michael Kamm (AU), Miquel Sans (ES)

- Crohn's disease: Where it all started and where it's all going: Lloyd Mayer (USA)
- The unmet therapeutic need in IBD: a European regulatory view: Sif Ormarsdottir (IS)
- Best abstract: Welcome: A randomized, double-blind, controlled trial comparing certolizumab pegol 400 mg every 2 weeks with every 4 weeks for maintenance of response and remission in patients with moderate-to-severe Crohn's disease with secondary failure to infliximab: Paul Rutgeerts (BE)
- Best abstract: Clinical course and cost of care in ulcerative colitis: Markov chain analysis of a European prospective population-based cohort: Selwyn Odes (DK)

Scientific Session 8

09:40 – 11:40

Laurent Beaugerie (FR), Geert D'Heans (BE), Sanja Kolacek (HR), Alastair Windsor (UK), Oded Zmora (IL)

- Optimizing IBD management: Case-based discussion: Limited ileocecal crohn's disease with a simple perianal fistula at presentation: Gianluca Sampiero (IT)
- Optimizing IBD management: Case-based discussion: Fistulizing CD: Dario Sorrentino (IT)
- Optimizing IBD management: Case-based discussion: Acute severe UC in 16 yr old female: Franck Carbonnel (FR)
- Best abstract: Laparoscopic-assisted versus open ileocolic resection for crohn's disease: Long term results of a prospective randomized trial: E. J. Eshuis (NL)

Scientific Session 9

11:40 – 12:50

Jean-Frederic Colombel (FR), Eduard Stange (DE)

- CD Consensus update presentation (Part 1): Alex Dignass (DE)
- CD Consensus update presentation (Part 2): Gert van Assche (BE)
- CD Consensus update presentation (Part 3): James Lindsay (UK)
- ECCO lecture: The unmet therapeutic need in IBD: Michael Kamm (AU)
- Concluding remarks: Jean-Frederic Colombel (FR)

3rd Congress of ECCO

February 28 – March 1, 2008, Lyon, France

Thursday, February 28, 2008

Welcome

13:00 – 13:10

Miquel Gassull (ES), Jean-Frédéric Colombel (FR)

Scientific Session 1: Pathogenesis of IBD:

What's New and What's the Relevance to Clinical Practice?

13:10 – 17:00

Stefan Schreiber (DE), Christian Mottet (CH)

- New Discoveries in IBD Genetics and insights into Therapeutic Development: Miles Parkes (UK), Severine Vermeire (BE)
- Of Mice and Men: Relevance of Animal Studies to Human Research: Fabio Cominelli (USA), Silvio Danese (IT)
- Best Abstract: Selective Influence of Tcf-4 Mediated Wnt Signaling on Intestinal Innate and Adaptive Immunity of Ileal Crohn's Disease: Maureen Koslowski (DE)
- Best Abstract: Evidence for Dysbiosis in Pouchitis Using 16srrna Sequencing: Simon D. McLaughlin (UK)
- Defensins: What's their Role in Crohn's Disease? Eduard Stange (DE)

Scientific Session 1 continued: Pathogenesis of IBD: What's New and What's the Relevance to Clinical Practice?

Daan Hommes (NL), Shomron Ben-Horin (IL)

- T-Cell Co-stimulation and Therapeutic Implications: Markus Neurath (DE)
- Best Abstract: Lymphoneogenesis: A New Component In Inflammatory Bowel Disease Pathogenesis: Silvio Danese (IT)
- Best Abstract: Probiotic E. Coli (Symbioflor® 2) Treatment Mediates Antimicrobial β -Defensin (hBD-2) Synthesis and Fecal Excretion in Humans: Jan Wehkamp (DE)

Friday, February 29, 2008

Scientific Session 2: Live Endoscopy

08:30 – 12:00

Guido Tytgat (NL), Geert D'Haens (BE), Jean-Frédéric Colombel (FR),

Gert de Hertogh (BE)

- Live Demonstrations via Satellite from Lille to Lyon (1): Brian Saunders (UK) Markus Neurath (DE), Gert Van Assche (BE), Jean-Marie Reimund (FR), Bernard Duclos (FR), Yoram Bouhnik (FR), Philippe Marteau (FR), Philippe Bullois, Jeanne Boitard, Vincent Maunoury
- Live Demonstrations via Satellite from Lille to Lyon (2)

Current Concepts on Cancer in Ulcerative Colitis

12:00-12:30

Guido Tytgat (NL)

Scientific Session 3 - Panel Discussion: Pathology, Radiology and Surgery in Adult and Paediatric IBD: What the Gastroenterologist Needs to Know

14:00 - 17:00

Marc Lemann (FR)

- Panel: Robert Lofber (SE)
- Panel: Gert de Hertogh (BE)
- Panel: Andre D'Hoore (BE)
- Panel: Andreas Schreyer (DE)
- Panel: Robert Heuschkel (UK)
- Case presentation 1: Longstanding UC with Dysplasia: Stephan Vavricka (CH) Case presentation 2: Refractory Pouchitis: Marc Ferrante (BE)
- Case presentation 3: Extensive Small Bowel in Crohn's Disease in an Adolescent: Laurent Peyrin-Biroulet (FR)
- Talk: Europe-wide perspectives, improving the lives of people with IBD: Rod Mitchell (UK)
- ECCO Fellowships & Grants: Miquel Gassull (ES), Simon Travis (UK)
- ECCO Fellowships 2007: Kostas Karmiris (GK)
- Announcement of ECCO Fellowships and Grants 2008:
- Historical Perspectives of the Management of Severe Colitis: Renzo Caprilli (IT), Miquel Gassull (ES), Simon Travis (UK)

Saturday, March 1, 2008

Scientific Session 4: Risks Associated with IBD

08:30 - 11:00

Boris Vucelic (HR), Martin Bortlik (CZ)

- Malignancy and Lymphoma in IBD: Larry Egan (UK)
- Best Abstract: Colonoscopic Surveillance in Inflammatory Bowel Disease improves Survival after Colorectal Cancer Diagnosis: Maurice Lutgens (NL)
- Best Abstract: Inflammatory Bowel Disease and Pregnancy: Preliminary Results of an European Multicenter Prospective Case-Control Study: Aurora Bortoli (IT)
- Opportunistic Infections in IBD, Diagnosis and Prevention (or if ready title should be changed into: ECCO consensus on opportunistic infections): Jean-Frédéric Colombel (FR), Jean-François Rahier (FR)
- Best Abstract: Long-term Efficacy of Infliximab and Colectomy-free Survival in Outpatients with Refractory Ulcerative Colitis: Marc Ferrante (BE)
- Best Abstract: Maintenance Therapy with Azathioprine (aza)/6-mercaptopurine (6-mp) in Crohn's Disease (cd) reduces the Risk of Re-operation particularly in Smokers: Pavol Papay (AT)

Scientific Session 5: Management of IBD

11:00 - 13:00

Pierre Michetti (CH), Walter Reinisch (AT)

- Complex Fistulizing Crohn's Disease: Marijana Protic (RS)
- The Evaluation of Fistulizing Perianal Crohn's Disease: André D'Hoore (BE)
- The Combined Management of Fistulizing Perianal Crohn's Disease: Remo Panacione (CA)
- Best Abstract: Assessment of Certolizumab Pegol in the Treatment of Crohn's Disease in Patients for Whom Infliximab Treatment was not Successful: Open-label Induction Preliminary Results from the WELCOME Study: Séverine Vermeire (BE)
- Best Abstract: Long Term Outcome and Quality of Life after Restorative Proctocolectomy in a Cohort of 955 Canadian Patients: Marco Scarpa (IT)
- Flexible Therapy in IBD: Is It Possible?: Paul Rutgeerts (BE)
- Concluding Remarks: Jean-Frédéric Colombel (FR)